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Abstract 
Methods for the discovery of bioactive small molecules are a constant 
source of innovation in drug discovery. Typically, medicinal chemists 
discover molecules in design-make-test cycles and invest equal resources 
into each molecule regardless of biological function. New and emerging 
workflows for the rapid discovery of bioactive small molecules aim to 
redistribute resources to high value, active small molecules. This thesis 
focuses on developing a discovery workflow that invests resources 
exclusively in high-value, active molecules, and circumvents limitations of 
traditional discovery workflows. 
Chapter 1 gives an overview of modern drug discovery practices and 
focuses on emerging methods for the integrated and high-throughput 
discovery of bioactive small molecules. Chapter 1 also outlines the biological 
and medicinal chemistry of the p53/MDM2 protein–protein interaction, and 
proposes the PPI as a target for activity-directed small molecule discovery.  
Chapter 2 describes the development of a computational map for the 
selection of catalysts in high-throughput reaction arrays. Principal 
component analysis of a library of 48 DFT-optimised rhodium(II) catalysts 
was used to build the map from a collection of bespoke computational 
descriptors. The map was compared to a variety of experimental data 
sources and found to be a useful tool for interpreting reaction outcomes. 
Chapter 3 describes the design and implementation of two high-throughput 
reaction arrays for the activity-directed discovery of inhibitors of the 
p53/MDM2 protein–protein interaction. 346 microscale reactions were 
performed and seven products were isolated from the scale-up of hit 
reaction mixtures. 
Chapter 4 describes the characterisation of hit molecules identified from the 
activity-directed synthesis workflow. The products were tested in orthogonal 
biological assays and four distinct series were found to have low micromolar 
inhibitory activity of the p53/MDM2 protein–protein interaction. Similarity 
analysis also demonstrated that the products have promising ligand 
efficiencies and that the products can provide new starting points for drug 
discovery. 
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Chapter 1 
Chemical Approaches for the Discovery of Small Molecules 
in Drug Discovery 
The identification of bioactive small molecules underpins drug discovery and 
is essential for the development of new therapeutics for diseases with an 
unmet clinical need. The drug discovery process has a high attrition rate with 
over 90% of candidates failing in clinical trials.1,2 While small molecule 
discovery is not the rate limiting step for the development of new medicines, 
a highly productive drug discovery pipeline is required to counteract the high 
failure rates of clinical trials.3 This is highlighted by the number of FDA drug 
approvals between 2010 and 2019, where new molecular entities make up 
over 75% of approvals.4 Efforts to reduce clinical failure rates include 
extensive target validation; ensuring a robust link between target biology and 
disease mechanisms; and optimisation of the chemical structure of a 
candidate for parameters such as selectivity, toxicity, metabolic liabilities, 
pharmacokinetics and pharmacodynamics.5–7 
Hit molecules suitable for progression through the discovery process can 
usually be identified a large majority of the time, but many campaigns target 
protein classes that are known to be compatible with small molecules.8,9 
Failure to identify a hit for a challenging class of protein targets can limit the 
development of first in class treatments.10,11 The inability to identify a hit can 
be due to a lack of structural information that can be used to direct screening 
efforts;12–14 poor protein stability in vitro;15 poor assay performance;16 or low 
availability of the isolated protein meaning high throughput screening cannot 
be conducted.17 In some cases, the chemical space covered by a screening 
library is not relevant to the targeted activity and prevents the identification of 
synthetically tractable hits.18–20 Deficiencies that impede the drug discovery 
process can lead to the discontinuation of projects, meaning alternative 
methods for molecular discovery could help bring first in class medicines to 
the clinic.21–23 
The aim of the research described in this thesis was to develop and 
demonstrate the effectiveness of activity-directed synthesis (ADS) as a 
method for the discovery and synthesis of small molecules against a 
challenging class of protein targets, protein-protein interactions. The key 
objective was to further develop ADS as an approach that can enable hit 
identification without recourse to elucidation of the structural basis for a 
- 2 - 
 
protein-ligand interaction. It was envisaged that the ADS will expand the 
toolkit of discovery techniques available for drug discovery and lead to the 
identification of new active small molecules that could not have been 
designed a priori. 
 
1.1 An Overview of Early-Stage Drug Discovery 
The drug discovery pipeline, for small molecules, is a linear process which 
begins with target identification and validation and is followed by hit 
discovery and hit-to-lead optimisation. The pipeline ends after successful 
progress through clinical trials (Figure 1.1).7 Biological targets are selected 
based on either an unmet clinical need to treat a disease, or to improve the 
standard of care for a disease that already has approved drugs 
available.24,25 Thorough identification and validation of the biological target 
ensures that, after successful hit-to-lead optimisation, a clinical candidate 
molecule can modulate the targeted biological mechanisms that underpin 
disease progression and act as a drug.7,26 In order to support the low 
success rate of clinical trials, where fewer than one in ten candidates are 
successfully marketed as drugs, the discovery pipeline must have an ample 
supply of new chemical matter.27,28 Therefore, technologies that enable fast 
and efficient hit discovery can improve downstream productivity and help 
bring drugs to market more quickly.29–31 
 
Figure 1.1. An outline of the number of active drug discovery programmes 
required, at each stage of the pipeline, to support the launch of one new 
small molecule drug.1 Each stage has a breakdown of likelihood of success, 
cycle time and cost. 
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During the early 2000s high-throughput screening (HTS) became a staple 
technique for the discovery of hit compounds, and pharmaceutical 
companies amassed libraries containing typically >106 molecules for 
screening.29,32 HTS relies upon screening an entire compound library against 
a drug target in a highly automated array process. Compounds found in HTS 
screening libraries often have molecular properties that obey the Lipinski 
“rule of five”, or stricter criteria such as lead-like space,33 and have a 
molecular weight below 500 Da, a logP lower than five, no more than five 
hydrogen bond donors, and no more than 10 hydrogen bond acceptors.34 
Identified hits are then characterised by structure-activity-relationship (SAR) 
studies and subjected to a rigorous optimisation programme to improve 
various properties including potency, ligand efficiency, lipophilicity and 
solubility.33,35–37 Lead compounds are then optimised further to improve 
pharmacokinetic and pharmacodynamic properties, and to elucidate 
structure-toxicity relationships to avoid failure in preclinical studies.38 HTS 
techniques can have significant shortcomings, including an inability to 
produce hits against new or challenging targets as compound libraries often 
contain large and complex molecules,39 and false positive results that are 
often caused by aggregators.40,41 
Fragment-based drug discovery (FBDD) is another approach for the 
discovery of small molecules that utilises carefully curated compound 
libraries to screen several thousand low-molecular weight, low-affinity 
molecules with tightly controlled molecular properties.39,42–44 A large number 
of early fragment libraries were based on the “rule of three”, where molecular 
weight was less than 300 Daltons (approximately 20 heavy atoms), and 
where each fragment contains fewer than three hydrogen bond donors and 
acceptors, less than three rotatable bonds and clogP less than three.45,46 
Modern fragment libraries are curated with a great deal of care and employ 
much stricter criteria on molecular properties including; molecular weight 
(fragments usually fall within 140 to 230 Da or 10 to 15 heavy atoms); logP (-
1 to 3); fragment complexity (3D-shape and fraction of sp3 character); 
synthetic tractability; pan-assay interference (PAINS) motifs; and 
solubility.47–52 
Fragments are screened against a biological target using sensitive high-
throughput biophysical or biochemical assays, allowing for the identification 
of weak binders (typically between 1 and 10 mM Kd).53 Examples of 
screening methods include X-ray crystallography; Surface Plasmon 
Resonance; protein- and ligand-observed NMR; and fluorescence-based 
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assays using labelled proteins to detect binding.54–56 In practice, fragments 
can form highly productive interactions with protein binding sites, and when 
elaborated, the subsequent lead compounds tend to conserve the original 
fragment binding modes (Figure 1.2).57 As fragments bind with low-affinity, 
the concept of ligand efficiency has been used to aid prioritising high quality 
hits and is defined below in equation 1.1.58 Generally, hits with ligand 
efficiency of 0.3 kcal mol-1 HA-1 or greater are prioritised and considered 
alongside SAR, binding model and potential for synthetic elaboration.59,60 
 
Figure 1.2. Fragment-based hit to lead strategies. A: Fragment linking – two 
fragments are linked together to conserve the combined activity of each 
individual fragment. B: Fragment growing – a single fragment is grown into 
adjacent binding sites. C: Fragment merging – two compounds that share 
structural similarities are combined into one molecule.57 
 
Equation 1.1:   







 × 𝑝𝐼𝐶50 
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The first successful example of FBDD was the discovery of Vemurafenib for 
the treatment of BRAFV600E mutant metastatic melanoma.61–63 The discovery 
campaign was initiated by screening a 20,000-fragment library against a 
panel of structurally diverse serine/threonine kinases to identify new 
scaffolds for FBDD.61 Initially, 238 hit fragments were identified using X-ray 
crystallography and evaluated based on their synthetic tractability for further 
development as new fragment scaffolds. A 3-substituted 7-azaindole 
scaffold was selected and quickly optimised into a potent kinase inhibitor. 
Over 100 solved co-crystal structures of compounds bound to B-rafV600E 
were produced as part of the optimisation (Scheme 1.1). 
Scheme 1.1. The development of Vemurafenib. The portions of the primary 
fragment are highlighted in blue. 
 
1.2 Chemical Transformations Used to Synthesise Small 
Molecules in Drug Discovery 
Medicinal chemists performing organic synthesis must produce active small 
molecules quickly, and iteratively, to advance from an initial hit to a lead 
compound that has the potential to be developed into a clinical candidate.7 
The chemical transformations commonly used by medicinal chemists tend to 
focus on reactions with well-established precedent and substrate scope, so 
that analogues can be generated without the need for reaction 
optimisation.64–69 An analysis of submissions to the Journal of Medicinal 
Chemistry, totalling 40,000 compounds, between 1959 and 2009 revealed 
that the molecular properties of drug-like molecules have significantly 
changed during this period.65 Modern molecules are on average heavier, 
more complex and flatter.64,67 Modern drug-like molecules also have larger 
polar surface areas, are more lipophilic and feature more hydrogen bond 
donors than acceptors.64 Overall, only three of the top twenty reactions 
featured in the Journal of Medicinal Chemistry in 2014 were developed after 
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1974, and two of the top six reactions were protecting group manipulations 
(Figure 1.3).  
 
Figure 1.3. The frequency of appearance for each transformation in papers 
published in J Med Chem in 1984 and 2014 (n = 125). Suzuki-Miyaura 
coupling was first described in 1981; Sonogoshira coupling in 1975; and 
Buchwald-Hartwig in 1994.65 
 
Metal-catalysed cross-coupling reactions are frequently used in the early 
stages of drug discovery as a method of forming key carbon-carbon and 
carbon-heteroatom bonds in drug-like molecules.65 Such cross-couplings 
dominate the reactions reported in pharmaceutical patents,68 and newer 
carbon-carbon bond forming reactions have not been readily embraced. 
Medicinal chemists are often slow to incorporate new synthetic methodology 
into discovery workflows, instead relying on methods with a higher likelihood 
of success, which can limit the diversity of compounds synthesised and 
tested.70 However, recent developments in photoredox chemistry and direct 
C–H bond functionalisation have been well received and implemented to 
support discovery efforts.70–72 Ultimately the value of a given molecule, or 
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class of molecules, drives medicinal chemists to try new methodologies. 
Molecules that fit robustly into a biological design hypothesis are more likely 
to have time invested into their synthesis due to their higher perceived 
value.70 Therefore, the application of new synthetic methodologies by 
medicinal chemists is linked to the rational design of small molecules. 
Advancements in high-throughput chemistry and micro-scale synthesis have 
enabled the design of predictive models for reactions between pairs of 
densely functionalised reagents, by facilitating the generation of large 
databases consisting of experimental data.73–75 These models could have 
potential applications in drug discovery by allowing medicinal chemists to 
select optimal reaction conditions without prior testing and bridge the gap 
between emerging synthetic methodologies and medicinal chemistry. 
 
1.3 Integrated Approaches for High-Throughput Chemistry 
and Molecular Discovery 
Integrated approaches for molecular discovery have several advantages 
over FBDD and HTS technologies. Firstly, there is no need to purchase or 
maintain an expensive library or screening collection which can result in 
substantial cost savings for research and development. HTS libraries 
typically cost between $400 million and $2 billion USD to acquire, maintain 
and screen, whereas integrated technologies can be implemented for a tiny 
fraction of the cost (less than 0.1%).76 Secondly, the chemical diversity of an 
HTS library cannot be readily adjusted to accommodate a specific protein 
meaning tractable chemical matter may not be found for challenging drug 
targets.29 Integrated technologies are frequently used in drug discovery and 
have even produced clinical candidates for a range of diseases where HTS 
or FBDD approaches failed.76–78 Integrated approaches typically conduct 
chemical synthesis directly before biological screening using highly efficient 
and optimised processes to create libraries of compounds that can be 
screened on-demand.76 These libraries can consist of pure compounds, 
crude reaction mixtures, or cocktails of compounds that can be individually 
identified by a tag containing information for each molecule. Reactions are 
usually conducted on the micro-scale and require only milligrams, or even 
micrograms, of each building block meaning expensive reagents can be 
routinely used.79–83 
- 8 - 
 
1.3.1  DNA-Encoded Libraries 
DNA-encoded library (DEL) technology enables the synthesis and screening 
of millions (or billions) of small molecules simultaneously by encoding the 
synthetic history of each molecule with a strand of covalently linked 
DNA.76,84,85 The process begins by mixing a pool of building blocks that are 
individually identified by a unique strand of DNA. The building blocks are 
then split into several pools that are each reacted with a new building block 
and a new section of DNA is ligated to the original DNA tag conferring the 
synthetic history of the new compound.76,86–88 The pools of compounds are 
then recombined and then subjected to successive rounds of the split and 
mix strategy to generate a DEL.89,90 Once a DEL has reached a desired size, 
or achieved a large enough level of chemical diversity, it will be screened for 
active molecules using a single affinity-selection assay with purified protein 
immobilised on a solid support. Often, DELs are stored in an aqueous buffer, 
in a single Eppendorf tube, and can be conveniently screened on-demand 
after synthesis.76 The DNA tags of compounds that bind to the target protein 
are then amplified and sequenced to obtain the identity of hits (Figure 1.4).91 
DEL’s can be constructed using various technologies including DNA-
recording,89,90 DNA-templated synthesis (DTS),92 yoctoReactor,93,94 DNA 
routing,95 and encoded self-assembling libraries (ESAC).96 
 
Figure 1.4. The split and mix strategy used in the synthesis of DNA encoded 
libraries. The DEL workflow illustrated above is an example of a DNA 
recording strategy. 
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DEL technology has delivered clinical candidates across different classes of 
protein targets and for a range of diseases with unmet clinical need.76 An 
example of successful hit identification using DEL technology through to a 
proposed clinical candidate is the discovery of GSK2982772, a small 
molecule targeting Receptor Interacting Protein 1 (RIP1) kinase.78,97–101 
Initially, the GlaxoSmithKline (GSK) kinase inhibitor library was screened to 
identify an inhibitor of RIP1 kinase, but no selective inhibitors were found, 
and the hits had poor synthetic tractability.98 The GSK HTS compound 
collection, comprised of approximately 2 million compounds, was then 
screened and a lead series was identified but the best inhibitor had poor oral 
bioavailability, and poor synthetic tractability, and was discontinued.99 The 
GSK collection of DNA-encoded small molecule libraries, containing 7.7 
billion compounds, was then screened and an inhibitor of RIP1 kinase with a 
unique chemotype was identified (Figure 1.5).101 The discovery programme 
was then successfully advanced to give GSK2982772, a clinical candidate 
for the treatment of immune-mediated inflammatory diseases.78,97,100 
 
Figure 1.5. Hits from GSK compound libraries screened against RIP1 
kinase. 
 
DEL technology often cannot fully exploit the full range of modern synthetic 
chemistry due to limitations in reaction conditions.76,102–104 This is commonly 
due to incompatibility of new transformations with the aqueous, buffered, 
conditions required for maintaining the integrity of DNA.105,106 Advances in 
DEL technology have demonstrated that libraries can be synthesised in 
organic solvents and under inert atmospheres107,108 but have yet to be 
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translated to molecular discovery. Examples of reactions commonly used in 
DEL synthesis include amidation, metal-catalysed cross-couplings, Diels-
Alder reactions, click chemistry, and nucleophilic substitution.105 Designing 
DELs that cover a broad area of chemical space can also prove challenging 
due to the limited toolkit of reactions available for consideration, meaning 
libraries tend to contain compounds with many aromatic rings and rotatable 
bonds.76,102–104 DELs that incorporate the principles of diversity-oriented 
synthesis (DOS) in building block design have been proposed to address the 
lack of structural and stereochemical diversity.102,109 One example of a DOS-
DEL, focussed on incorporating stereoisomeric small molecules, used a 
palladium-catalysed C–H arylation of azetidines and pyrrolidines to create a 
library of DOS-inspired initial building blocks.110 The building blocks were 
then attached to DNA and subjected to two rounds of split and mix synthesis 
(Figure 1.6). One set of building blocks were installed using a DNA-
compatible Suzuki reaction and the other set using a range of nitrogen-
capping reactions. Cheminformatic analysis of the DOS-DEL demonstrated 
that most compounds had drug-like physicochemical properties, and 
similarity analysis showed that the library contained extensive chemical 
diversity. The DOS-DEL was also screened against carbonic anhydrase and 
several potent inhibitors were identified, showing that specific DNA-
compatible complexity generating reactions are not required for increasing 
the diversity of DELs. 
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Figure 1.6. Library design for a DOS inspired DEL. Top panel: the DOS 
inspired scaffolds used to synthesise the DEL. Bottom panel: active products 
identified and synthesised off-DNA for characterisation. 
 
DEL technology is largely limited to affinity-selection assays for hit 
identification, rather than activity-based assays, meaning that inhibitors of 
targets such as transcription factors, ion channels, receptors and protein-
protein interactions cannot be directly identified.76,111,112 Instead individual hit 
molecules must be retested after affinity selection, and re-synthesised off-
DNA, using an activity-based assay to confirm the desired biological 
mechanism of action. Advancements in microfluidics have demonstrated that 
it is possible to directly screen a DEL using an activity-based assay, but 
targets such as protein-protein interactions are still yet to be directly 
interrogated.111–113  
In summary, DEL technology offers several advantages over HTS by 
providing a flexible method for screening huge libraries of compounds 
without the overhead of synthesising and maintaining the corresponding 
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screening collection. The ability to tailor the properties of a DEL towards a 
specific target also allows for the progression of discovery campaigns where 
more traditional methods have not produced desired results. DELs also 
allow for hit identification against targets where structural information has not 
been elucidated, meaning that discovery for targets that are challenging for 
FBDD can be progressed. 
 
1.3.2 Integration of Nanoscale Chemical Synthesis and Screening 
for Small Molecule Discovery 
The miniaturisation of chemistry allows hundreds or thousands of reactions 
to be conducted in parallel on the microscale.75,79,80,82,83,114–116 Each reaction 
uses only a small amount of material, usually less than a milligram per 
reaction (approximately 1 µmol), meaning that large libraries of building 
blocks can be investigated for both reactivity and bioactivity.114 This has led 
to the optimisation of challenging reactions in drug discovery and 
development73,115 more quickly than when using traditional reaction 
optimisation strategies. The coupling of microscale chemical synthesis and 
biological screening has allowed for a substantial increase in the chemical 
space tested against a target.75,80,81 The leveraging of accessible reactive 
space for one or more chemical transformations allows for the discovery of 
unexpected reaction products with interesting biological properties.83 
Integrated approaches for microscale chemical synthesis and biological 
testing typically synthesise compounds in batch, plate-based formats, and 
screen crude reaction mixtures, but some workflows include in-line 
purification, or use flow chemistry.79,81–83,117–123 
Reaction arrays have been conducted on the nanoscale, using micrograms 
of material per reaction (typically between 50 and 5 µg) and total volumes 
between 1 and 2 µL.75,80,81 Nanoscale synthesis with affinity ranking 
(NanoSAR) is an example of this approach where both reaction space and 
biological activity space were investigated to yield potent inhibitors of 
kinases.81 Active products were identified using affinity-selection mass-
spectrometry (ASMS) assays to identify hit compounds from crude reaction 
mixtures. NanoSAR was validated by synthesising screening libraries to 
identify new inhibitors of Extracellular Signal-Regulated kinase 2 (ERK2), 
Mitogen-Activated Protein Kinase 2 (MK2), and Checkpoint Kinase 1 
(CHK1). The reactions used to synthesise the library were based on the 
most popular transformations used in small molecule discovery and included 
amidation, Suzuki-Miyaura cross-couplings, and Buchwald-Hartwig cross-
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couplings.64,65,67,68 Each reaction was analysed by ultra-high-performance 
liquid chromatography – mass spectrometry (UPLC-MS) to identify reactions 
giving the desired product and to estimate the yield.75 Initially, productive 
conditions were identified for each class of reactions before moving onto 
library synthesis. In total over 1,500 reactions were conducted to scout ideal 
reaction conditions (Figure 1.7). 
 
Figure 1.7. NanoSAR workflow for the synthesis and optimisation of small 
molecules. Reactions are performed in a 384-well plate, at 1.2 µL total 
volume, in a glovebox and dispensed using microfluidic dispensing robotics. 
Active products are identified using affinity-selection mass-spectrometry for 
a protein target. 
 
Each protein target was assigned a different scaffold building block that was 
elaborated with one or more of the coupling reactions. For each type of 
coupling reaction used to decorate the scaffolds, the reaction conditions and 
capping groups were widely varied. In total, 435 building blocks were used 
across all three targets and UPLC-MS analysis showed that 396 of the 
combinations gave a product (over 1,700 reactions conducted). The libraries 
were then screened for affinity towards ERK2, MK2 or CHK1 depending on 
the starting scaffold and a range of hits were identified (Figure 1.8). Each 
well was screened at multiple concentrations to estimate the potency of each 
hit by decreasing the concentration of protein in the ASMS assay. The 
products that function as ligands were identified from the protein-bound 
fraction and selectivity was tested by the presence of a fixed concentration 
of a competitor protein. Each active product was also resynthesized on a 20 
mg scale and re-tested in the ASMS assay, and tested in a functional 
biochemical assay, to confirm the nanoscale results correlated with the 
activity of the pure compounds. 
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Figure 1.8. Example results from three NanoSAR screening libraries for 
ERK2, MK2 and CHK1 using amidation, Suzuki-Miyaura cross-coupling, and 
Buchwald-Hartwig C–N cross-coupling reactions respectively. Other 
reactions employed included the Sonogashira coupling, and S–H and O–H 
coupling. The most potent compounds are those with detectable binding via 
ASMS at the lowest protein concentrations. 
 
Interestingly, if the libraries were synthesised using a single set of reaction 
conditions only a fraction of the available chemical space would have been 
sampled. For example, the C–N cross-couplings required extensive 
optimisation of reaction conditions before the nanoscale screening library 
could be synthesised. This is because the optimised reaction conditions 
varied as a function of substrate combinations. Twenty-four different reaction 
conditions had to be tested with five different amine building blocks to 
identify four reaction conditions that were robust enough to be used with the 
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96 amines selected for the nanoscale library. Overall, 92 of the 96 possible 
C–N cross-coupling products were successfully synthesised as part of the 
library. Therefore, NanoSAR may enable a diversification of the toolkit of 
reactions used to synthesise small molecules as methodologies with narrow 
scopes, or that are challenging to optimise, can be explored as part of a drug 
discovery workflow. 
 
1.3.3 Activity-Directed Synthesis 
Biosynthetic pathways evolve in nature when a natural product confers a 
competitive advantage to the host organism – these pathways are structure-
blind and driven purely by the function of bioactive products. Activity-directed 
synthesis (ADS) takes some inspiration directly from the evolution of 
biosynthetic pathways and applies it to the discovery of active small 
molecules. Active products emerge in tandem with their synthetic routes 
through iterative rounds of microscale reaction arrays and integrated 
biological screening of crude reaction mixtures (Figure 1.9). Selection 
pressure can be increased by raising the threshold required for a crude 
reaction mixture to be identified as active, and efforts can be focussed solely 
on the characterisation of active products. Due to the low purification and 
characterisation overhead, a less established toolkit of chemistry can be 
employed, with minimal risk, to aid the discovery of new bioactive molecules. 
The utility of ADS has been shown for the discovery of bioactive small 
molecules.82,83,123 Two successive publications described the use of α-diazo 
compounds with metal catalysts for the discovery previously unknown 
classes of ligands for the androgen receptor.82,83 Metal-catalysed carbene 
chemistry was chosen to intentionally leverage the possibility that multiple 
products could be formed in each reaction mixture. Reaction arrays were 
carried out in 100 µL 96-well PTFE plates, under ambient conditions, and the 
product mixtures were scavenged for metals and assayed using a time-
resolved fluorescence resonance energy transfer (TR-FRET) assay for 
agonism against the androgen receptor. The activity data was then analysed 
to identify active product mixtures, which subsequently informed the design 
of a second-generation array. Selection pressure was increased after each 
round, by screening at successively lower concentrations, optimising for both 
activity and yield. After the final round was complete, active product mixtures 
were scaled-up, purified and characterised to determine the identity of the 
active compounds. ADS has also been shown effective in the discovery of 
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anti-microbials using phenotypic assays and a different toolkit of 
chemistry.123 
 
Figure 1.9. Activity-directed synthesis workflow for the discovery of agonists 
of the androgen receptor. 
 
Initially, three rounds of ADS were conducted with 16 α-diazo amides (1.1 – 
1.16) bearing a 4-cyano-3-trifluoromethylphenyl moiety and a range of metal 
catalysts to harness intramolecular transformations (Figure 1.10).82 In round 
one 36 reactions were conducted using 12 α-diazo amides 1.1 – 1.12, three 
catalysts and one solvent, and the products were assayed at a 10 µM total 
product concentration. Four diazo substrates 1.1, 1.3, 1.6 and 1.7 were 
identified as yielding active products which informed the design of the next 
reaction array. In round two, 192 reactions were conducted using six 
substrates 1.1, 1.3, 1.6, 1.7, 1.11 and 1.12 in combination with eight 
catalysts and four solvents, and the products were assayed at 1 µM total 
product concentration. Diazo substrates 1.11 and 1.12 did not produce any 
reaction mixtures with detectable activity and were discounted. Two 
substrates 1.1 and 1.3 were identified as responsible for the most active 
products and four analogues 1.13 – 1.16 were synthesised to exploit this. In 
round three 108 reactions were conducted using six substrates 1.1, 1.3, 1.13 
– 1.16, six catalysts and three solvents, and the products were assayed at 
100 nM total product concentration. Eight reactions were identified as 
producing the most promising bioactive products and scaled-up to obtain the 
pure products for analysis. Three active compounds 1.17 – 1.19 were 
identified with sub-micromolar activity demonstrating that ADS can be used 
to discover potent and novel scaffolds. ADS also enables the optimisation of 
the most active product between rounds of reaction arrays meaning activity 
and yield can be optimised simultaneously. 
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Figure 1.10. ADS with intramolecular reactions for the discovery of novel 
agonists of the androgen receptor. A: Diazo substrates. B: Biological activity 
of crude reaction mixtures at each round of ADS. C: Active products 
identified from the scale-up, purification, and characterisation of crude 
reaction mixtures. 
 
A second series of ADS experiments was also used to investigate the 
activity-directed discovery of androgen receptor ligands with intermolecular 
reactions (Figure 1.11).83 Again, a toolkit featuring metal-catalysed carbene 
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chemistry was utilised, but this time for activity-directed fragment growth. A 
range of co-substrates with diverse structure and reactivity was selected to 
enable the growth of an N-[4-cyano-3-(trifluoromethyl)phenyl]-N-
methylacetamide fragment (IC50: 92 µM). In round one 192 reactions, out of 
a possible 480, were conducted featuring a random combination of four 
substrates, nine co-substrates (plus one without co-substrate), six catalysts 
and two solvents. The products were assayed at 10 µM total product 
concentration and two active product mixtures were identified, both of which 
originated from diazo substrate 1.20 with either cyclohexene or indole as co-
substrate, Rh2(S-DOSP)4 and DCM. In round two 86 reactions, out of a 
possible 360, were conducted using two diazo substrates, 18 co-substrates 
based on cyclohexene and indole, five catalysts and two solvents. The 
products were assayed at 5 µM total product concentration and five active 
product mixtures were identified originating from diazo substrate 1.20 with 
either dihydronaphthalene, dihydropyran or indene. In round three all 48 
possible reactions were conducted with diazo substrate 1.20, 12 co-
substrates and four catalysts, and the products were assayed at 1 µM total 
product concentration. Co-substrate 6-benzopyran-carbonitrile yielded active 
product mixtures with all four catalysts, however, the dihydropyran co-
substrate only gave an active mixture with Rh2(R-DOSP)4. Consequently, 
the most active product mixtures and a selection of inactive mixtures were 
scaled up and characterised to study the emergence of the bioactive 
products. 
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Figure 1.11. ADS using intermolecular reactions for the discovery of agonists 
of the androgen receptor. 
 
Compounds 1.21 and 1.22 were the only active compounds identified during 
round one and both the product of intermolecular transformations, a C–H 
insertion into the C3 position of indole and a cyclopropanation of 
cyclohexene respectively. Characterisation of a selection of inactive wells 
from round one revealed that a diverse range of products had been formed 
and a large area of chemical space explored but ultimately discarded in 
favour of the active products. Round two capitalised on the introduction of a 
varied set of alternative substrates to expand the range of cyclopropanation 
products and identified alternative compounds. Finally, co-substrates 
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containing new functionality (alcohol and nitrile groups) were introduced in 
round three and yielded active products from unexpected reactions. The 
reaction forming 1.23 was unlikely to have been rationally predicted as 
enantioselective O–H insertions using racemic starting material were not 
previously known. ADS has, therefore, been shown to be capable of 
identifying novel transformations through the pursuit of bioactivity, mimicking 
the action of evolutionary biosynthesis. 
ADS is a complementary method to other medicinal chemistry strategies for 
molecular discovery and could be integrated into existing drug discovery 
workflows. ADS has been demonstrated as an effective strategy for scaffold 
discovery,82 fragment growth,83 and expansion of SAR.123 Scaffold hopping 
is a key challenge in medicinal chemistry,124 and ADS has not yet been used 
in this context. ADS has also been used for molecular discovery against a 
limited range of targets with evolved small molecules binding sites 
(androgen receptor82,83 and the penicillin binding protein of Staphylococcus 
aureus123). Employing ADS against non-traditional drug targets would widen 
the number of ways ADS can be applied in medicinal chemistry settings. 
 
1.4 The p53/MDM2 Protein-Protein Interaction 
Murine double minute 2 (MDM2) is an oncoprotein that acts as a negative 
regulator of the p53 tumour suppressor, downregulating p53 and limiting the 
transcription of genes associated with tumour suppression.125–127 Under 
normal cellular conditions p53 is controlled through an autoregulatory 
feedback loop in which p53 activates MDM2 expression, and then MDM2 
supresses p53 action.128–133 MDM2 acts through binding of p53 at its 
transactivation domain, activation of cellular signalling pathways that lead to 
p53 nuclear export, and activation of a ubiquitin ligase that promotes p53 
degradation.134,135 
The first crystal structure of the p53/MDM2 complex characterised the 109-
residue N-terminal domain of MDM2 bound to the 15-residue transactivation 
domain of p53.136 It revealed that MDM2 has a deep apolar cleft, to which 
p53 binds as an amphipathic α-helix. The interface of this interaction relies 
on steric compatibility between the MDM2 peptide binding cleft and the 
apolar face of the p53 α-helix, referring to F19, W23 and L26 residues of p53 
(Figure 1.12). Alanine scanning studies, which systematically replaced each 
residue in the p53 transactivation domain with an alanine residue, 
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demonstrated that p53 analogues containing F19A or W23A substitutions 
lost all affinity towards MDM2.137,138 An L26A substitution also significantly 
reduced binding affinity towards MDM2 demonstrating that F19, W23 and 
L26 are key hot-spot residues for the p53/MDM2 protein-protein 
interaction.137 
 
Figure 1.12. Co-crystal structure of the p53 transactivation domain bound to 
Human-MDM2 (PDB: 1YCR).136 The sub-pockets targeted by p53 hotspot 
residues F19 (red), W23 (blue) and L26 (green) are shown. 
 
1.4.1 Inhibition of the p53/MDM2 Protein-Protein Interaction 
MDM2 is overexpressed in some cancers, therefore, targeting of the 
p53/MDM2 PPI and restoring the tumour suppressor functions of p53 has 
potential to be a mechanism for the development of new cancer 
therapeutics.127 Protein-protein interactions typically occur over a large 
surface area and binding interactions are usually driven by the interaction of 
hotspot residues of one protein with another.139–141 Inhibitor design for PPIs 
has traditionally been guided by structural and experimental analysis of an 
interaction and designs tend to mimic the hotspot residues that bind to a 
target protein.142–147 Inhibitors of the p53/MDM2 PPI usually target all three 
of the MDM2 sub-pockets for the p53 hotspot residues F19, W23 and L26. 
This allows a small molecule to mimic the p53 transactivation domain and 
act as an antagonist of MDM2 (Figure 1.13). Several small molecule 
antagonists of MDM2 have been progressed to clinical trials for solid 
tumours, lymphoma, neuroblastoma and other cancers (Figure 1.14).148 
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Figure 1.13. p53/Human-MDM2 PPI inhibitors, the sub-pockets targeted by 
p53 hotspot residues F19 (red), W23 (blue) and L26 (green) are shown. 
Panel A: Structure of MDM2 in complex with RG7112 (PDB: 4IPF) and 
overlay of RG7112 with p53 transactivation domain (PDB: 1YCR). Panel B: 
Examples of clinical candidates that target the p53/MDM2 PPI.149–152 
 
Clinical candidates that target the p53/MDM2 PPI employ many different 
approaches for orienting functional groups that can act as mimics of p53 hot-
spot residues.148 Some scaffolds, for example RG7388153 and AMG232,154 
use a small saturated ring system to project aromatic moieties into the W23 
and L26 sub-pockets. Alternatively, CGM097155 uses a 
tetrahydroisoquinoline core to interact with the L26 subpocket, and place an 
aromatic ring in the W23 subpocket, and then project an extended series of 
rings along the peptide binding cleft, similarly to the p53 peptide. RG7112149 
also uses this strategy with a methanesulfonylpropyl group to mimic the p53 
peptide (Figure 1.13, panel A). Other scaffolds, such as MI-77301150,151 and 
ATX-265,156 use a fused ring system to place an oxindole or isoindole ring in 
the W23 subpocket and orient substituents to mimic the alpha helix of p53. 
The diversity in approaches for building scaffolds mirrors the techniques that 
have been used to initiate drug discovery campaigns against the p53/MDM2 
- 23 - 
 
PPI and include virtual screening, structure-based drug discovery and 
HTS.148 
 
Figure 1.14. A selection of clinical molecules with known structure that have 
recruited, conducted, or reported results from clinical trials. RG7112 was 
discontinued after Phase 1b clinical trials in favour of RG7388, and the 
development of MI-77301 was also discontinued. Data obtained using 
Pharmaprojects, accessed 08/06/2020. Each highlighted molecule targets all 
three of the MDM2 sub-pockets. 
 
1.4.2 Dissection of the Nutlin RG7112 
The nutlin class of MDM2 antagonists are based on a cis-imidazoline core 
scaffold that allows the projection of the para-chlorophenyl moieties into the 
MDM2 sub-pockets targeted by p53 hotspot residues W23 and L26.149,157 
The anisole ring engages with the sub-pocket usually targeted by the p53 
residue F19 and is important to overall affinity. The sulfone cap installed 
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onto the piperidine ring of RG7112 extends outwards into the solvent face, 
engaging MDM2 residue G58 and the peptide binding cleft. 
The clinical candidate RG7112 was retrospectively deconstructed to assess 
whether a drug discovery campaign, in principle, could have been initiated 
by FBDD instead of HTS.158 Functional groups were systematically removed 
to give a range of fragment-sized molecules containing substructures of 
RG7112 (Figure 1.15). The fragments were then tested for MDM2 binding 
using NMR and SPR assays to identify the smallest molecules with 
detectable binding. The fragments containing mimics for two of the three 
hotspot residues, where one of the mimics targets the W23 sub-pocket, were 
found to bind to MDM2 (using biophysical methods) demonstrating that a hit 
molecule could have been discovered from a fragment-based approach. A 
limitation of this approach is that none of the fragments with detectable 
binding to MDM2 were commercially available, meaning a custom fragment 
library would have to be synthesised to target the p53/MDM2 PPI. 
 
Figure 1.15. Deconstruction of RG7112 (SPR Kd 0.22 µM) to determine key 
groups for binding to MDM2. 
 
1.5 Project Outline 
Activity-directed synthesis is a proven and powerful method for the discovery 
of ligands of protein targets with an evolved small molecule binding site. A 
key aim is to build upon the existing activity-directed framework and enable 
the discovery of ligands for more challenging biological targets, specifically a 
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target without an evolved small molecule binding site. Protein-protein 
interactions, specifically the p53/MDM2 PPI, offer an ideal platform for the 
validation of ADS as a discovery tool for more challenging protein targets. 
The medicinal chemistry of the p53/MDM2 PPI has been well explored but 
has not been targeted by integrated methods of synthesis and biological 
screening for small molecule discovery. Therefore, if ADS can facilitate the 
discovery of inhibitors containing novel chemotypes for inhibitors of the 
p53/MDM2 PPI then the approach will be showcased as an efficient tool for 
identifying new bioactive chemical space. 
 
1.5.1 Development of a Catalyst Map for Rhodium(II) Catalyst 
Selection in Activity-Directed Synthesis 
Intermolecular reactions between rhodium(II)-carbenes and multi-functional 
substrates, as part of an ADS experiment, offer opportunities for the 
identification of new small molecule scaffolds that can modulate protein 
function. This is because transformations catalysed by rhodium(II) 
complexes can be controlled through their corresponding ligand properties 
(Chapter 2, section 2.2). It was proposed that a knowledge base for 
interpreting the reactive space of rhodium(II)-carbenes would facilitate the 
selection of catalysts with complementary ligand properties and potentially 
facilitate unexpected reaction outcomes. This could allow for a better 
exploration of the reactive space within an ADS reaction array as each 
catalyst could direct reactions towards products in different areas of 
chemical space. 
To validate and exemplify a knowledge base approach for catalyst selection 
a database of computational parameters describing rhodium(II) complexes 
must be built and analysed. This would create a map for navigating catalyst 
properties and would aid in the selection of catalysts for ADS array design. 
The chemical relevance of the map must also be demonstrated to ensure 
correlation between the knowledge base and the observed reactivity in 
rhodium(II)-catalysed reactions. Ideally, the knowledge base will enable the 
optimisation of ADS reaction arrays by reducing the number of catalysts 
required to identify structurally distinct classes of ligands. Further detailed 
objectives for this work are described in Chapter 2. 
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1.5.2 Activity-Directed Discovery of Inhibitors of the p53/MDM2 
Protein-Protein Interaction 
MDM2 does not have an evolved small molecule binding site meaning the 
identification of fragment-sized ligands is extremely challenging. Fragment 
libraries often do not contain molecules suitable for screening against 
protein-protein interactions, and have not been used for drug discovery 
targeting the p53/MDM2 PPI. It was proposed that ADS could be used for 
experimental scaffold hopping to target pairs of MDM2 sub-pockets and 
discover structurally distinct inhibitors of this PPI. Reaction arrays would be 
designed to leverage mimics of p53 hot spot residues, and rhodium(II)-
carbene chemistry, to identify new scaffolds that target the p53/MDM2 PPI. 
Successful application of ADS in this context would demonstrate that the 
method can fill gaps in current discovery methods without extensive 
investment in chemical synthesis. This work, including detailed objectives, is 
described in Chapters 3 and 4. Chapter 3 focussed on the design and 
implementation of two ADS reaction arrays, and the isolation of products 
from the scale-up of hit crude reaction mixtures. Chapter 4 focussed on the 




- 27 - 
 
Chapter 2 
Construction of a Catalyst Map for Rhodium(II) Catalysts 
Metal-catalysed cross-coupling reactions, such as the Suzuki-Miyaura and 
Buchwald-Hartwig reactions, are frequently used to aid in the discovery of 
bioactive small molecules.65–69,159–161 More recent advances in metal-
catalysed carbon-carbon and carbon-heteroatom bond forming reactions 
have not yet been widely adopted by the medicinal chemistry community.159 
The slow uptake of these methods may stem from a poor understanding of 
substrate scope, a perceived low success rate or poor availability of newly 
reported catalysts.65,69,159  
Recent advances in high-throughput experimentation (HTE) have allowed 
hundreds, or thousands, of metal-catalysed reactions between densely 
functionalised pairs of substrates to be optimised and employed in molecular 
discovery workflows.73,75,80,81,114,115,162 The increased availability of these 
information rich datasets has also spurred along work deploying machine 
learning (ML) or statistical learning approaches to predict catalyst 
performance and gain mechanistic insights.73,74,163–166 These approaches 
rely on a combination of experimental data and computational 
parameterisation data.167,168 ML techniques often lead to the development of 
virtual screening platforms where computational parameters describe 
features of the substrate pairs,73,74,169,170 whereas statistical learning 
approaches can reveal mechanistic details by describing features of catalytic 
intermediates or transition states.164,171,172 Both approaches rely on 
experimental and computational data and can reveal trends that were not 
obvious from the standard processing of experimental data. Models that 
allow medicinal chemists to easily interpret the most important factors for 
successfully implementing new reactions could stimulate their uptake into 
molecular discovery workflows.168,173–176 
 
2.1  Computational Parameterisation for Catalysis 
The computational parameterisation of catalysts, or ligands, has been used 
in combination with experimental data to rationalise outcomes when 
developing new synthetic methodologies.176 An example of this approach is 
the development of a ligand-controlled stereospecific Pd-catalysed C–C 
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bond forming reaction.164 A suite of second-generation molecular descriptors 
for phosphine ligands was developed so that statistical learning methods 
could be applied to the optimisation and mechanistic rationalisation of the 
enantio-divergent Pd-catalysed coupling of alkylboron nucleophiles with aryl 
halides (Scheme 2.1).  
 
Scheme 2.1. Ligand-controlled enantio-divergent cross-coupling reactions 
using alkyl trifluoroborate nucleophiles. 
 
The authors noted that electron-withdrawing substituents on the aryl halide 
substrate lead to diminished stereo-retention, whereas electron-donating 
substituents maintained stereospecificity. This trend suggested that 
manipulating the electronics of the system could influence the mechanism of 
transmetallation and the product stereochemistry. A high-throughput screen 
of phosphine ligands was then initiated, and correlation analysis performed 
to identify computational parameters that captured factors important to the 
stereospecificity of transmetallation.  
The modelling workflow began by performing molecular mechanics (MM) 
conformational searches for each ligand to identify low-energy conformers, 
followed by geometry optimisation using DFT. Parameters were then 
extracted, and seven computational descriptors (four electronic and three 
steric) were responsive to the observed stereo-retention. Four additional 
descriptor subsets were also defined to capture the conformational dynamics 
of the ligands, including Boltzmann weighted average parameters. Two 
ligand classes were eventually identified from a virtual screen of phosphine 
ligands (Figure 2.1): biaryl phosphines bearing electron-withdrawing 
substituents that resulted in stereo-retention (L1); and bulky tri-alkyl 
phosphines that resulted in stereo-inversion (L2). 
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Figure 2.1. Experimental investigation for the ligand controlled stereospecific 
Pd-catalysed arylation of alkyl boron nucleophiles with a range of aryl 
chlorides. L1 gives stereo-retention and L2 gives stereo-inversion. 
 
Machine learning techniques have also been used for the prediction of highly 
selective chiral phosphoric acid catalysts for the acid-catalysed thiol addition 
to N-acylimines.166 The workflow began with an in silico library of over 800 
chiral phosphoric acid catalysts with two different scaffolds, one with fully 
aromatic binaphthyl backbones and another with a saturated ring in place of 
the fused binaphthyl aromatic ring. Approximately 400 synthetically 
accessible substituents were included at the 3,3’ positions of the two 
scaffolds to create the library of catalysts (Figure 2.2). The authors then 
invented a new descriptor called average steric occupancy (ASO) designed 
to capture steric information about an entire ensemble of conformers for a 
single molecule. ASO provides this information as a matrix of values that 
represents the weighted spatial occupancy of substituents for each 
conformer of the ligand, as a function of the energetic profile for the 
ensemble of conformers.  
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Figure 2.2. Design of computational workflow for the prediction of 
enantioselectivity for the phosphoric acid-catalysed formation N,S-acetals. 
 
A subset of ligands covering the broadest area of available chemical space 
within the in silico library was then selected using principal component 
analysis (PCA) combined with the Kennard-Stone algorithm. The authors 
attribute this sampling method to the ultimate success of the workflow as it 
guarantees uniform selection of catalysts across all regions of chemical 
space (including boundary cases and outliers). The ASO descriptor and 
catalyst training set (selected using PCA and Kennard-Stone) were then 
validated by creating a predictive model for the enantioselective formation of 
N,S-acetals. The authors were able to build high performance statistical 
models for: the prediction of catalyst performance against reactions forming 
new products; the prediction of new catalysts external to the model against 
known products; and prediction of new catalysts forming new products, both 
external to the model. Finally, a deep feed-forward neural network was able 
to accurately recapitulate the experimental selectivity data, successfully 
predicting the most selective reactions when half of the training data was 
omitted. These results demonstrate the power of chemically relevant 
molecular descriptors when applied to the virtual screening of catalysts. 
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Computational parameterisation of rhodium(II)-carbenes has also been 
undertaken to investigate the Rh2esp2-catalysed intermolecular C–H 
insertion of β-carbonyl ester carbenes.177 The model is based upon 
parameterisation of a β-carbonyl diazo ester substrate and the resulting 
carbene formed with Rh2esp2. The authors quantified steric effects related to 
the diazo substituents by calculating the 1,5-interaction between the diazo 
substituent and the ester carbonyl (captured in terms of an r value) in the 
Rh2esp2 carbene complex. Electronic effects were also quantified by 
calculating the proton affinity (PA) of the β-carbonyl. Analysis of the 
calculations formed a potential energy surface allowing the relative enthalpy 
(ΔH kcal mol-1) to be mapped onto the r and PA values for each carbene 
complex. The authors noted that regions of large ΔH values correlated with 
the formation of side-products through the Wolff rearrangement. This 
inspired the design of a series of β-carbonyl diazo ester substrates that 
could undergo alkyl C–H insertion reactions in moderate yields (Figure 2.3). 
The experimental results showed that increasing the size of the β-carbonyl 
substituent leads to a decreased yield of the C–H insertion product. 
 
Figure 2.3. Parameters for β-carbonyl diazo esters and observed trends with 
experimental data. 
 
The Bristol Ligand Knowledge Base (LKB)178–182 was based on a wide range 
of computational descriptors for monodentate P-donor ligands (348 ligands) 
and has been expanded to include bidentate ligands. The monodentate LKB 
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uses a set of 28 electronic and steric descriptors that were derived from DFT 
optimised geometries of gold, platinum and palladium complexes. The 
descriptors included frontier molecular orbital energies, proton affinities, 
adduct formation, and metal coordination.179 The knowledge base was then 
used to build a PCA model, and thereby create a map of chemical space 
from which underlying chemical features could be elucidated for rational 
phosphorus(III) ligand design (Figure 2.4).179,180 
PCA is a method for revealing a simplified structure from a highly 
dimensional dataset by extracting relevant information that is often hidden in 
higher dimensional space.183 PCA achieves dimension reduction by setting 
the goal to compute the most meaningful basis to represent a dataset. PCA 
is a linear transformation, and it simplifies the number of possible basis sets 
by assuming that the data is continuous and is, therefore, restricted to re-
expressing the data as a linear combination of its basis vectors (i.e. as 
principal components).183,184 PCA retains the integrity of the data, in this 
case the chemical descriptors, as the underlying data is not manipulated. In 
the LKB catalysts with similar properties will be near neighbours in the PCA 
map, while dissimilar catalysts will be further apart. The benefit of PCA is 
that the resulting model is representative of the original chemical 
observations as PCA represents the variance between data points, not the 
data points themselves, so the analysis does not project absolute values. 
 
Figure 2.4. Bristol LKB PCA map for monodentate P-donor ligands.180 
 
The Bristol LKB effectively captured ligand similarities and differences by 
sampling a wide range of chemical space. The LKB included 117 
commercially available ligands meaning the model could be used for the 
design of experiments and reaction optimisation.180 The PCA model also 
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captured some trends in the experimental data for a palladium-catalysed 
amination reaction and some of the descriptors were used to build a multi-
variate predictive model for product yield with good accuracy. A model to 
predict bond dissociation energies was also built using descriptors from the 
knowledge base which would allow for optimisation of a catalytic process 
through rational ligand design. The LKB, and catalyst map, has proved to be 
a useful tool for the optimisation of palladium-catalysed cross-coupling 
reactions and allows for the rational exploration of catalyst space.167,184 
 
2.2 An Overview of Rhodium(II)-Carbene Chemistry 
Rhodium(II)-catalysed carbenoid chemistry provides access to a wide range 
of transformations including selective insertion into C–H bonds, and insertion 
into O–H, N–H and S–H bonds, cyclopropanation and ylide formation.185–190 
The selectivity of many rhodium(II)-catalysed transformations can be tuned 
by considered selection of both the functional groups that decorate a diazo 
substrate and the catalyst.191–195 Diazo precursors, for the formation of 
rhodium(II)-carbenes, can be separated into two categories: those with only 
electron withdrawing substituents (acceptor and acceptor/acceptor); and 
those with both electron donating and withdrawing substituents 
(donor/acceptor) (Scheme 2.2).187 
 
Scheme 2.2. An overview of a catalytic cycle for C–H insertion185 and 
common substituents incorporated into acceptor, acceptor/acceptor, and 
donor/acceptor diazo compounds. 
 
Acceptor and acceptor/acceptor carbenes are highly reactive and often 
undergo intramolecular transformations, preferentially forming five-
membered rings due to their electron withdrawing nature and inability to 
stabilise the electrophilic carbene centre – although the formation of four and 
six membered rings are also common.190–192 Donor/acceptor substituted 
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carbenes are less reactive than acceptor and acceptor/acceptor carbenes 
due to their greater ability to stabilise the electrophilic carbene 
centre.185,187,196 This allows donor/acceptor carbenes to undergo the site-
selective intermolecular C–H functionalisation of complex molecules at 
primary, secondary, or tertiary C–H bonds.185,194,195,197,198 Selective C–H 
insertions are achieved through steric and electronic control of the carbene 
and substrate, not through site-directing functional groups which is common 
for other C–H activation chemistries.199 Substrates that feature sites able to 
stabilise a build-up of positive charge react significantly faster than those 
unable to do so, and sites adjacent to a heteroatom are also more 
reactive.185 However, the reaction rate can be negatively impacted if the site 
is sterically hindered. For example, tertiary C–H bonds have slower reaction 
rates than secondary C–H bonds despite their ability to stabilise positive 
charge more effectively.185,197,198 As such, electronic effects are not the sole 
contributions to consider and a much more complicated analysis of 
electronic and steric effects for both substrate and catalyst are required to 
determine reactivity (Figure 2.5). 
 
Figure 2.5. Controlling factors for increasing reactivity controlled by 
electronic and steric effects in reactions with donor/acceptor diazo 
compounds and Rh2(S-DOSP)4.185,197 Relative rates refer to the rate of C–H 
insertion into a cyclohexyl C–H bond, normalised to one. 
 
The ligand controlled nature of rhodium(II) catalysts allows for high levels of 
chemo-, regio-, and stereo-selectivity in a variety of contexts.200 For 
example, donor atom type and fluorination of the bidentate ligand backbone 
leads to switchable chemoselectivity in a substrate with multiple reactive 
sites (Scheme 2.3).191,192 Intermolecular C–H insertion reactions can also be 
tuned through ligand effects to give highly regioselective insertion into 
primary or tertiary C–H centres (Scheme 2.3).198 These catalysts employ 
large aliphatic ligands that intrude into the co-ordination sphere of the 
rhodium(II) core and give control over unactivated and unfunctionalized 
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substrates. This reactivity is challenging to analyse and predictive modelling 
of this reaction170,201 has resorted to substrate observed parameters due to 
the size of the catalysts and the complexity of the ligand effects.  
 
Scheme 2.3. Control over two alternative reaction pathways by Rh2pfb4 and 
Rh2cap4,191 and ligand controlled regio- and stereoselective C–H insertion by 
Rh2(R-TCPTAD)4 and Rh2(S-tris(p-tBuC6H4)TPCP)4.198 (r.r. regioisomer 
ratio). 
 
The variety of reactivity of rhodium(II)-carbenes makes accurate mechanistic 
studies challenging. In the above examples, modification of the ligand 
backbone affects the selectivity of the proceeding reaction when multiple 
competitive pathways are accessible. A further complication is that 
rhodium(II)-carbenes can undergo transition state bifurcations (Scheme 
2.4).202 If the products of the transition state bifurcation can then react to 
form the desired product then any modelling effort is only relevant to the 
specific modelled case. Catalyst parameterisation approaches have used 
calculated steric and electronic parameters for substrates,201 or a 
surrogate,170 or structural analysis of the relationship between the catalyst 
and substrate.177 For these approaches, careful parameter design enabled 
the development of predictive models for specific reactions, but are not 
generalisable for other rhodium(II)-catalysed reactions. 
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Scheme 2.4. Transition state bifurcations for the intramolecular processes of 
rhodium(II) carbenes. Each rhodium complex is bound to four bidentate 
ligands, however three are omitted for clarity. 
 
2.3 Design of a Knowledge Base for Rhodium(II) Catalysts 
Knowledge bases, such as the Bristol LKB, are databases of parameters, or 
descriptors, that describe the steric and electronic properties of interesting 
organometallic complexes.167,184 Parameters are usually captured from DFT-
optimised geometries which allows for the investigation of many more 
complexes than would be experimentally plausible. Development of a 
knowledge base for rhodium(II) catalysts could enable the inclusion of 
underutilised carbon-carbon and carbon-heteroatom bond forming reactions 
into molecular discovery workflows. The rhodium(II) knowledge base was 
built in collaboration with Dr Natalie Fey at the University of Bristol and 
employs similar techniques as the Bristol LKB for catalyst parameterisation. 
The parameters used to construct the catalyst knowledge base were 
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designed to capture chemically relevant and mechanistically independent 
information about rhodium(II) complexes. A range of structural and electronic 
parameters were captured for the rhodium(II) complex (1) and the 
corresponding rhodium(II)-carbene complex (2) generated from a 
symmetrical α-diazo malonamide precursor (Scheme 2.5). 
 
Scheme 2.5. Dirhodium(II) complexes modelled using standard DFT 
methods (B3LYP/6-31G(d) and MWB28 on rhodium atoms or BP86/6-
31G(d) and MWB28 on rhodium atoms). 
 
Initial calculations that seeded the knowledge base were conducted using 
three model complexes Rh2OAc4 (3a), Rh2cap4 (4a) and Rh2pfb4 (4h) 
(Figure 2.6). The complexes were chosen for test calculations due to the 
range of different substituents on each respective ligand backbone, and for 
the ligand donor atom types (carboxylate or carboxamidate). The standard 
B3LYP203–206 density functional with the DZP basis set 6-31G(d)207,208 was 
used on all atoms apart from rhodium where the Stuttgart/Dresden effective 
core potential MWB28209 was used. Acetonitrile was used as an ancillary 
ligand adduct for all three complexes to add additional parameters, such as 
axial ligand dissociation energies, to the initial survey of responsive 
parameters. Three types of complexes with ancillary ligands were selected 
for initial evaluation: the bi-axially coordinated rhodium complex furnished 
with two acetonitrile ligands; the mono-axially coordinated rhodium complex 
with one acetonitrile ligand; and the bi-axially coordinated rhodium complex 
bearing one acetonitrile ligand and one carbene ligand. For the 
carboxamidate complex 4a, the acetonitrile ligand was found to have a 
destabilising effect (see Figure 2.6, panel B2 and C2), in line with 
experimentally observed findings.210 Acetonitrile adducts were removed from 
all further calculations and analysis because carboxamidates are a major 
class of ligands for rhodium(II) catalysts and are essential for inclusion in an 
effective database.211,212 
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Figure 2.6. Example acetonitrile adducts calculated at B3LYP/6-
31G(d)/MWB28 level of theory. A1: Complex 3a and 2 acetonitrile ligands. 
C1: Complex 3a with a carbene ligand and one acetonitrile ligand. A2: 
Complex 4a with one acetonitrile ligands. B2: Complex 4a with one 
acetonitrile ligand. C2: Complex 4a with a carbene ligand and one 
acetonitrile ligand. A3: Complex 3h with two acetonitrile ligands. B3: 
Complex 3h with one acetonitrile ligand. C3: Complex 3h with a carbene 
ligand and one acetonitrile ligand. Complex 3a with one acetonitrile ligand 
could not be converged and was omitted. 
 
Moving to the BP86213,214 density functional using the 6-31G(d) DZP basis 
set and MWB28 core potential allowed for the rapid generation of 96 
converged rhodium(II) complexes. The BP86 function may produce slight 
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over-binding effects but is computationally robust and allowed for expansion 
of the scope from the three initial complexes 3a, 4a and 3h to 48 diverse 
complexes (Figure 2.7). A conformer search, using molecular mechanics, 
conducted by Dr Natalie Fey at the University of Bristol, found that the DFT 
optimised geometries accurately represented each complex. 
Figure 2.7. All 48 ligands used to generate the knowledge base. Ligands are 
drawn with the coordinating atoms at the bottom and the labels describe the 
rhodium(II) complex bound to these ligands. Catalysts that were purchasable 
commercially are highlighted (circle) or that were later experimentally tested 
(square). 
 
The knowledgebase contains a wide range of carboxylate (O,O) and 
carboxamidate (N,O) ligands that were selected, or designed, to give an 
even distribution of empirically predictable electronic and steric features 
such as donor atom type, substitution patterns, steric bulk and synthetic 
feasibility. The ability to select and synthesise any given catalyst is an 
important feature for this knowledgebase to have wider applications in the 
activity-directed discovery of molecules because many rhodium(II) catalysts 
are not commercially available and available sets offer poor catalytic 
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diversity. Complexes bearing ligands with features including heteroatom 
substitution (e.g. 3k, 3l, 4c, 4h, 4k, 4n and 4q), fluorination (3e-3i, 4t-4u and 
4w-4x) and unsaturation (4i, 4l, 4o and 4r) were included to probe electronic 
effects propagated through the ligand backbone. Carboxamidate ligands 
with different cyclic ring sizes were also designed to investigate structural 
changes to the rhodium(II) core (4a-4x). Finally, several ligands bearing 
large ligand substituents that can control the nearby environment of the 
metal coordination sphere (e.g. 3r-3u and 4e, 4m, 4p and 4s) were included 
to complete the reported scope of ligand effects.198 
A wide range of descriptors were then captured, from DFT-optimised 
geometries, to investigate the range of possible electronic and steric effects 
arising from different ligand types (Figure 2.8 and Table 2.1). The features 
captured by each descriptor were classified into three categories: electronic 
(HOMO, 1, LUMO, 1, Q Rh, Q(L, mean), Q(Donor Atoms, mean) and 
ΔE(FMO)); electronic and steric (r(Rh-Rh), ∡(Rh-Rh-L), ∡(O-C-X), ∡(C-C-C), 
r(αC-R1), r(Rh-C) and ΔE(coord)); and steric (He8 and |wV|). The descriptor 
He8180 approximates the steric influence of a ligands substituents by 
modelling the approach of a reactant to the complex with a ring of eight 
Helium atoms. |wV|215,216 measures the steric bulk of a ligand while 
accounting for the proximity of the ligand to an important atom, in this case 
the rhodium atom forming the carbon bond. Both descriptors were calculated 
using the optimised geometry of the corresponding carbene complex 2 with 
the carbene ligand removed and aligned with the rhodium-rhodium bond.  
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Figure 2.8. Examples of calculated structural, steric and electronic 
parameters used in construction of the knowledgebase. For He8 the ring of 
Helium atoms was positioned 1.9 Å from the Rh atom forming the carbene 
bond, and |wV| was aligned along the vector of the Rh-Rh bond. 
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Table 2.1. Computational parameters considered for inclusion in the 
knowledge base. 
Descriptor Derivation Diagram Median Value Range 
r(Rh-Rh) Rh-Rh bond length (Å), 1 and 2 
 
2.41 Å 0.09 Å 
r(Rh-L) 
Average Rh-Ligand bond length 
(Å), 1 and 2 
 
2.06 Å 0.02 Å 
∡(Rh-Rh-L) 




∡(O-C-X) Average ligand bite angle, 1, 2 
 
125.99 7.34 









Average αC-Ligand Backbone (R1) 
bond length (Å), 1 
 
1.52 Å 0.19 Å 
HOMO, 1 
Energy of HOMO for complex 1 
(a.u.) 
Figure 2.8 -0.15 a.u. 0.12 a.u. 
LUMO, 1 
Energy of LUMO for complex 1 
(a.u.) 
Figure 2.8 -0.13 a.u. 0.10 a.u. 
Q Rh, 1 Charge on Rhodium atoms - 0.66 0.30 




Mean charge on ligand donor 
atoms 
- -4.27 1.30 
ΔE(FMO), 1 
ΔE between HOMO and LUMO 
(a.u.) 
- 0.03 a.u. 0.03 a.u. 
|wV| Distance-Weighted Volume,19 2 











Interaction energy for 2 and ring of 
8 Helium atoms16 (kcal mol-1) 
He8 = E(He8.[Rh-
Rh])) – E(He8) – 
E([Rh-Rh])) 




Energy for diazo precursor to form 
the carbene complex (kcal mol-1), 2 
ΔE(coord) = (E1 + 
EDiazo) – (E2 + 
EN2) 
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Correlation analysis was then performed on the knowledge base to evaluate 
the performance of the chosen descriptors and to contextualise the 
information captured (Figure 2.9). Strong correlations between r(Rh-Rh) and 
∡(Rh-Rh-L), with R values between 0.8 and 1.0, reflect the rigidity of the 
paddlewheel Rh2L4 scaffold. Changes to the Rh-donor atom distances, 
either through electronic effects or steric clashes, affect the Rh-Rh bonding 
along with the geometry of the ligand coordination. Trends such as 
increasing r(Rh-Rh) between the axially unbound complexes and carbene 
complexes were universal across donor atom type (0.079 Å increase on 
average for O,O ligands and 0.072 Å for N,O ligands). However, N,O ligands 
with cyclic backbones have shorter Rh-Rh bonds on average (2.404 Å and 
2.387 Å for unbound O,O/N,O ligands respectively), in part, due to the 
constrained geometry of the amide functional group when part of a cyclic 
ring (e.g. ∡(O-C-X) 126.7 o for O,O ligands and 125.5 o for N,O ligands). 
A different form of steric effect, described as the extent to which the ligand 
substituents intrude into the site of reaction, was captured by |wV| and was 
important for controlling the geometry of the rhodium(II)-carbene and the 
subsequent angle of attack of a reactant. This steric effect was likely 
responsible for control of the regio- and stereo-selectivity of each 
catalyst.198,211,212 Catalysts 3r-3u and 4d, 4g, 4m and 4s have the largest 
|wV| values due to ligand projection over the axial face. Weak correlations 
between |wV| and all other parameters confirms that this was a unique and 
purely steric descriptor, with R values ranging between 0 and 0.4. Electronic 
effects are also important for regio- and chemo-selectivity.190–193 Modulating 
the Lewis acidity of a catalyst can bias the outcome of a transformation 
where multiple competing pathways occur and was an important feature to 
capture.191 Moderate correlations between purely electronic parameters and 
those that capture a mixture of electronic and steric effects, such as Q(L, 
mean) and r(Rh-Rh) (R 0.5 – 0.6), demonstrates that steric effects do not 
dominate the knowledge base. 
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Figure 2.9. Calculated Pearson R correlation coefficient map 
 
2.4 Principal Component Analysis for the Construction of a 
Catalyst Map 
A model for interpreting the knowledge base using principal component 
analysis (PCA) was then implemented. A relevant subset of descriptors must 
be selected for use in principal component analysis to ensure the 
subsequent model can be reliably interpreted and deconvoluted. This means 
that the model must be generated from descriptors that can be related to 
chemical features important to the properties of the catalyst. Inclusion of 
redundant descriptors will make the PCA model harder to interpret as each 
principal component will not contribute as clearly to clustering.  
To simplify the number of PCA plots that need to be analysed manually the 
best solution for each discrete number of descriptors (n) was calculated 
(Figure 2.10). PCA results can be ranked by the total variance captured and 
by the mean squared error of projection, which is the amount of information 
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lost through PCA. The top solution for n descriptors was selected by the 
highest percentage variance captured (for solutions, see Table 2.2). For 
qualitative and unsupervised analyses, such as PCA, there is often no 
correct number of parameters for a model, instead models must also be 
considered in terms of their descriptor loading and interpretability. Models 
that give even descriptor loadings are favoured over those that bias results 
towards a fewer number of descriptors, as they are often better at 
highlighting complex relationships in the original data. 
 
Figure 2.10. Percentage variance and mean squared error of projection for 
PCA solutions of n descriptors. 
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4 r(Rh-Rh) 2, HOMO, 1, LUMO, 1, ΔE(FMO) 1.82x10-31 99.9 
5 r(Rh-Rh) 1, r(Rh-Rh) 2, HOMO, 1, LUMO, 1, ΔE(FMO) 0.0049 99.5 
6 
r(Rh-Rh) 1, r(Rh-Rh) 2, HOMO, 1, LUMO, 1, Q Rh, 1, 
Q(L, mean), 1 
0.014 98.6 
7 
r(Rh-Rh) 1, ∡(O-C-X), r(Rh-Rh) 2, HOMO, 1, LUMO, 1, 
Q Rh, Q(L, mean), 1 
0.0234 97.7 
8 
r(Rh-Rh) 1, ∡(O-C-X), r(Rh-Rh) 2, Rh-L Angle Carbene, 
HOMO, 1, LUMO, 1, Q Rh, 1, Q(L, mean), 1 
0.038 96.2 
9 
r(Rh-Rh) 1, ∡(Rh-Rh-L) 1, r(Rh-Rh) 2, ∡(Rh-Rh-L) 2, 
HOMO, 1, LUMO, 1, ΔE(FMO), Q Rh, 1, Q(L, mean), 1 
0.0516 94.8 
10 
r(Rh-Rh) 1, ∡(Rh-Rh-L) 1, ∡(O-C-X), r(Rh-Rh) 2, ∡(Rh-




r(Rh-Rh) 1, r(Rh-Rh) 2, ∡(Rh-Rh-L) 2, r(Rh-C), ∡(C-C-
C), ΔE(coord), He8 Ring Interaction, HOMO, 1, LUMO, 
1, Q Rh, 1, Q(L, mean), 1 
0.0846 91.5 
12 
r(Rh-Rh) 1, ∡(O-C-X), r(Rh-Rh) 2, ∡(Rh-Rh-L) 2, ∡(C-C-
C), ΔE(coord), He8 Ring Interaction, HOMO, 1, LUMO, 
1, ΔE(FMO), Q Rh, 1, Q(L, mean), 1 
0.0993 90.1 
13 
r(Rh-Rh) 1, ∡(Rh-Rh-L) 1, ∡(O-C-X), r(Rh-Rh) 2, ∡(Rh-
Rh-L) 2, ∡(C-C-C), ΔE(coord), He8 Ring Interaction, 
HOMO, 1, LUMO, 1, ΔE(FMO), Q Rh, 1, Q(L, mean), 1 
0.1132 88.7 
14 
r(Rh-Rh) 1, ∡(Rh-Rh-L) 1, ∡(Rh-Rh-L) 1, ∡(O-C-X), 
r(Rh-Rh) 2, r(Rh-L) 2, ∡(Rh-Rh-L) 2, ∡(C-C-C), 
ΔE(coord), He8 Ring Interaction, HOMO,1 , ΔE(FMO), Q 
Rh, 1, Q(L, mean), 1 
0.1253 87.4 
15 
r(Rh-Rh) 1, r(Rh-L) 1, ∡(Rh-Rh-L) 1, ∡(O-C-X), r(Rh-Rh) 
2, r(Rh-L) 2, ∡(Rh-Rh-L) 2, ∡(C-C-C), ΔE(coord), He8 
Ring Interaction, HOMO, 1, LUMO, 1, ΔE(FMO), Q Rh, 
1, Q(L, mean), 1 
0.1373 86.3 
16 
r(Rh-Rh) 1, r(Rh-L) 1, ∡(Rh-Rh-L) 1, ∡(O-C-X), r(Rh-Rh) 
2, r(Rh-L) 2, ∡(Rh-Rh-L) 2, r(Rh-C), ∡(C-C-C), 
ΔE(coord), He8 Ring Interaction, HOMO, 1, LUMO, 1, 
ΔE(FMO), Q Rh, 1, Q(L, mean), 1 
0.1537 84.6 
17 
r(Rh-Rh) 1, ∡(Rh-L) 1, ∡(Rh-Rh-L) 1, ∡(O-C-X), r(Rh-
Rh) 2, r(Rh-L) 2, ∡(Rh-Rh-L) 2, r(Rh-C), ∡(C-C-C), 
ΔE(coord), He8 Ring Interaction, HOMO, 1, LUMO, 1, 




r(Rh-Rh) 1, r(Rh-L) 1, ∡(Rh-Rh-L) 1, ∡(O-C-X), r(αC-R1) 
, r(Rh-Rh) 2, r(Rh-L) 2, ∡(Rh-Rh-L) 2, r(Rh-C), ∡(C-C-
C), ΔE(coord), He8 Ring Interaction, HOMO, 1, LUMO, 
1, ΔE(FMO), Q Rh, 1, Q Ligand Donor Atoms, Q(L, 
mean), 1 
0.203 79.7 
19 All available descriptors 0.2328 76.7 
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As more descriptors were added to the PCA model, the percentage of 
variance captured decreased, and the mean squared error of projection 
increased. This was because the solutions with fewer descriptors have less 
information to capture and can effectively be represented with only three 
principal components. While a PCA model that captures 100% of the 
available information appears useful from a metric point of view, it fails to 
consider the quality of the clustering in the model or the relevance of the 
captured information. Therefore, the PCA plots were evaluated for their 
individual interpretability in the context of rhodium(II) chemistry and an 
optimal model was selected. Analysis of the first two principal components 
(PC1 and PC2) (Figure 2.11) shows that for all combinations of n descriptors 
catalysts were separated by their ligand donor atoms along PC1. Further 
separation of catalyst sub-types begins along PC1 once 11 descriptors were 
utilised, highlighting complexes 4y, 4z and 4aa (acyclic N,O ligands). PC2 
clusters the most electron-withdrawing carboxylate ligands 3e, 3f, 3h and 3i 
immediately, but does not delineate complexes 3g, 3o or 3p from the bulk 
carboxylate cluster again until 11 descriptors were used. 
Analysis of the first and third principal components (PC1 and PC3) (Figure 
2.12) shows that full separation of complexes by ligand donor atoms did not 
fully occur until 6 descriptors were used, allowing the formation of discrete 
clusters with three principal components. Complexes 4y, 4z and 4aa were 
fully separated from the bulk carboxamidate cluster with 11 descriptors, and 
the 13 descriptor model highlighted carboxamidate complexes with sterically 
demanding substituents (4d, 4g, 4m and 4s) in a new cluster with PC3. For 
both series of plots (PC1/PC2 and PC1/PC3), the clustering boundaries 
become less clear when all the available descriptors were added to the PCA 
model, which was consistent with lower amounts of captured variance and 
lower descriptor loadings. While the PCA models with greater numbers of 
descriptors are not bad, models using between 11 and 15 descriptors have 
the most well-defined clusters and are, therefore, easiest to interpret. 
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Figure 2.11. PC1/PC2 plots for the highest performing solutions with n 
descriptors. 
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Figure 2.12. PC1/PC2 plots for the highest performing solutions with n 
descriptors. 
- 50 - 
 
For solutions using 11 to 15 descriptors most of the main catalyst groups 
were captured by discrete clusters (O,O vs. N,O, EDG-substituents, EWG-
substituents, acyclic N,O ligands and sterically demanding N,O ligands). 
However, the sterically demanding carboxylate complexes were not 
represented by a distinct cluster in any of these models. An extra descriptor, 
|wV|, was added to the 13 descriptor PCA model to create a new 14 
descriptor solution (Figure 2.13) that formed a new cluster for the bulky O,O 
ligands (3d, 3r, 3s, 3t and 3u). Comparative models with 11, 12, 13, 14 and 
15 descriptors were also generated, but the 14-descriptor model gave the 
best clustering performance and was chosen as the final model. 
 
Figure 2.13. Optimal solution for the PCA of Rhodium(II) catalysts capturing 
85.5% total variance. PC1/PC2/PC3 explained variance: 53.6, 21.7 and 
10.5% respectively. Mean squared error loss from projection: 0.142. The 
corresponding descriptor loading plots for the PC1/PC2 and PC1/PC3 PCA 
plots are also shown. 
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The final PCA model gives high descriptor loading performance implying that 
there was minimal bias towards a specific subset of ligand features (Table 
2.3). Analysis of the eigenvectors for the 14 descriptors demonstrates that 
each has unique contributions to the observed clustering. The separation of 
complexes along PC1 by ligand donor atom type was driven by the 
electronic descriptors Q Rh and ΔE(FMO), and the combined electronic and 
steric descriptor ΔE(coord) for carboxylate complexes. Carboxamidate 
clustering along PC1 was driven by Q(L, mean) and the steric descriptor He8 
highlighting the larger ligand backbones. The increased fluorination of the 
carboxylate ligands, leading to decreased PC2 values, was represented by a 
mixture of electronic and steric descriptors indicating that PC2 captures the 
Lewis acidity of the complexes. PC2 also captures the ring size of the 
carboxamidate ligands with 5- and 6/7-membered ligands separated into 
distinct clusters. PC3 captures predominantly steric information, creating 
new clusters for carboxylate and carboxamidate complexes with sterically 
demanding ligand substituents (3d and 3r-3u, and 4d, 4g, 4m and 4s) and a 
separate cluster for acyclic carboxamidates (4y-4aa). 









% contribution to variance 53.6 21.7 10.5 
r(Rh-Rh), 1 -0.2955 -0.3171 0.0404 
∡(Rh-L), 1 0.2306 0.3339 0.1460 
∡(C=O-αC-X), 1 0.1023 -0.4817 -0.2274 
r(Rh-Rh) 2 -0.2516 -0.3947 0.0341 
∡(Rh-L) 2 0.2697 0.3292 0.0003 
∡(N-C-N) 0.2978 -0.1411 0.2007 
ΔE(coord) 0.2866 -0.1394 0.3720 
He8 Ring Interaction -0.3294 0.0445 -0.1815 
HOMO, 1 -0.2854 0.3033 0.2599 
LUMO, 1 -0.2287 0.3498 0.0652 
ΔE(FMO) 0.2793 -0.0685 -0.0900 
Q Rh, 1 0.3278 0.0686 -0.3680 
Q(L, mean), 1 -0.3260 0.1223 -0.2720 
|wV| -0.0901 0.1084 -0.6506 
 
Analysis of the PCA scores and loadings plots demonstrates that many of 
the descriptors capture information on only a few features of each catalyst 
subset, creating an underlying trend that drives the distinct clustering 
observed. For example, the large, aliphatic carboxylate ligands were 
separated from the largest cluster of carboxylate ligands by greater |wV| and 
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He8 loadings values on PC3 (Figure 2.13). Complexes bearing carboxylate 
ligands were separated from carboxamidate ligands by the descriptor r(Rh-
Rh), and 5- and 6/7- membered cyclic N,O ligands were separated by ∡(Rh-
Rh-L) and He8. These contributions illustrate the usefulness of PCA to 
highlight complex chemical relationships, from appropriate chemical 
descriptors, where many complexes have remarkably similar values for 
many other parameters.  
A separate PCA decomposition was also conducted for the O,O and N,O 
sub-classes of rhodium(II) complexes to investigate the variation in catalyst 
properties for each ligand donor atom type. PCA of the carboxylate sub-
class (Figure 2.14) separates complexes by electronic properties along PC1, 
with complexes bound to electron-withdrawing ligands (3e – 3i) between 
PC1: 4-6, and by steric properties along PC2 with the complexes bound to 
sterically demanding ligands (3d,  3r – 3u) between PC2: 1-4. These trends 
were similar to the full PCA model but with greater distance between each 
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Figure 2.14. PCA plot of O,O dirhodium(II) catalysts capturing 87.4% total 
variance. PC1/PC2/PC3 explained variance: 66.6, 13.8 and 7.0% 
respectively. Mean squared error loss from projection: 0.126. 
 
PCA of the carboxamidate sub-class (Figure 2.15) separates complexes 
based on the cyclic backbone ring size (5 or 6/7- membered rings) and 
electronic properties along PC1. For example, 4t, a 5-membered lactam ring 
substituted with fluorine atoms, was at the peak of the right-hand cluster 
(PC1: 3) and the urea 4q, an unsubstituted 5-membered lactam ring, was on 
the opposing edge (PC1: 0). This trend was similar in the left-hand cluster 
with 4u, a 6-membered lactam ring substituted with fluorine atoms, located 
at PC1: -1 and the catalyst on the opposing edge was the unsubstituted 6-
membered lactam 4c. PC2 separates the N,O complexes by steric factors 
with the acyclic ligands located at the top of the plot (PC2: 2-6) and the 
sterically demanding complexes at the bottom (PC2: -2 - -4). Analysis of the 
carboxamidate cluster individually gives greater resolution of electronic 
ligand effects, when compared to the full model, due to the lower density of 
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clustering, and shows that the Lewis acidity of carboxamidate complexes 
was also captured by the model. 
 
Figure 2.15. PCA plot of N,O dirhodium(II) catalysts capturing 80.3% total 
variance. PC1/PC2/PC3 explained variance: 39.5, 28.7 and 12.1% 
respectively. Mean squared error loss from projection: 0.196. 
 
In summary, the PCA model generated from the catalyst knowledge base 
offers an interpretable representation of the chemical space covered by a 
broad range of rhodium(II) complexes. Key ligand features drive clustering 
and give a map that delineates catalyst properties into a continuum of 
effects, such as steric hinderance and Lewis acidity. Principal component 
analysis of the carboxylate and carboxamidate complexes separately 
showed that there is considerable diversity within each class and that the 
final model captures a huge range of catalyst diversity. 
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2.5 Correlation of the Catalyst Map with Experimental 
Outcomes 
Creating computational models that interpret experimental data can provide 
useful information for the design of experiments and could promote a 
broader adoption of metal-catalysed reactions into medicinal chemistry 
workflows.73,114,159,167,184 Four different model reactions, representative of 
rhodium(II)-catalysed transformations, were investigated experimentally to 
test whether the principal components derived from the knowledgebase 
correlate with observed reactivity. A C–H insertion involving tetrahydrofuran 
(7),197 a cyclopropanation of styrene (8),217,218 and an O–H insertion 
involving phenol (9)219 using a donor/acceptor diazo ester (5), and a 
cyclopropanation of styrene (10) using an acceptor/acceptor diazo ester (6) 
(Scheme 2.6). Catalysts were selected according to their actual availability, 
and structural and electronic diversity where possible. 
 
Scheme 2.6. The four reactions selected for comparison with the PCA 
model. 
 
The reactions were performed in a high-throughput, micro-scale, format in 
96-position plates equipped with 700 µL glass vials and stirring fleas. Each 
vial contained 20 µmol of a diazo compound (5 or 6), 200 µmol substrate 
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(THF, styrene or phenol) and 1 mol% catalyst. After 24 hours, the product 
mixtures were analysed by quantitative UPLC (Table 2.4).  
Table 2.4. Observed yields and standard deviations for the screened 
catalysts in all four transformations.  





Catalyst Yield % Yield % dr ratioa Yield % Yield % 
Rh2OAc4, 3a 44 ± 5 38 ± 4 98:2 30 ± 5 d 22 ± 2 
Rh2piv4, 3b 51 ± 11 38 ± 5 96:4 38 ± 1 d 41 ± 2 
Rh2oct4, 3c 51 ± 1 (52 c) 49 ± 1 98:2 36 ± 9 d 35 ± 2 
Rh2tfa4, 3e 45 ± 3 80 ± 2 (70 c) 95:5 42 ± 10 d 36 ± 7 
Rh2pfb4, 3h 44 ± 2 75 ± 4 95:5 49 ± 3 d (57 c) 38 ± 1 
Rh2esp2, 3q 50 ± 4 61 ± 6 96:4 39 ± 1 d 39 ± 4 
Rh2S-DOSP4, 3r 53 ± 7 56 ± 8 97:3 27 ± 12 d 32 ± 2 
Rh2S-tertPTTL4, 3u 56 ± 12 53 ± 7 97:3 40 ± 11 d 42 ± 4 
Rh2S-PTAD4, 3s 43 ± 13 61 ± 4 (48 c) 99:1 40 ± 13 d 45 ± 2 
Rh2cap4, 4a 19 ± 5 20 ± 14 96:4 10 ± 4 d 11 ± 7 
Rh25R-MEPY4, 4g 19 ± 5 d 22 ± 8 96:4 34 ± 10 d 15 ± 2 
Outcome of the four model reactions, including standard deviations for 
replicates (n = 3) completed on different days from fresh stock solutions. a 
Yield determined by UPLC with an external standard. b Diastereomer ratio 
determined by UPLC. c Isolated yield of purified product using 100 mg of the 
diazo 5 or 6 as substrate. d Yield obtained in duplicate. 
 
The high-throughput UPLC screening gave a range of yields for 7, 8, 9, and 
10 with carboxylate catalysts generally giving higher yields than 
carboxamidate catalysts. The C–H insertion gave a moderate range of yields 
from 18-56% for product 7. Intermolecular C–H insertion is known to be 
dependent on the rate of diazo addition to the reaction mixture, which cannot 
be controlled while using multi-channel liquid dispensing and appears to be 
limiting the observed yield for the best performing catalysts.197 O–H insertion 
gave a similar, but narrower, range of yields (10-49%) for product 9. Phenols 
are also documented to be poor substrates for rhodium(II) catalysts, and the 
narrow range of yields was expected.220 Cyclopropanation of the 
acceptor/acceptor diazo ester 10 also had a narrower range of yields (10-
45%) due to the effect of using dichloromethane as a solvent (for full details, 
see Chapter 5, section 5.2.1). The cyclopropanation of styrene gave the 
largest range of yields for product 8, from 20-80%, and 3e and 3h stood out 
as the best catalysts for this reaction. Several selected reactions were also 
repeated on a 50-fold larger scale in conventional labware to assess 
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reproducibility, demonstrating that reaction optimisation on the microscale 
was translatable to reactions on preparative scale. 
Many of the descriptors gave moderate positive or negative correlations with 
all three reactions (Figure 2.16). Q Rh, an electronic descriptor, had the 
strongest positive correlation with the yield of 7 (R = 0.89) indicating 
electronic properties of the catalyst were important. He8 also had a strong 
negative correlation (R = -0.89) for the yield of 7, further highlighting the 
importance of the steric properties of the ligand backbone. ΔE(coord) gave 
the best correlation with the observed yield for products 8 (R = 0.85) and 9 
(R = 0.83) demonstrating that the calculated descriptors captured the Lewis 
acidity of the catalyst. Q Rh also gave a strong positive correlation with the 
observed yield of 10 (R = 0.9), along with a strong negative correlation with 
He8 (R = -0.84), indicating that electronic and steric descriptors were 
relevant for interpreting reaction outcomes with an acceptor/acceptor diazo. 
 
Figure 2.16. Best descriptors for univariate correlation with experimental 
screening data. Carbene binding energy is given in kcal mol-1. 
 
The yield of the cyclopropanation reaction between 5 and styrene varied 
widely as a function of the catalyst, indicating there was a catalyst effect. 
Mapping the observed yields for the cyclopropanation onto the PCA model 
showed two clusters of higher yield: one cluster populated by catalysts with 
fluorinated ligands (3e and 3h); and the other by catalysts with sterically 
demanding ligands (3r, 3s and 3u) (Figure 2.17). Based on this clustering 
r2: 0.79 r2: 0.72 
r2: 0.69 
r2: 0.80 
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PC2, representing the Lewis acidity of the catalyst, and PC3, representing 
steric intrusion into the reactive site, can represent catalyst performance for 
this reaction. For the catalysts with carboxylate ligands, the yield of the 
cyclopropanation product 8 and the principal components were correlated 
(PC1: R = 0.81 and r2 = 0.66, and PC2: R = -0.48 and r2 = 0.23). Catalysts 
with higher PC1 values and lower PC2 values gave higher yields in this 
cyclopropanation reaction indicating that the PCA model captures relevant 
information for further model building for the prediction of reaction 
performance. The remaining reactions, C–H and O–H insertion (products 7 
and 9), and acceptor/acceptor diazo cyclopropanation (product 10), are also 
responsive to the PCA model demonstrating that the map is useful for 
interpreting the results for different types of reactions (for overlay plots, see 
Chapter 5 section 5.3.9) 
 
Figure 2.17. An overlay of the outcome of a cyclopropanation reaction with 
the PCA map. 
 
Rhodium(II) catalysts can also give selectivity between two competitive 
reaction pathways under identical conditions.191 The reported selectivity for a 
rhodium(II)-catalysed intramolecular cyclisation was shown to be highly 
dependent on the specific catalyst used (Figure 2.18). Catalysts with 
carboxylate ligands were selective for cyclohepatriene formation, and 
catalysts with carboxamidate ligands were selective for γ-lactam formation. 
Principal component 1 captures the features responsible for this selectivity 
as catalysts with positive PC1 values were selective for cyclohepatriene 
formation and those with negative PC1 values were selective for the γ-
lactam. The descriptor loadings plot (Figure 2.13) indicates catalysts with 
positive PC1 values had been clustered due to the covariance of PC1 with 
the descriptors Q Rh, ΔE(FMO), ΔE(coord) and ∡(C-C-C), whereas catalysts 
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with negative PC1 values had been clustered due a more complicated 
subset of ligand features. Complexes 4a and 4y have negative PC1 and 
positive PC2 values due to the covariance of both PC1 and PC2 with the 
descriptors Q(L, mean), HOMO, 1 and LUMO, 1 suggesting the electronic 
effects are predominantly responsible for the differences in selectivity 
between catalyst classes. 
 
 
Figure 2.18. The effect of catalyst on reaction outcome for a reaction with 
two precedented pathways. 
 
Rhodium(II) catalysts had previously been used in the activity-directed 
discovery of androgen receptor agonists by harnessing intramolecular 
cyclisation reactions of α-diazo amides.82 Over three rounds of ADS, four 
reaction solvents (CH2Cl2, THF, Toluene and THF) and ten different 
rhodium(II) catalysts were used: 3a, 3r, and 4g in round one; 3a, 3e, 4a, 4d, 
and 4m in round two; and 3a, 3c, 3e, 3h, 3q, and Rh2tpa4 in round three. In 
round one catalyst 3a afforded the most active reaction mixture with diazo 
1.3 and was used to guide the design of the round two reaction array. Round 
two expanded the coverage of catalyst space by including more catalysts 
with carboxamidate ligands (4a, 4d and 4m) and adding an electron-
deficient carboxylate ligand (3e). Catalysts 3a and 4a gave the most active 
reaction mixtures with diazo 1.3, but only 3a and 3e were carried forward 
into round three. An overlay of percentage activity onto the PCA map shows 
that the observed activity of crude reaction mixtures was clustered based on 
the location of the catalyst (Figure 2.19). 




Figure 2.19. The relationship between the catalyst space captured by the 
PCA map and the activity of the crude reaction mixtures for rounds one, two, 
and three of ADS using intramolecular reactions.82 Screening concentrations 
decreased with each round (10, 1, and 0.1 µM respectively). 
 
Catalysts 3a, 3c and 3q produced the best agonist 1.17 in similar yields (68-
75%) but with different reaction solvents (EtOAc for 3a, and CH2Cl2 for 3c 
and 3q) in round three. These catalysts were clustered by both PC1 and 
PC2 on the PCA map demonstrating that selective formation of the most 
- 61 - 
 
active product was controlled by catalyst properties. Catalyst 3e gave a 
different major product 13 when reacted with the same diazo providing 
further evidence that the map was responsive to catalyst properties. 
Unfortunately, none of the active reaction mixtures using a catalyst with a 
carboxamidate ligand were scaled up, but were highlighted as potentially 
interesting by the PCA map. The round two crude reaction mixture 
containing carboxamidate catalyst 4a showed particularly promising activity, 
in both toluene and CH2Cl2, but was discarded in favour of catalysts with 
carboxylate ligands. The PCA map could, therefore, serve as a tool for the 
selection of diverse catalysts in an initial reaction array, and as a tool for the 
selection of related catalysts when peaks of activity are found.  
Overall, the PCA map built from the rhodium(II) knowledge base was 
responsive to different types of reactions, demonstrating that the 
parameterisation of the catalysts was independent of mechanism. Catalysts 
that have been clustered together have similar reaction performance and the 
map could be used to design experiments using rhodium(II) catalysts. The 
map shows that the diversity of readily available catalysts with carboxylate 
ligands was relatively poor (Figure 2.13). This was further highlighted by the 
modest variation in the yields for the products 7, 9, and 10. However, the 
available chemical space was large and could be better utilised (Figure 
2.14), and the catalyst map acts a useful tool for selecting new catalysts that 
expand this space. 
 
2.6 Conclusions 
The development of tools for reaction design has shaped the classes of 
transformations routinely used by process chemists in pharmaceutical 
companies.115,161,221 New tools could also enable a wider incorporation of 
new synthetic methodologies by medicinal chemists into molecular discovery 
workflows.159,168,174,175 The catalyst map could serve as a useful tool for the 
selection of rhodium(II) catalysts for specific transformations, such as late-
stage C–H functionalisation. The catalyst map gives a reliable, and general, 
interpretation of reactive space for rhodium(II)-carbenes and could enable 
the identification of fertile regions of largely unexplored catalyst space. The 
range of commercially available rhodium(II) complexes was relatively poor 
and the catalyst map could serve as a guide for creating screening libraries 
comparable to those for phosphorous ligands, such as the Bristol LKB. 
Application of the catalyst map in drug discovery could also increase the 
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diversity of the molecules synthesised by medicinal chemists, because many 
of the bonds formed by rhodium(II)-catalysed reactions are 
underrepresented in the scaffolds of small molecule ligands. 
Further computational development of the catalyst map could include 
implementing more complicated steric descriptors, such as average steric 
occupancy,166,222 to better evaluate the influence of very large ligand 
substituents. This may allow for greater resolution of the interplay between 
electronic and steric effects for site selective C–H insertion reactions, and 
aid in the development of more predictive models. Synthesis of a diverse set 
of rhodium(II) complexes, chosen using the catalyst map, could also allow 
for the creation of a broad catalyst screening library for the optimisation of 
rhodium(II)-catalysed reactions. This screening library could also have 
considerable utility for future activity-directed synthesis experiments using 
rhodium(II) carbene chemistry. 
Activity-directed synthesis experiments rely on the diverse reactivity and 
selectivity of rhodium(II)-carbenes to identify novel bioactive compounds. An 
ideal ADS experiment would use many functionally dissimilar catalysts to 
cover the largest range of possible reaction outcomes. The catalyst map 
could enable the selection of dissimilar catalysts that complement the range 
of potential transformations in a reaction array, and aid in the selection of 
similar catalyst in subsequent reaction arrays. Greater synergy between the 
catalysts, diazo substrates, and multi-functional co-substrates could also 
promote a larger number of successful reactions across an array, meaning a 
greater likelihood of identifying interesting bioactive molecules. As such, the 
catalyst map can form part of the workflow for array design and inform 
catalyst selection for optimising the compatibility between the designed 
diazo substrates, co-substrates and catalysts. 
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Chapter 3 
Design and Implementation of Activity-Directed Synthesis 
Reaction Arrays 1 and 2 
It was proposed that ADS could be used for the discovery of inhibitors of 
protein targets without an evolved small molecule binding site. The 
p53/MDM2 PPI represents an appropriate target for demonstrating the utility 
of ADS for small molecule discovery. Fragment-sized molecules have not 
previously been identified as inhibitors of the PPI during drug discovery 
campaigns, and FBDD approaches have also not been used. However, 
molecules that can interact with a pair of MDM2 sub-pockets, where one of 
the interactions is with the tryptophan MDM2 sub-pocket, can have 
detectable binding to MDM2.158 It was proposed that ADS could be used to 
identify new scaffolds that link pairs of fragment-sized reactants together to 
give a range of structurally-diverse small-molecule antagonists of MDM2. A 
series of activity-directed experiments for the discovery of new inhibitors of 
the p53/MDM2 PPI was subsequently designed and executed to test this 
hypothesis. 
An initial exhaustive microscale reaction array of diazo substrates and co-
substrates was designed to consider a number of factors including: similarity 
to known MDM2 ligands; reactivity with rhodium(II) catalysts; and coverage 
of the available chemical space. The set of diazo substrates proposed for 
synthesis, and co-substrates selected for purchase, were chosen to consider 
the number of potential array products that would be capable of making 
interactions with two or three of the MDM2 sub-pockets (Figure 3.1). 
Combinations that do not obviously form potential products capable of 
interacting with two sub-pockets were also included to avoid biasing the 
outcome of the array towards products with higher similarity to known MDM2 
ligands. 
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Figure 3.1. Combinations of diazo substrate and co-substrate from the initial 
activity-directed synthesis array showing hypothetical products containing 
two or three MDM2 hot-spot mimics. 
 
3.1 Design of an Initial Reaction Array 
Design of the first reaction array was aided using cheminformatic software 
(Pipeline Pilot and RDKit223) to filter chemical supplier databases and find 
relevant molecules that could then be selected manually to complete 
libraries of diazo substrates and co-substrates. The finalised array used all 
combinations involving seven diazo substrates (D1 – D7), ten co-substrates 
(S1 – S10) and two rhodium(II) catalysts, giving 154 microscale reactions 
(including in-line controls, described in section 3.3). 
A database containing commercially available compounds from Sigma 
Aldrich, Fluorochem, Enamine and Alfa Aesar was filtered through two 
separate workflows in Pipeline Pilot to select amines to be used in diazo 
synthesis, and molecules to be used as co-substrates (Figure 3.2). The aim 
was to identify potential substrates and co-substrates with favourable 
molecular properties. Compounds with molecular weight lower than 300 Da, 
fewer than three rotatable bonds, and cLogP values between -2 and 5 were 
prioritised for inclusion. Both workflows filtered the database of compounds 
to remove undesirable molecules, such as compounds containing functional 
groups found in Pan-Assay Interference Compounds (PAINS).224,225 The first 
workflow was designed to identify primary and secondary amines that could 
be used as reactants in the diazotization methodologies outlined in section 
3.1.1 to yield diazo substrates. The second workflow was implemented to 
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select co-substrates that contain functional groups known to react with 
rhodium(II)-carbenes. This was achieved by matching the database of 
commercially available compounds with a set of substructures to select 
potentially reactive molecules. 
Potential amines to be used for diazo synthesis and co-substrate molecules 
identified by the Pipeline Pilot or RDKit workflows were then evaluated to 
select a library of compounds to synthesize or purchase (Figure 3.3 and 3.4 
respectively). Amines were selected manually from the enumerated diazo 
library to create a library of diazo reactants with a wide range of functional 
groups capable of making interactions with the sub-pockets in the peptide 
binding cleft of MDM2, for example: the alkyl groups on 3.3, 3.4, 3.5 and 3.6 
could interact with the leucine sub-pocket; the aromatic groups on 3.1, 3.12 
and 3.13 could interact with the phenylalanine sub-pocket; and the functional 
groups on 3.7 and 3.15 could interact with the tryptophan sub-pocket. 
Several of the designed substrates could also interact with two sub-pockets, 
for example 3.5, 3.6 and 3.9 could interact with the leucine and tryptophan or 
the phenylalanine and tryptophan sub-pockets.  
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Figure 3.2. Workflows for the selection of amines for diazo synthesis and co-
substrates. Molecular properties were calculated within Pipeline Pilot or 
RDKit, and molecular fingerprints were generated in pipeline pilot using the 
ECFP4 fingerprint algorithm. Top panel: Workflow for the enumeration of 
diazo substrates. Bottom panel: Workflow for the selection of co-substrates. 
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Figure 3.3. Diazo substrates selected for synthesis from the enumerated 
diazo library. 
 
Co-substrates containing multiple potentially reactive sites with rhodium(II) 
carbenes were prioritised for selection in the library. For example, alkenes 
for cyclopropanation (S4, S5, S9, and S10), alcohols for O–H insertion (S2 
and S8), and C–H bonds next to α-nitrogen atoms or in benzylic positions 
(S3, S4 and S5). Co-substrates that were used in the initial reaction array 
reaction array (S1 – S10) contain compatible functional groups in contexts 
that are precedented for rhodium(II)-catalysed reactions, for example indole-
C2 and -C3 C-H insertion (S1), and C–H insertion at positions adjacent to 
nitrogen occur most commonly when the nitrogen is part of an amide or 
carbamate (S4 and S5).185,226,227 C–H insertion reactions α-to oxygen atoms 
or at allylic positions are significantly more dependent on the electronic and 
steric properties of the rhodium(II)-carbene species, and also the extent the 
desired reaction site is activated by the oxygen atom, so co-substrates were 
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not prioritised based on containing these centres despite several co-
substrates matching these fingerprints (S6, S8, S9 and S10).185 
 
Figure 3.4. Selected co-substrates for synthesis or purchase. 
 
Two rhodium(II) catalysts, Rh2piv4 and Rh2pfb4, were chosen on the basis of 
the principal component analysis in Chapter 2 for use in the initial reaction 
array, completing the array design. There are five main classes of 
rhodium(II) catalyst, as identified in Chapter 2, and catalysts from the 
carboxylate cluster of the analysis were prioritised due to significantly 
greater literature precedence for intermolecular transformations when 
compared to rhodium(II) catalysts with carboxamidate ligands.211 Rh2piv4 
was selected due to favourable solubility in organic solvents when compared 
to close analogues, such as Rh2OAc4. Rh2pfb4 was chosen because of the 
low predicted similarity with Rh2piv4 and contrasting contributions from the 
strongly electron-withdrawing perfluorobutyrate ligand. In summary, a library 
of potential diazo substrates (Figure 3.3) was prioritised for synthesis and 10 
co-substrates (S1 – S10) (Figure 3.4) were selected for purchase in the first 
reaction array. 
 
3.1.1 Synthesis of Diazo Substrates for an Initial Reaction Array 
The next step towards completing an ADS reaction array is to synthesise the 
required reagents. α-Diazo amides are commonly accessed through five 
general synthetic routes (Figure 3.5): decomposition of a hydrazone; 
acylation; diazo transfer; α-substitution of α-diazo amides by cross-coupling; 
and direct diazotization of primary amines.187,228 Reaction conditions from 
synthetic routes using decomposition and diazo transfer strategies were 
prioritised for the synthesis of the proposed diazo compounds due to 
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superior tolerance of substituent functionality compared to direct 
diazotization and acylation strategies.187 
 
Figure 3.5. Strategies for synthesising α-diazo amides. 
 
Synthesis of diazo substrates D4 – D6, and 3.1, 3.12, 3.14 and 3.16 through 
decomposition of the corresponding α-hydrazone amide was achieved using 
reported conditions (Scheme 3.1).229 Accordingly, glyoxylic acid was 
condensed with tosyl-hydrazide to afford the intermediate hydrazone 3.17, 
which was then subjected to an acid chloride amide coupling with the parent 
amines, and finally decomposed using a non-nucleophilic base, 
triethylamine, to give the α-diazo amide products in moderate to good yields 
(24-90%). The diazo substrates 3.2, 3.4, 3.8 and 3.10 proved to be 
synthetically inaccessible via decomposition of the corresponding α-
hydrazone amides due to degradation of either the product α-diazo amide or 
α-hydrazone amide intermediate into a complex mixture.230,231 The diazo 
3.11 could be synthesised through decomposition of the corresponding α-
phenylhydrazone amide in trace yields and was not considered for inclusion 
as a substrate. In the case of diazo 3.3 the α-hydrazone intermediate could 
be readily formed from diisopropylamine, but subsequent decomposition to 
the corresponding α-diazo amide did not proceed using triethylamine or 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) as a base. Using considerably more 
forcing conditions (12 M aqueous sodium hydroxide, aliquat-336 (a phase 
transfer catalyst), heating between 30-60 oC and toluene as solvent) were 
also screened but the hydrazone remained stable and could not be 
decomposed to the diazo. Ultimately seven α-diazo amides were 
synthesised through the decomposition of hydrazone 3.17 and considered 
for use as substrates in the initial reaction array. 
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Scheme 3.1. Synthesis of diazo compounds via decomposition of a 
hydrazone. 
 
Diazo substrate D3 was synthesised by diazo transfer to the parent 
diphenylacetamide in one pot. An amide coupling between 4-
chlorophenylacetic acid, 4-chloro-N-methylaniline and DCC formed the 
intermediate diphenylacetamide which was then treated with p-ABSA and 
DBU to yield the product diazo (Scheme 3.2). Synthesis of D1 proceeded 
with acetylation of 4-chloro-N-methylaniline, forming the β-ketoamide which 
then underwent diazo transfer using identical conditions to D3 (Scheme 3.2).  
 
Scheme 3.2. Synthesis of D3 and D1 by diazo transfer using p-ABSA. 
 
Attempts to synthesise diazo substrates 3.5 – 3.7, 3.9, 3.13 and 3.15 by 
diazo transfer were unsuccessful despite consumption of the parent 
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phenylacetamide and p-ABSA diazo transfer reagent.232 Due to the limited 
success in synthesising α-diazo acetamides using diazo transfer and 
hydrazone decomposition methodologies two diazo esters, D2 and D6, were 
synthesised to try and exploit more established diazo synthesis that were not 
originally considered (Figure 3.2). The corresponding phenyl acetates were 
synthesised by Fischer esterification, using catalytic sulfuric acid, and then 
diazotized by diazo transfer using p-ABSA and DBU to yield the final two 
diazo compounds D2 and D6 (Scheme 3.3). 
 
Scheme 3.3. Synthesis of D2 and D6 via diazo transfer using p-ABSA. 
 
In summary, nine α-diazo acetamides (D1, D3 – D5, D7, 3.1, 3.12, 3.14 and 
3.16), from the initially proposed set of 21 substrates, were synthesised and 
available for selection in the first reaction array along with two additional 
diazo esters (D2 and D6). All ten selected co-substrates were available for 
purchase and included in the final array design. The final array design 
includes diazo substrates D1 – D7 and co-substrates S1 – S10, as shown in 
Figure 3.6. Diazo compounds D1, D2 and D3 were selected as they contain 
a para-chlorophenyl moiety that mimics the hotspot tryptophan residue of the 
p53 transactivation domain and has been extensively reported in known 
MDM2 ligands. Diazo compounds D4 and D6 were chosen as they feature 
phenyl rings that can mimic the conserved phenylalanine or leucine residues 
on the p53 transactivation domain. Finally, diazo compounds D5 and D7 
were chosen to increase the diversity of functionality featured on each diazo, 
D5 is substituted with a homologated analogue of morpholine with the 
nitrogen atom extruded from the six membered ring, and D7 contains a small 
isoxazole heterocycle which has not been included in any of the other 
substrates. 
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Figure 3.6. Summary of reaction components for the initial reaction array. 
Rh2OAc4 and Rh2pfb4 were selected as catalysts. 
 
3.2 Establishment of a Fluorescence Anisotropy Assay for 
the p53/MDM2 Protein-Protein Interaction 
In order to effectively identify active crude reaction mixtures from the initial 
reaction array a primary, high-throughput assay was required. The assay 
needed to be capable of screening hundreds of reactions quickly and have 
adequate controls for evaluating positive and negative results. A 
fluorescence anisotropy assay, using the p53-transactivation domain and 
Human-MDM2 (hDM2), was chosen as the main assay for screening the 
crude reaction mixtures. 
Fluorescence anisotropy is a sensitive technique for studying protein-protein 
and protein-ligand interactions.233 Typically a protein or peptide is labelled 
with a fluorescent tag, such as fluorescein or rhodamine, to create a 
molecular probe, commonly called a tracer, that can then be used to 
investigate the binding interaction between a tracer and an unlabelled 
protein.234 At a molecular level, when a fluorophore is excited with polarised 
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light the emitted light is also polarised, and the degree of polarisation is 
related to the macro-molecular properties of the fluorophore meaning that it 
can be used as a sensor.235,236 The extent of polarisation is a function of the 
Brownian molecular rotation of the peptide-tracer or protein/peptide-tracer 
complex, so a protein-protein interaction can be studied by measuring 
changes in polarisation caused by changes in the rate of the Brownian 
molecular rotation.237 An unbound tracer will have a lower anisotropy value 
than the protein-bound tracer as the unbound tracer depolarises the plane-
polarised light by rotational diffusion during the lifetime of the fluorescence 
(Figure 3.7). 
 
Figure 3.7. Binding of a fluorescently labelled peptide to an unlabelled 
protein changing the extent of emitted polarised light (PDB: 1YCR).  
 
A fluorescence anisotropy assay using a fluorescein-tagged p53 peptide 
(p5315-31 Flu), spanning the p53 transactivation domain, and hDM2 (serine-17 
to asparagine-125, hDM217-125) was chosen as the primary high-throughput 
screening technique for assessing the outcome of the activity-directed 
reaction array outlined in section 3.1. The assay described here is based on 
a reported assay and adapted to improve the performance in a high-
throughput single point screen.238,239 Initially, a serial dilution of hDM217-125 
(20 – 0.006 µM) was added to a fixed concentration of p5315-31 Flu (54.5 nM) 
in an aqueous phosphate buffer pH 7.5 (40 mM phosphate, 200 mM NaCl 
and 0.02 mg/mL Bovine Serum Albumin, PBSA buffer) to give a 60 µL total 
volume per assay well. Each dilution was performed in triplicate and Kd was 
estimated from the fraction of bound p5315-31 Flu tracer (Figure 3.8 and Figure 
3.9). 
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Figure 3.8. Fluorescence anisotropy titration of hDM217-125 (20.75 to 0.0006 
µM) into a fixed concentration of p5315-31 Flu (54.5 nM) in PBSA buffer.  
 
 
Figure 3.9. Fluorescence anisotropy titration of hDM217-125 (20.75 to 0.0006 
µM) into a fixed concentration of p5315-31 Flu (54.5 nM) in PBSA buffer. FB = 
fraction of bound tracer. FB * [Tracer] = FB * Tracer concentration.  
 
To test the performance of the assay for measuring the inhibition of the 
hDM217-125/p5315-31 Flu protein-protein interaction with a small-molecule ligand 
a serial dilution of Nutlin-3a, a potent and extensively studied inhibitor, was 
added to fixed concentrations of hDM217-125 (150 nM) and p5315-31 Flu (25 nM) 
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in PBSA buffer (Figure 3.10). The measured IC50 for Nultin-3a in this assay 
is 95.2 ± 1.6 nM and the literature reported value is 90 nM,157 demonstrating 
that the assay performs well in competition experiments for determining the 
inhibition of the p5315-31 Flu/hDM217-125 protein-protein interaction. The serial 
dilution of Nutlin-3a also gives the expected rmin and rmax values (-0.025 and 
0.04 respectively, estimated from Figure 3.8) for the assay conditions 
described above, so Nutlin-3a can be used as a positive control in the 
upcoming single concentration high-throughput screening of crude reaction 
mixtures. 
 
Figure 3.10. Dose response of Nutlin-3a in the hDM217-125/p5315-31 Flu (150 
nM and 25 nM concentrations respectively) fluorescence anisotropy assay 
using PBSA buffer. Observed EC50: 95.2 ± 1.6 nM, reported EC50: 90 nM.157 
 
The components for the first reaction array were then pre-screened in the 
fluorescence anisotropy assay to detect any compounds that could interfere 
with the results by inhibiting the p5315-31 Flu/hDM217-125 protein-protein 
interaction before a reaction had taken place. The substrates and co-
substrates, outlined in Figure 3.6, were screened at single concentrations in 
the fluorescence anisotropy assay to investigate the compatibility of the 
assay with high concentrations of reactants (Figure 3.11). Diazo substrates 
were screened at 50 µM, and co-substrates at 100 and 250 µM 
concentrations to determine the activity of a crude reaction mixture up to 50 
µM total product concentration. Diazo substrate D3 showed a small amount 
of inhibition of the PPI, but not enough to warrant exclusion from the initial 
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reaction array, and all other substrates and co-substrates showed no 
residual inhibition. 
 
Figure 3.11. Substrate and co-substrate controls for the initial reaction array. 
Diazo substrates were screened at 50 µM, and co-substrates at 100 and 250 
µM, in duplicate with hDM217-125 (150 nM) and p5315-31 Flu (25 nM), with 
Nutlin-3a as a positive control (10 µM) and 1% DMSO as a negative control. 
 
Overall, the fluorescence anisotropy assay using p5315-31 Flu and hDM217-125 
was a robust assay and compatible with the screening conditions required 
for investigating the activity of crude reaction mixtures. Nutlin-3a acts as a 
suitable positive control for detecting activity in the assay and will be used as 
a reference compound for determining the activity of crude reaction 
mixtures. It was decided that the initial reaction array would be screened at 
20 µM total product concentration (referenced to the diazo substrate starting 
concentration), with five equivalents of co-substrate, as there will be no 
background activity associated with the diazo substrates or co-substrates. 
 
3.3 Implementation and Analysis of Reaction Array 1 
The initial reaction array was performed using the design outlined in Figure 
3.6. The reaction array consisted of 154 reactions, using diazo substrates 
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D1 – D7 and co-substrates S1 – S10, and was conducted at 100 mM diazo 
concentration, with a co-substrate (500 mM) and a rhodium(II) catalyst (1 
mM, Rh2piv4 or Rh2pfb4) in dichloromethane (100 µL total volume, 100 mM 
final diazo concentration). In-line controls to detect activity from reactions 
between a diazo substrate and a rhodium(II) catalyst, or a co-substrate and 
a rhodium(II) catalyst were also included in the reaction array. 
The reactions were performed in a 96-well reaction block with micro-scale 
borosilicate vials equipped with a stirring flea and sealed using a Teflon 
sheet. The diazo substrates and co-substrates were dissolved in 
dichloromethane and the rhodium(II) catalysts were dissolved in 
tetrahydrofuran (1.25 M, 6.25 M, and 12.5 mM respectively) to create 
individual stock solutions. Catalysts were added to the reaction vials and the 
solvent was allowed to evaporate under a stream of nitrogen gas. The 
reaction solvent (80 µL) was then added and the wells stirred for 5 minutes. 
The reagents were then dispensed serially across the reaction block using a 
8-channel pipette, sealed and allowed to react for 24 hours (for plate maps 
and experimental details: see Chapter 5). The crude reaction mixtures were 
then scavenged to remove the catalysts, using a QuadrapureTM TU resin (30 
mg per well), and the bulk solvent evaporated under a stream of nitrogen 
gas. The crude material was then dissolved in DMSO and filtered to remove 
the resin, giving the master stocks (50 mM) from reaction array 1 which were 
used for all analysis. 
All 154 reactions from the initial reaction array were analysed by LC-MS to 
investigate how many combinations had produced a mass corresponding to 
an expected product (Figure 3.12). All samples were diluted to 1 mg/mL 
concentrations (with respect to the starting diazo concentration) from the 
original 50 mM DMSO master stock. Reaction wells containing diazo and 
substrate were analysed for intermolecular products by searching for a 
combined mass of the substrate and co-substrate minus N2, and blank 
control wells were analysed for intramolecular products.  
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Figure 3.12. LC-MS heatmap for reaction array one. Dark green squares 
indicate clear m/z for the desired product(s) and a clear corresponding UV 
peak(s). Light green squares indicate m/z for the desired product(s) and 
either weak or no corresponding UV peak(s). Blank squares indicate that no 
m/z was observed for the desired product(s). 
 
Overall, 112 out of 154 reactions (73%) showed the presence of an 
expected product mass, by LC-MS, of which 78 reactions (51%) also 
showed distinct UV peaks. The number of successful reactions varied per 
diazo substrate and per catalyst, presumably as a function of the substrate 
scope of each rhodium(II)-carbene. For example, the crude reaction mixture 
containing D2, S10 and Rh2piv4 shows a clear new peak corresponding to a 
product whereas analysis for the same diazo substrate and co-substrate with 
Rh2pfb4 indicates no reaction occurred (Figure 3.13, panel A). Similarly, the 
crude mixture containing D6 and S3 shows no new products with either 
Rh2piv4 or Rh2pfb4 as catalyst, but the reaction mixture with D7 and S3 
shows product formation with both catalysts (Figure 3.13, panels B and C 
respectively). For all 70 combinations of diazo and co-substrate, excluding 
intramolecular controls, only 8 combinations out of 70 (11%) failed to give 
detectable product mass when considering reactions across both catalysts. 
The functionality of the co-substrates, therefore, contributes less to reaction 
outcomes than the reactivity of the rhodium(II)-carbenes across the first 
reaction array. This highlights the importance of including multiple catalysts 
with different reactivity to improve the number of productive substrate and 
co-substrate pairs. 
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Figure 3.13. LC-MS extracted ion chromatograms for crude reaction 
mixtures. A: D2 and S10. B: D6 and S3. C: D7 and S3. 
 
All 154 crude reaction mixtures were then assessed for inhibition of the 
p5315-31 Flu/hDM217-125 protein-protein interaction using the fluorescence 
polarisation assay (Chapter 3.2) at a single concentration of 20 µM total 
product concentration (Figure 3.14). All reaction wells containing D3 showed 
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a decrease in anisotropy, including wells without a co-substrate, indicating 
that a product formed from only D3 was likely responsible for the activity. 
Four other reaction mixtures, containing both a diazo and co-substrate, 
showed greater than 35% reduction in anisotropy when compared to the 
activity of Nutlin-3a at 10 µM. Three of the reactions were catalysed by 
Rh2piv4 (D1 and S6, D2 and S10, and D4 and S8) and one by Rh2pfb4 (D2 
and S1), of which three reaction mixtures also showed the formation of a 
desired product by LC-MS (D2 and S10, D4 and S8, and D2 and S1). 
 
Figure 3.14. Single concentration screening data for the first activity-directed 
reaction array at 20 µM total product concentration (referenced to the initial 
concentration of each diazo substrate). 
 
The four hit crude reaction mixtures were then assayed in dose-response 
mode to enable the validation of the activity observed in the single 
concentration high-throughput screen (Figure 3.15). Crude reaction mixtures 
containing D2 and S1 (Rh2pfb4, panel A), D3 (panel B), and D4 and S8 
(Rh2piv4, panel C) show clear dose-dependent decreases in anisotropy 
consistent with inhibition of the p5315-31 Flu/hDM217-125 interaction. The crude 
reaction mixture containing D2 and S10 (Rh2piv4, panel A) results in a much 
smaller decrease in anisotropy which could indicate a product with lower 
activity or a product that was formed in a lower yield. As a result, all four 
active combinations were taken forward for scale-up (see section 3.5). 
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Figure 3.15. Dose-dependent inhibition of the p5315-31 Flu/hDM217-125 
interaction by crude reaction mixtures. A: D2, S10 and Rh2piv4. B: D3 and 
Rh2piv4. C: D4, S8 and Rh2piv4. D: D2, S1 and Rh2pfb4. 
 
3.4 Design and Implementation of Reaction Array 2 
A second reaction array containing a range of new diazo compounds and 
co-substrates, from active combinations in the initial reaction array, was 
designed (Figure 3.16). New diazo substrates (D8 and D9) and co-
substrates (S11 – S21) were inspired by hit reactions identified in the 
previous reaction array. It was expected that D10 could mirror the observed 
reactivity of D7, where all but three reactions had been observed by LC-MS 
to give intermolecular products, but none which inhibited the p5315-31 
Flu/hDM217-125 interaction. Co-substrate S9 was also included in the second 
reaction array as it had produced several reaction mixtures with lower levels 
of activity, specifically with D2 and D4, so could prove productive with new 
diazo substrates. 
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Figure 3.16. Diazo substrates and co-substrates for the second reaction 
array. 
 
Diazo substrates D8 and D9 were synthesised by diazo transfer, using 
identical conditions to D1 – D3 and D6, and D10 was synthesised by 
decomposition of a hydrazone. Diazo D8 was synthesised directly from 6-
chloro-1,3-dihydroindol-2-one by diazo transfer in a moderate yield (Scheme 
3.4, panel A), likely due an azo-coupling side reaction depleting the product 
diazo.232 The precursor ester for D9 was first synthesised from 
cyclobutanemethanol and 4-chlorophenylacetic acid using Steglich 
esterification conditions,240 then diazotized by diazo transfer (Scheme 3.4, 
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panel B) to give D9. Diazo D10 was synthesised by coupling 3-(4-
chlorophenyl)-1,2-oxazol-5-amine to 3.17 to give the intermediate α-
hydrazone amide which was then decomposed to the product diazo in good 
yield (Scheme 3.4, panel C). 
 
Scheme 3.4. Synthesis of new diazo substrates for the second reaction 
array. 
 
The second reaction array totalled 192 reactions, comprised of six diazo 
substrates (D2 – D4 and D8 – D10), 16 co-substrates (S1, S8, S9, S10 and 
S11 – S21) and two catalysts (Rh2piv4 and Rh2pfb4). The reaction 
components were pre-screened at two concentrations (5 and 25 µM for 
diazo substrates, and 25 and 100 µM for co-substrates) to detect residual 
activity that could interfere with the interpretation of the reaction array assay 
results. The pre-screening assay gave control data for effective 
concentrations between 5 µM and 20 µM for screening crude reaction 
mixtures and showed that none of the reagents have significant residual 
activity (Figure 3.17). 
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Figure 3.17. Diazo substrate and co-substrate controls for the initial reaction 
array. Diazo substrates were screened at 5 and 20 µM, and co-substrates at 
25 and 100 µM, in duplicate with hDM217-125 (150 nM) and p5315-31 Flu (25 
nM), with Nutlin-3a as a positive control (10 µM) and 1% DMSO as a 
negative control. 
 
An identical workflow to the initial reaction array was followed, and after 24 
hours the reactions were scavenged and evaporated, and the crude reaction 
mixtures were screened initially at 5 µM total product concentration in the 
fluorescence anisotropy assay (for data see: Chapter 5). However, no hits 
were identified from the single concentration high-throughput screen of the 
crude reaction mixtures at 5 µM. The reaction mixtures were re-screened at 
20 µM total product concentration and five new hit combinations were 
identified (Figure 3.18). New reaction mixtures containing D8 and S12, D8 
and S17, D8 and S20 and D2 and S12, catalysed by Rh2piv4, all showed at 
least a 30% reduction of anisotropy compared to 10 µM Nutlin-3a. One new 
reaction mixture containing D8 and S1, catalysed by Rh2pfb4, also 
decreased anisotropy by greater than 30%, and the D2 and S1 active 
combination from the initial reaction array reappeared in the second array. 
Five new reaction mixtures from the second reaction array, along with the 
four active reaction mixtures from the initial reaction array, were then 
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prioritised for scale-up in conventional lab-ware to identify products 
responsible for the observed activity. 
 
Figure 3.18. Single concentration screening data for the second reaction 
array at 20 µM total product concentration. 
 
3.5 Identification of Products from Hit Reaction Mixtures 
After completing both high-throughput reaction arrays active reaction 
mixtures were scaled-up to a 50-fold larger scale. Products were isolated 
from the reaction mixtures by flash column chromatography with the aim of 
identifying the compounds responsible for the observed activity. The 
Rh2piv4-catalysed intramolecular reaction of diazo D3 was initially scaled up 
and found to yield two products, the oxindole P3 and the α-keto amide P4 
(Scheme 3.5). The other Rh2piv4-catalysed reactions with D4 and S8, D8 
and S17 or S20 were found to yield products P2, P5 and P7 respectively. P5 
was isolated as a single diastereomer, consistent with literature reports of 
rhodium(II)-carbene catalysed cyclopropanation reactions with styrene.217 P5 
also produced a diagnostic 1H NMR shift for the indol-2-one-4H hydrogen at 
5.84 ppm indicating an interaction between the indol-2-one-4H hydrogen and 
the 4-chlorophenyl aromatic ring and confirming that the cyclopropane ring 
has a cis-configuration.241 
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Scheme 3.5. Scale-up of hit reaction mixtures from the first and second 
reaction arrays. 
 
The Rh2piv4-catalysed reaction between D2 and S10 was not found to give 
an intermolecular product when repeated on a larger scale. The Rh2pfb4-
catalysed reactions with D2 and S1, and D8 and S1 were found to give 
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products P1 and P6 respectively. Reactions between D2 and S12, and D8 
and S12 did not proceed when repeated at a larger scale, instead immediate 
precipitation of the Rh2pfb4 catalyst occurred when S12 was added to the 
reaction mixture.  
Three types of rhodium(II)-catalysed reactions yielded products from the 
scale-up of the selected reaction mixtures, including O-H insertion (P2 and 
P4), C-H insertion (P1, P3 and P6) and cyclopropanation (P5 and P7). The 
diversity of productive reactions was enabled by using rhodium(II) catalysts 
with significant differences in their reactivity and substrate scope, as 
highlighted by the C-H insertion between D2 and S1, where only Rh2pfb4 
gives an active product, and the O-H insertion between D4 and S8, where 
only Rh2piv4 gives an active product. In summary, seven products were 
isolated from the nine reactions prioritised for scale-up after testing the crude 
reaction mixtures in the fluorescence anisotropy assay (Scheme 3.5). 
 
3.6 Conclusions 
Two high-throughput reaction arrays were designed and executed in series 
to identify potential inhibitors of the p53/MDM2 protein-protein interaction, 
leading to the scale-up of nine hit reaction mixtures and isolation of seven 
new compounds (P1 – P7). The first reaction array was designed to consider 
the reactivity of diazo substrates and co-substrates with rhodium(II) 
catalysts, and similarity with features of known MDM2 ligands. The second 
reaction array was inspired by hit combinations of diazo substrates and co-
substrates from the first reaction array. Catalyst choice for both arrays was 
aided by the catalyst map described in Chapter 2, and several products were 
isolated from reactions catalysed by only one of the catalysts demonstrating 
the utility of exploring catalyst reactivity. 
A total of 346 crude reaction mixtures was screened in the fluorescence 
polarisation assay, at 20 µM total product concentration, and all 154 crude 
reactions were analysed by LC-MS from the initial reaction array indicating 
up to 73% had yielded an intermolecular product. Nine potential hit reaction 
mixtures were identified and scaled up to give seven products (P1 – P7) 
from both the first and second reaction array.  The characterisation and 
validation of the purified products (P1 – P7) as hDM217-125 ligands and 
inhibitors of the p5315-31 Flu/hDM217-125 protein-protein interaction is described 
in Chapter 4. 
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Chapter 4 
Validation and Characterisation of Hit Compounds from 
Activity-Directed Synthesis 
Typically hit molecules that emerge from discovery campaigns are tested in 
orthogonal assays to corroborate the observed activity and gain information 
on the binding interaction with the protein target.7,16,242 Hit molecules that 
emerge from the activity-directed synthesis workflow need to be tested as 
pure compounds to validate their activity and characterise their function. For 
the seven products identified from the activity-directed synthesis workflow 
(P1 – P7, Figure 4.1) a series of experiments using a competition assay and 
a binding assay were devised to identify inhibition of the p53/hDM2 protein-
protein interaction.  
 
Figure 4.1. Products isolated from the scale-up of hit reactions from reaction 
arrays 1 and 2 (described in Chapter 3). The origin of each structure is 
highlighted in black for contributions from the diazo substrate and green for 
contributions from the co-substrate, and new bonds are highlighted in grey. 
 
4.1 Characterisation of Putative Inhibitors Using a 
Fluorescence Anisotropy Assay 
The purified products were tested in the fluorescence anisotropy assay as 
an initial step towards validation as inhibitors of the p5315-31 Flu/hDM217-125 
protein-protein interaction. The products (P1 – P7) were serially diluted in 
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DMSO, using a two-fold or three-fold dilution series, and then diluted further 
using an aqueous phosphate buffer pH 7.5 to achieve effective 
concentrations between 0.24 and 480 µM and 3% DMSO. The serially 
diluted products were then diluted three-fold and tested in the assay 
containing 150 nM hDM217-125, 25 nM p5315-31 Flu, and 1% DMSO (final 
product concentrations: 0.08-160 µM). Products P2 and P6 gave full dose-
dependent decreases in anisotropy, consistent with inhibition of the protein-
protein interaction, and IC50 values of 15.0 ± 0.1 µM and 0.94 ± 0.03 µM 
respectively (Figure 4.2). 
 
Figure 4.2. Evaluation of the dose-dependent activity of products P2 (black, 
IC50: 15.0 ± 0.1 µM) and P6 (red, 0.94 ± 0.03 µM) in the p5315-31 Flu/hDM217-
125 fluorescence polarisation assay using aqueous phosphate buffer pH 7.5 
containing 40 mM phosphate, 200 mM NaCl and 0.02 mg/mL Bovine Serum 
Albumin. Nutlin-3a (blue, IC50: 95 ± 1.6 nM) is shown for comparison. 
 
Products P3 – P5 also gave dose-dependent decreases in anisotropy that 
were consistent with inhibition of the interaction. However, the products were 
not sufficiently soluble in aqueous phosphate buffer pH 7.5, with final DMSO 
concentrations of between 1 and 3%, to reach product concentrations 
capable of producing the minimum anisotropy value for the free tracer 
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(Figure 4.3). IC50 values for products P3 – P5 were, therefore, estimated by 
fitting the bottom asymptote of the dose-response curve to the minimum 
anisotropy value of the Nutlin-3a control, giving 102 ± 20 µM, 36 ± 11 µM 
and 11.4 ± 1.2 µM values respectively. Product P7 was not active in the 
fluorescence anisotropy assay and did not give a dose-dependent decrease 
in anisotropy at higher concentrations (up to 320 µM) suggesting that the 
active components in the D8, S20, and Rh2piv4 reaction mixture had not 
been isolated. 
 
Figure 4.3. Evaluation of the dose-dependent activity of products P3 (black, 
IC50: 102 ± 20 µM), P4 (red, IC50: 36 ± 11 µM) and P5 (blue, IC50: 11.4 ± 1.2 
µM) in the p5315-31 Flu/hDM217-125 fluorescence polarisation assay, using 
aqueous phosphate buffer pH 7.5 containing 40 mM phosphate, 200 mM 
NaCl and 0.02 mg/mL Bovine Serum Albumin. Nutlin-3a (green, IC50: 95 ± 
1.6 nM) is shown for comparison. 
 
Despite P1 being apparently soluble throughout the dilution series, the 
anisotropy of the free tracer was not observed at high concentrations of P1 
(IC50: 3.6 ± 0.4 µM) (Figure 4.4). This was indicative of more complex 
behaviour between hDM217-125, p5315-31 Flu and P1 and further experiments 
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using orthogonal assays may be able to validate P1 as an MDM2 ligand 
(such experiments are described in section 4.2).  
 
Figure 4.4.  Evaluation of the dose-dependent activity of product P1 (black, 
IC50: 3.6 ± 0.4 µM) in the p5315-31 Flu/hDM217-125 fluorescence polarisation 
assay, using aqueous phosphate buffer pH 7.5 containing 40 mM 
phosphate, 200 mM NaCl and 0.02 mg/mL Bovine Serum Albumin. Nutlin-3a 
(red, IC50: 95 ± 1.6 nM) is shown for comparison. 
 
In summary, the seven pure products from the scale-up of crude reaction 
mixtures were tested in the fluorescence polarisation assay and were carried 
forward for testing in orthogonal biophysical assays. Five products (P2 – P6) 
gave low micromolar IC50 values, and the other two products (P1 and P7) did 
not result in the expected dose-dependent decrease in anisotropy. 
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4.2 Characterisation of the Binding of Putative Inhibitors to 
Human-MDM2 by NMR Spectroscopy 
Biophysical assays are widely used to authenticate the observed activity of 
small-molecule ligands in discovery workflows.7,30,243 All seven of the pure 
products (P1 – P7) were tested in a protein-observed 1H/15N-HSQC NMR 
experiment using 15N-labelled hDM217-125. The products that demonstrated 
binding to 15N-hDM217-125 were considered validated ligands. 
Protein-observed 1H/15N-HSQC NMR is a well-established technique for 
verifying interactions between a small-molecule ligand and a target 
protein.55,243 1H/15N-HSQC NMR is very sensitive and may be used to 
estimate the binding affinity of weak ligands (1 µM to 1000 µM typically).243 
The technique can also give some low-level structural information on the 
binding site of a ligand and allows for detection of non-specific protein-ligand 
interactions such as protein unfolding or aggregation.55,243 As such, 1H/15N-
HSQC NMR experiments may be used to demonstrate dose-dependent 
binding of a ligand to a protein, and biophysically validate ligands. 
 
4.2.1 Titration Experiments for the Characterisation of Putative 
Inhibitors 
Increasing amounts of products P1 – P7 (25 – 300 µM) were sequentially 
titrated into a fixed concentration of 15N-labelled hDM217-125 (50 µM) and the 
1H/15N-HSQC spectrum recorded for each sample. Reporter peaks in the 
peptide binding cleft of 15N-labelled hDM217-125, identified by their N-H HSQC 
cross-peak resonances,239,244 were selected for the observation of chemical 
shift perturbations of the HSQC spectrum. The chemical shift perturbation for 
each reporter peak was then recorded and used to estimate Kd for the 
protein-ligand interaction (for full details, see Chapter 5.3.9).  
Two products, P3 and P7, did not give dose-dependent shifts of reporter 
cross-peaks in the 1H/15N-HSQC spectrum. Both the spectral quality and 
intensity were significantly reduced as the molar ratio of P3 increased 
through the titration series indicating that the product was causing protein 
unfolding or aggregation.243 The spectral quality remained consistent as the 
concentration of P7 increased, however no chemical shift perturbation 
occurred, indicating that the product simply does not bind hDM217-125 under 
the conditions of the assay. 
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Products P2 and P4 – P6 all gave dose-dependent chemical shift 
perturbation of the reporter cross-peaks, in fast-exchange kinetic regimes, 
and Kd could be estimated (Figure 4.5).243 The measured Kd values for P2 
and P4 were broadly similar to the IC50 values measured in the fluorescence 
anisotropy assay (35 ± 13 µM and 35 ± 16 µM respectively). The measured 
Kd values for P5 and P6 were found to be significantly lower than the 
concentration of 15N-labelled hDM217-125 (50 µM 15N-hDM217-125 and Kd: <10 
µM each) in each titration experiment, so should not be considered accurate 
estimates of binding affinity, but still confirm a protein-ligand interaction in 
each case. 
 
Figure 4.5. 1H/15N HSQC titration curves for products P2 and P4 – P6 (25 – 
300 µM) with 15N-labelled hDM217-125 (50 µM) in aqueous phosphate buffer 
pH 7.5 containing 100 mM phosphate, 1 mM DTT, 2.5% glycerol, 10% D2O 
and 1% DMSO. Kd was estimated using established fitting procedures.243 
 
The recorded 1H/15N-HSQC spectrum for the titration of P1 gave chemical 
shift perturbations in the intermediate exchange kinetic regime, which means 
Kd cannot be straightforwardly estimated, and the overall spectrum quality 
was slightly reduced. To investigate if P1 was competitive with p5315-31 for 
hDM217-125 binding, a separate 1H/15N-HSQC experiment was devised 
- 94 - 
 
(Figure 4.6). Firstly, the 15N-labelled hDM217-125/p5315-31 complex was formed 
in a one-to-one molar ratio (50 µM, Figure 4.6 panel A) and four molar 
equivalents of P1 were added (200 µM, Figure 4.6 panel B). No subsequent 
chemical shift perturbation of the HSQC spectrum was observed which 
suggests that P1 does not form ternary or multimeric complexes with the 
hDM217-125/p5315-31 complex or displace the p5315-31 peptide. This is an 
expected result as the p53 transactivation domain has a tight binding 
interaction and should not be displaced by a weak small-molecule ligand at 
one-to-one hDM217-125/p5315-31 molar ratios.238 
Secondly, the 15N-labelled hDM217-125/P1 complex was formed in a one-to-
one molar ratio (50 µM, Figure 4.6 panel C) and p5315-31 was titrated into the 
sample in 0.25 molar equivalents (12.5 – 50 µM, Figure 4.6 panel D). A 
dose-dependent perturbation of HSQC cross-peaks from the P1 bound 15N-
labelled hDM217-125 complex to the p5315-31 bound complex was observed, 
demonstrating that P1 binds to the hDM217-125 peptide binding cleft reversibly 
and competitively with p5315-31. 
 
Figure 4.6. 1H/15N-HSQC NMR competition assay to displace hDM217-
125/ligand complexes with competitor. Experiments were conducted with 15N-
labelled hDM217-125 (50 µM), p5315-31 (12.5 or 50 µM) and P1 (50 or 200 µM), 
using aqueous phosphate buffer pH 7.5 containing 100 mM phosphate, 1 
mM DTT, 2.5% glycerol, 10% D2O and 1% DMSO. Spectra were recorded 
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for the displacement of the 15N-labelled hDM2/P1 complex with p53 after 24 
hours and no additional chemical shift was observed. 
 
Due to the unexpectedly high anisotropy observed at high concentrations of 
P1 in the fluorescence anisotropy assay (Section 4.1, Figure 4.4) a third, 
ligand-observed NMR experiment was conducted to determine the binding 
affinity of P1 to hDM217-125. Product P1 contains a trifluoromethyl functional 
group meaning a 19F-ligand observed NMR experiment was possible and 
could be used to determine the Kd of the P1/hDM217-125 interaction. Carr-
Purcell-Meiboom-Gill (CPMG) pulse sequences are used in fragment-based 
screening to detect binding of a fragment to a protein by measuring changes 
in chemical shift anisotropy.245 CPMG experiments are reliant on measuring 
the transverse or spin-spin T2 relaxation times for an observed nucleus and 
record the resonance for molecules with longer relaxation times.245,246 The 
relationship between the T2 relaxation of a molecule and its molecular weight 
is inverse meaning that large molecules have short relaxation times.245,247 
Therefore, a small molecule ligand will give a clear resonance as an 
unbound monomer in solution and its signal will decrease in intensity when a 
target protein is added as a function of the increasing fraction of bound 
ligand.245,246 
Three spectra for the free P1 ligand (100 µM) in aqueous phosphate buffer 
pH 7.5 were initially recorded, firstly a standard 19F NMR spectrum, and then 
two 19F-CPMG spectra at 50 ms and 300 ms delay times. Varying the delay 
times in the CPMG pulse sequence allows for filtering of complexes of 
varying sizes, with shorter delay times removing larger complexes from the 
spectrum.245,248 Free ligands that are sensitive to CPMG delay times, 
primarily through line-broadening or decreasing intensity, are usually 
exhibiting behaviour typical of aggregation mechanisms which are the 
primary cause of false positive hits in high-throughput screening.41,248–252 All 
three spectra showed a clear 19F-signal corresponding to the trifluoromethyl 
group of P1 at -119 ppm demonstrating that the free ligand is a monomer in 
aqueous solution.248 
Aliquots of hDM217-125 (0.25 – 10 µM) were then titrated into the P1 sample 
(100 µM) and a dose-dependent decrease in 19F-signal was observed 
(Figure 4.7) indicating a protein-ligand interaction. The spectrum was not 
sensitive to a decrease in delay time (50 and 300 ms) indicating that the 
protein is not aggregating upon ligand binding. The addition of 2 µM hDM217-
125 completely suppressed the 100 µM P1 signal indicating that P1 binds 
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tightly to hDM217-125. Compounds with low micro-molar binding affinity (P1 
FA IC50: 3.6 ± 0.4 µM and 1H/15N-HSQC NMR Kd: <10 µM) are at the edge of 
what can be reliably determined using NMR-based assays, and tight-binding 
compounds often quickly reach the limit for determining Kd.243,245 The sharp 
suppression of the 19F-CPMG signal could also indicate that the interaction 
between P1/hDM217-125 is super-stochiometric.245 CPMG experiments are 
not sensitive enough to determine the exact multiplicity of a protein-ligand 
complex, but it is likely that P1 is initiating the formation of a complex that 
involves multiple molecules of hDM217-125 and, or, multiple molecules of 
P1.253 The nature of protein multimerization may be complex, particularly of 
multimers mediated by small-molecule ligands, and given that this specific 
multimeric complex does not form in the presence of p5315-31, product P1 
was not investigated further. 
 
Figure 4.7. Ligand-observed 19F-CPMG NMR titration experiment with P1 
(100 µM) and hDM217-125 using aqueous phosphate buffer pH 7.5 containing 
100 mM phosphate, 1 mM DTT, 2.5% glycerol, 10% D2O and 1% DMSO. 
 
Of the five products taken forward for testing in orthogonal biological assays 
four products (P2 and P4 – P6) demonstrated dose-dependent binding to the 
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peptide binding cleft of hDM217-125. P2 and P4 – P6 were also shown to be 
competitive with the p5315-31 peptide in the fluorescence anisotropy assay. 
Positive results that corroborate the findings of two independent experiments 
provides ample evidence to conclude that P2 and P4 – P6 are validated 
ligands of hDM217-125 and can be analysed in greater detail to gain structural 
insights. 
 
4.2.2 Structural Insights into the Binding of Putative Inhibitors to 
Human-MDM2 
Protein-observed 1H/15N-HSQC NMR experiments can give some low-level 
structural information for a protein-ligand interaction through the chemical-
shift perturbation of specific residues and can aid in identifying the binding 
site of a ligand.243,254 The 1H/15N-HSQC spectrum for hDM217-125 has been 
partially assigned239,244 and several of the key residues in the hDM217-125 
peptide binding cleft (L57, G58, I74, L81 and V93) can be used to infer 
structural information for products P2 and P4 – P6 (Figure 4.8).  
Residues L57 and L81 are important surface residues found in the 
tryptophan sub-pocket on hDM217-125. Addition of ligands P2 and P4 – P6 
give clear chemical shift perturbations of the corresponding L57 and L81 
cross-peaks, indicating that all four products make a key interaction with the 
Tryptophan-hotspot residues which have been shown to be essential for 
binding (highlighted in Figure 4.8).158 Residue G58 is found on the edge of 
the tryptophan and phenylalanine sub-pockets and the corresponding cross-
peak is also perturbed by addition of the products. Residue V93 is on the 
upper edge of the leucine and tryptophan hotspots and the corresponding 
cross-peak is robustly perturbed by P2 and P4 – P6 demonstrating that 
these products are primarily binding to the tryptophan and leucine sub-
pockets (Figure 4.9). Interestingly, P6 appears to demonstrate a secondary, 
flipped, binding mode where it can bind either a combination of leucine and 
tryptophan sub-pockets or tryptophan and phenylalanine sub-pockets. 
Perturbation of the cross-peak for residue I74, which is part of a structural β-
sheet near the phenylalanine sub-pocket, shows significant chemical shift 
perturbation in the presence of P6 indicating binding to the phenylalanine 
sub-pocket (highlighted in Figure 4.8). However, the other key surface 
residues in the phenylalanine sub-pocket have not been assigned and 
further structural detail cannot be extracted. 
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Figure 4.8. A: Highlighted residues.  B: 1H/15N-HSQC NMR spectra for 
products P2 and P4 – P6, where the black cross-peaks represent free 
hDM217-125 (50 µM) and the red cross-peaks hDM217-125 fully bound to a 
product ligand (100, 200 or 300 µM). Important residues involved in small-
molecule binding to the hDM217-125 peptide binding cleft are highlighted and 
the respective perturbation of each 1H/15N cross-peak is expanded. 
 
The products P2 and P4 – P6 were docked into an X-ray crystal structure of 
Human-MDM2 (hDM2) bound to a small molecule inhibitor (PDB: 6Q9H) 
using Autodock Vina (for experimental details, see: Chapter 5).255 The 
products were docked as single stereoisomers and the top ten docked 
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poses, scored by Vina, were then compared to the 15N/1H HSQC chemical 
shift perturbation data, and representative structures were chosen (Figure 
4.10). Docking studies were also performed by Dr Chris Tinworth using 
MOE256 that identified similar predicted binding poses. Products P2, P4 and 
P5 showed good correlation with the experimental NMR data, forming a key 
interaction with the tryptophan and leucine sub-pockets in the top ranked 
structures. Products P2 and P4 demonstrate similar binding poses, rotating 
the bonds between the two phenyl rings to engage the peptide binding cleft 
and pointing the amide-carbonyl towards the solvent. Each enantiomer of P2 
gave similar predicted binding poses and rankings suggesting that the 
absolute configuration of the ligand is not important for hDM2 binding. 
Interestingly the (R)- and (S)-enantiomers of P6 have different predicted 
binding poses, with (R)-P6 predicting only interactions with the tryptophan 
and leucine sub-pockets, and (S)-P6 predicting interactions with either the 
tryptophan and leucine, or tryptophan and phenylalanine sub-pockets. This 
result mirrors observations in the 15N/1H HSQC experimental data, in that a 
flipped binding mode was possible for P6, however the individual 
enantiomers of P6 have not been isolated so this conclusion cannot be 
attributed to stereochemistry alone.  
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Figure 4.9. 1H/15N HSQC chemical shift perturbation of assigned peaks 
for 50 µM 15N-labelled hDM217-125 on addition of ligand (A: 200 µM P2; B: 
300 µM P4; C: 100 µM P5; D: 200 µM P6) (unassigned residues highlighted 
in grey). The ligands (P2 and P4 – P6) are docked into hDM2 (PDB: 
6Q9H) using Autodock Vina. 
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Figure 4.10. Products P2, P4, P5, (R)-P6 and (S)-P6 docked into the MDM2 
peptide binding cleft (PDB: 6Q9H); the sub-pockets targeted by p53 hotspot 
residues F19 (red), W23 (blue) and L26 (green) are shown. 
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In summary, analysis of the 1H/15N-HSQC titration experiments elucidated 
some low-level structural information that confirmed the product ligands 
were interacting with the peptide binding cleft of hDM217-125 and were 
primarily occupying the tryptophan and leucine sub-pockets. A docking study 
predicted that P2 and P4 – P6 were preferentially interacting with the 
tryptophan and leucine sub-pockets yielding further structural information. 
 
4.3 Development of Structure-Activity Relationships for 
Selected Human-MDM2 Inhibitor Classes 
Development of structure-activity relationships are key in medicinal 
chemistry for the identification of functional groups that are important for the 
observed binding between a ligand and a protein target.7,55,257 A range of 
analogues for P2, P5 and P6, that maintained the core scaffold of each 
ligand, was subsequently synthesised to elucidate structure-activity 
relationships between the chemotypes found in the validated product 
ligands. The analogues were synthesised using similar conditions to the 
scale-up of hit reaction mixtures described in chapter 3, using either Rh2piv4 
or Rh2pfb4 as a catalyst (1 mol%), a diazo substrate (100 mM), and a co-
substrate (Scheme 4.1).   
Initially two analogues of P2, in which one of the aromatic rings had been 
removed, 4.1 and 4.2, were synthesised (Scheme 4.1) and tested in the 
fluorescence anisotropy assay for inhibition of the p5315-31 Flu/hDM217-125 
protein-protein interaction (Figure 4.11) Neither analogue displayed a 
significant decrease in anisotropy up to 320 µM of 4.1 or 4.2 indicating that 
both aromatic rings are essential for the observed activity of P2. All four 
stereoisomers of P2 were also individually prepared from enantiomerically 
pure starting materials (Scheme 4.1), tested in the fluorescence anisotropy 
assay and found to have similar activity: P2a (S,R) IC50 28.2 ± 3.0 µM; ent-
P2a (R,S) IC50 36.5 ± 3.5 µM; P2b (S,S) IC50 26.0 ± 3.8 µM; and ent-P2b 
(S,R) IC50 28.6 ± 2.9 µM (Figure 4.11). This result is consistent with the 
docking pose predictions (Chapter 4, section 4.2.2) where each 
stereoisomer of P2 was able to adopt a similar binding pose that places the 
chlorophenyl aromatic ring in the tryptophan sub-pocket and the phenyl ring 
in the leucine sub-pocket. 
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Scheme 4.1. Synthesis of P2 analogues. 
 
- 104 - 
 
 
Figure 4.11. Dose-response experiments for analogues 4.1 (purple, IC50: 
>200 µM) and 4.2 (gold, IC50: >200 µM), and P2 single enantiomers P2a 
(black, IC50: 28.2 ± 3.0 µM), ent-P2a (red, IC50: 36.5 ± 3.5 µM), P2b (blue, 
IC50: 26.0 ± 3.8 µM) and ent-P2b (green, IC50: 28.6 ± 2.9 µM) in the p5315-31 
Flu/hDM217-125 fluorescence polarisation assay, using aqueous phosphate 
buffer pH 7.5 containing 40 mM phosphate, 200 mM NaCl, 0.02 mg/mL 
Bovine Serum Albumin and 1% DMSO. 
 
Analogues of P5 and P6 with chlorine atoms in different positions were also 
prepared and tested in the fluorescence anisotropy assay (Scheme 4.2). 
Analogue 4.3 was found to have reduced activity compared with P5 and a 
full dose-response curve could not be obtained due to poor solubility in 
aqueous phosphate buffer pH 7.5 (4.3: >50 µM and P5: 11.4 ± 1.2 µM). 
Analogue 4.4 was also found to have reduced activity compared to P6 (4.4: 
3.5 ± 1.1 µM and P6: 0.94 ± 0.03 µM) confirming that the position of the 
chlorine atom was important for binding in both series of ligands. 
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Scheme 4.2. Synthesis of P5 and P6 analogues. 
 
In summary, several analogues of products P2, P5 and P6 were synthesised 
(4.1 – 4.4, P2a, ent-P2a, P2b and ent-P2b) and tested in the fluorescence 
anisotropy assay. The observed activity of the analogues highlighted some 
simple structure-activity relationships demonstrating that the chlorophenyl 
and phenyl rings are key for inhibition of the p5315-31 Flu/hDM217-125 
interaction. 
 
4.4 Molecular Similarity and Comparisons with Known MDM2 
Ligands 
One of the central aims of an activity-directed synthesis experiment is to 
discover new, active molecules that are highly dissimilar to molecules 
discovered using more traditional discovery workflows. To assess the 
distinctiveness of the products, P2 and P4 – P6 were compared to 1314 
ligands with annotated activity against MDM2 in the ChEMBL database.258 
The compounds included in the ChEMBL database cover at least eight 
discovery campaigns for clinical candidates, including RG7112,149 
RG7388,153 MI-77301,150 AMG232,154 DS-3032,259 HDM201,155 CGM097155 
and MK-8242,260 and compounds from over 300 scientific papers. 
Comparison of the products with compounds deposited into the ChEMBL 
database, therefore, represents a robust assessment of the diversity of 
products that can emerge from activity-directed synthesis experiments. 
- 106 - 
 
The Morgan fingerprint (generated in RDKit) of each product was compared 
in a pair-wise manner to the Morgan fingerprint of each of the ligands 
deposited into ChEMBL using the Tanimoto similarity coefficient. The 
coefficient scores the similarity between a pair of molecular fingerprints 
where the maximum score indicating an identical molecule is one, and the 
minimum score indicating no similarity is zero.261 For the analysis of organic 
small molecules, scores >0.7 indicate a pair of molecules with considerable 
similarity and scores <0.5 indicate molecules with little similarity.261,262 When 
compared in a pair-wise manner, each of the products gave very low 
similarity scores with known MDM2 ligands, with an average score of 0.37 
across all four products, demonstrating that P2 and P4 – P6 are novel 
MDM2 ligands (Figure 4.13).  
 
Figure 4.13. Molecular similarities (Tanimoto coefficient) of the products P2 
and P4 – P6 and their nearest neighbour MDM2 ligands in ChEMBL. 
 
The products also have low similarity scores with each other, a feature 
driven by the diversity in core scaffolding functionality between P2 and P4 – 
P6 (Figure 4.13). This is a result of the different fragment optimisation 
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strategies that have emerged from each of the product forming reactions. 
The O-H insertion reaction forming P2 is comparable to fragment linking 
where two fragments are tethered by a flexible linker, while the 
cyclopropanation and C-H insertion reactions forming P5 and P6 are 
comparable to fragment merging where two fragments are joined through a 
rigid core.57,263,264 Finally, the O-H insertion and oxidation reactions that form 
P4 act as a method of fragment growth where an existing ligand is altered to 
improve its activity.57,263 Discovering multiple series of new ligands from a 
single set of experiments with such diversity in scaffold functionality is 
uncommon and demonstrates the advantages of conducting activity-directed 
experiments for initial molecular discovery. 
To further compare the similarity of the products with known MDM2 ligands, 
the top predicted docking poses for P2 and P4 – P6 (Section 4.2.2) were 
compared with X-ray crystal structures from the most similar ligands bound 
to MDM2 (Figure 4.14). All four of the products show significant 
complementarity between their docked binding poses and the X-ray 
structures of their nearest neighbours. Each product places the key aromatic 
moieties in the leucine and tryptophan sub-pockets in similar orientations to 
the known ligands, indicating that activity-directed experiments can be used 
as a method of experimental scaffold hopping.265,266  
Each overlay also indicates potential vectors for elaboration of the products. 
For example, substitution of the P2 pyrrolidine-C2 position with an ethyl, 
(iso)propyl or sec-butyl group could engage the phenylalanine hotspot and 
create a ligand that interacts with all three MDM2 sub-pockets. Substitution 
of the P5 cyclopropyl ring with a polar functional group at the C1’ position, 
could engage the solvent facing edge of the peptide binding cleft and 
addition of an alkyl group at the C2’ position could interact with the 
phenylalanine hotspot. This could create an analogue of P5 that interacts 
with all three hot-spots and the solvent facing part of the peptide binding cleft 
similarly to the most potent inhibitors of the p53/MDM2 interaction. Clear 
growth vectors for P4 and P6 are also suggested by the overlays, 
specifically: substitution of the P4 amide methyl group with a larger alkyl 
group; and addition of a polar functional group at the P6 indole-C2 position 
could also create new interactions with the MDM2 peptide binding cleft. 
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Figure 4.14. Overlays of the predicted binding poses for products P2 and P4 
– P6, and crystal structures of their nearest neighbour MDM2 ligand in the 
ChEMBL database.151,155,267 
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The ligands discovered by activity-directed synthesis (P2 and P4 – P6) have 
favourable molecular properties with ligand efficiencies ranging from 0.28 to 
0.4, molecular weights below 400, and fewer than three rotatable bonds. A 
common method of assessing the quality of a small molecule ligand is to 
compare the ligand efficiency (LE) and lipophilic ligand efficiency (LLE).35,58 
LLE is a useful measure of a ligand’s affinity towards its protein target 
compared to its affinity towards octanol, meaning that scores >0 indicate 
favourable binding to a protein. Ligands identified during early-stage drug 
discovery for protein-protein interactions typically have LE >0.2 due to the 
challenging nature of identifying ligands for proteins that do not have an 
evolved small molecule binding site.35 Ligands with LE >0.3 and LLE >0 are 
considered desirable starting points for a hit-to-lead medicinal chemistry 
effort.35,57,58 Often when hit molecules are optimised into lead compounds LE 
is maintained and LLE is improved, and clinical candidates typically have 
high LLE values (>5).35 
Products P4 and P6 both have LE >0.3 and LLE >0 (LE: 0.31 and LLE: 0.32, 
and LE: 0.39 and LLE: 1.15 respectively) making them highly tractable 
starting points for further development as inhibitors regardless of target or 
discovery method (Figure 4.15). Products P2 and P5 also have favourable 
LE and borderline LLE (LE: 0.26 and LE: -0.14, and LE: 0.34 and LLE: -0.78 
respectively) and may also be starting points for the discovery of inhibitors of 
protein-protein interactions. Interestingly, only 8 ligands in the analysis, 
including P6, have LE ≥ 0.4 and ≤ 21 heavy atoms which reflects on the 
main discovery methods employed against MDM2 (HTS and virtual 
screening) and the fact that no fragment screening campaigns have been 
reported. Comparing the LE and LLE of the products with the hit molecules 
that were identified at the start of the discovery campaigns yielding the 
clinical candidates AMG-232,154 CGM097,155,268 MI-77301150 and RG7388153 
shows that the products occupy the same ideal molecular property space as 
the original hit molecules (Figure 4.15).  
The hit molecule that initiated the discovery of AMG-232 (4.5) is also the 
most similar ligand to P2, and surprisingly both molecules have similar 
potency in their respective fluorescence anisotropy assays (4.5: 11.7 ± 1.8 
µM and P2: 15.0 ± 0.1 µM). The most similar ligand to P5 is the hit molecule 
that was synthesised early in the structure-based design approach that was 
used for the discovery of MI-77301, and has very similar LE/LLE values (4.6, 
LE: 0.31 and LLE: -1.3, and P5, LE: 0.34 and LLE: -0.78). The most similar 
ligand to P4 is a molecule that was synthesised during the hit-to-lead 
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campaign for the discovery of CGM097 and P4 has superior ligand efficiency 
compared to the initial hit (hit, LE: 0.22 and LLE: 1.62, and P4: LE: 0.31 and 
LLE: 0.32). The ligands discovered by activity-directed synthesis, therefore, 
occupy a section of chemical space that is highly relevant to the p53/MDM2 
protein-protein interaction and to medicinal chemists undertaking drug 
discovery projects. Ultimately, each of the ADS products could have been 
used to initiate a drug discovery campaign against this PPI. 
 
Figure 4.15. Comparison of lipophilic ligand efficiency (LLE) and ligand 
efficiency (LE), and the change in both values as drug development 
progresses from hit to lead to clinical candidate. Product ligands P2 and P4 
– P6 are highlighted in green, clinical candidates AMG-232, CGM097, MI-
77301 and RG7388 are in black, and ligands deposited to ChEMBL are in 
grey. 
 
In summary, products P2 and P4 – P6 were found to be unique starting 
points for molecular discovery campaigns due to their low similarity to known 
MDM2 ligands and favourable LE/LLE metrics. The activity-directed 
workflow has also enabled an experimental scaffold hopping approach 
where the product ligands can make similar interactions with the MDM2 
peptide binding cleft but with very different core scaffolds. The four-product 
series each represent significant chemical matter that could be used to form 
the basis of a drug discovery effort to make novel inhibitors of the 
p53/MDM2 protein-protein interaction. 
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4.5 Conclusions 
In summary, activity-directed synthesis has been demonstrated as an 
effective tool for the discovery of inhibitors against a challenging biological 
target that does not have an evolved small molecule binding site. The 
efficiency of activity-directed synthesis allows for large-scale exploration of 
chemical space with a remarkably low requirement for multi-step chemical 
synthesis. This is highlighted by the low number of reactions conducted in 
conventional labware. For the two high-throughput reaction arrays, totalling 
346 microscale reactions, ten diazo substrates and one co-substrate were 
synthesised, and nine hit reaction mixtures were scaled up. The total 
number of reactions completed in conventional labware to discover the four 
product ligands was 20, which represents a time and resource efficient 
method for the identification of bioactive small molecules.  
In traditional early-stage drug discovery, fragment or HTS compound 
libraries are meticulously curated and optimised for diversity in parameters 
such as shape, molecular properties and novelty to give hits favoured by 
medicinal chemists. Through the utilisation of highly reactive and 
promiscuous rhodium(II)-carbene chemistry each of the ligand series 
discovered by activity-directed synthesis have distinct scaffolds and high 
novelty, without the need for predetermined engineering of the reaction 
products. This could enable the discovery of new ligands for targets that do 
not have elucidated structural information for the biological interaction of 
interest, or ligands for targets where many molecules have been reported 
and a new starting point is desired. 
The observed diversity of reaction products has been driven by two factors. 
Firstly, by using diazo substrates and catalysts with different reactivity 
multiple types of scaffold forming reactions can occur, and additionally these 
reaction types are underrepresented in the synthesis of screening 
collections. Secondly, by utilising α-diazo amide substrates the product 
molecules have low similarity with known ligands, as carbon-carbon bond 
forming reactions α-to amide carbonyls are not very common. Also, the 
fragment-like properties of the diazo substrates and co-substrates gives the 
products favourable molecular properties. As a result, each of the product 
ligand series fall within limits imposed during the evaluation of hits commonly 
identified by high-throughput screening.  
The active products also have comparable potency and efficiency to the hit 
molecules that started drug discovery campaigns for several clinical 
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candidate molecules targeting the p53/MDM2 protein-protein interaction. 
The products from activity-directed synthesis experiments could have been 
selected for further investigation in a pharmaceutical setting and used as 
starting points for drug discovery. Retrospective analysis of the discovery of 
the nutlin ligands showed that fragment-based drug discovery could have 
been used to identify the critical chemical matter for drug discovery, but that 
suitable fragment libraries would not have been available at the time. 
Activity-directed synthesis could alternatively form the basis of an approach 
for the discovery of these ligand classes without the need for extensive 
investment in chemical synthesis. This could allow for a reduction in the size 
of the screening collections maintained by pharmaceutical companies as 
early screening can be conducted with low requirements for synthetic 
chemistry. Activity-directed synthesis, therefore, enables a more dynamic 
approach to small molecule discovery as the chemical matter screened is 
not fixed at the time of library design and could allow for target specific 
information to be better incorporated into early work.  
Future applications of activity-directed synthesis could focus on the 
application of late-stage functionalisation chemistry for the elaboration of hit 
molecules for the p53/MDM2 protein-protein interaction (Figure 4.16). 
Employing activity-directed synthesis in a hit-to-lead paradigm would 
demonstrate that the approach could also be used in the optimisation of a 
known ligand, as well as for hit discovery. Late-stage functionalisation such 
as hydroxylation, fluorination, C-H activation and C-H amination, and 
decarboxylative cross-couplings are well established techniques for the site-
selective modification of complex molecules and could be used in an activity-
directed synthesis workflow for the optimisation of hit molecules.269 
Photoredox-based Minisci chemistry could be used for the late-stage 
modification of hit molecules and the chemistry has been established in 
activity-directed synthesis format by Dr Andrew Gomm. The photoredox-
mediated process is cross-dehydrogenative between a saturated N-
heterocycle and a heteroarene and is ideal for the site-specific elaboration of 
a ligand, for example 4.7 (Figure 4.17). The primary p5315-31 Flu/hDM217-125 
fluorescence anisotropy assay has also been shown to tolerate a number of 
different reaction conditions for these transformations and, as such, the 
approach could be implemented within the established high-throughput 
screening protocol outlined in Chapter 3 (Appendix A).  
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Figure 4.16. Workflow for identifying a potential hDM2 ligand, 4.7, as a 
photoredox substrate. A closely related analogue was also reported to have 




Figure 4.17. Hypothetical ADS reaction products from a reaction array using 
the photoredox Minisci reaction. 
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Activity-directed synthesis experiments work robustly for the identification of 
new hit molecules, and future work focussing on developing a workflow for 
the hit-to-lead optimisation of a ligand would demonstrate a well-rounded 
platform for molecular discovery. Ultimately, the work described in this thesis 
has shown that activity-directed synthesis can drive molecular discovery, 
while also augmenting other well-established methods, and could be a highly 
productive addition to current pharmaceutical screening technologies. 
 
 




5.1 General Information and Instrumentation 
Reagents were purchased from commercial suppliers and used without 
further purification (Sigma-Aldrich, Fluorochem, Strem Chemicals, Enamine 
BB (EU), and Scientific Laboratory Supplies). Rhodium catalysts were 
purchased from Sigma-Aldrich or Strem Chemicals and used as supplied. 
Rh2(5R-MEPY)4 was synthesised using a reported literature procedure.271 
Water-sensitive reactions were performed in anhydrous solvents obtained 
from a PureSolv MD5 Purification System. Solvents were removed under 
reduced pressure using a Büchi rotary evaporator with a Vacuubrand 
PC2001 Vario diaphragm pump, or under N2 blowdown at 40 oC. Flash 
column chromatography was carried out using silica gel 60 (35-70 μm 
particles) supplied by Merck or using RediSep Rf silica cartridges and a 
Teledyne ISCO CombiFlash automatic chromatography companion. Thin-
layer chromatography was conducted with Macherey-Nagel Polygram SIL 
G/UV254 0.2mm silica gel 60 with fluorescent indicator plates.  
Ultra-high performance liquid chromatography (UPLC) was performed using 
an Agilent 1260 Infinity System (5-minute method, 1 mL/min, 0.5 μL 
injection) equipped with an X-select Waters Charged Surface Hybrid (CSH) 
C18 2.5μm (30 x 2.1 mm) C18 column (XP) or an Agilent 1290 Infinity II 
system (1-minute method, 2.2 mL/min, 0.5 μL injection) equipped with an X-
select Waters Charged Surface Hybrid (CSH) C18 2.5μm (30 x 2.1 mm) C18 
column (XP) at 40 oC and 220 nm wavelength. Analytical LC-MS was 
performed using several systems. Firstly, a system comprising an 
Ultimate3000 HPLC instrument with a Brucker Amazon Speed MS detector 
with electrospray ionisation. The system ran with a positive and negative 
switching mode and UV diode array detector using a Phenomenex Kinetex 
C18 (50 mm × 2.1 mm × 2.6 μm) column and gradient elution with two binary 
solvent systems: MeCN/H2O or MeCN/H2O plus 0.1% formic acid. Secondly, 
analytical LC-MS was conducted on a Waters Acquity UPLC instrument 
equipped with an Acquity UPLC CSH C18 column and Waters micromass 
ZQ MS using alternate-scan positive and negative electrospray. Analytes 
were detected as the summed UV wavelength of 210–350 nm. Accurate 
mass spectrometry (HRMS) was performed using electrospray ionisation on 
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a Bruker MaXis Impact spectrometer equipped with a Phenomenex Luna 
C18 50 x 2 mm 5 micron column with two solvent systems: MeCN/H2O + 
0.1% formic acid or MeCN/H2O. Mass-directed automatic purification 
(MDAP) was conducted on either an Xbridge C18 column or Sunfire C18 
column at ambient temperature using a modified acetonitrile-water gradient 
(as specified in the experimental section). MS analysis was carried out using 
a Waters ZQ MS using alternate-scan positive and negative electrospray 
and a summed UV wavelength of 210–350 nm. 
NMR analysis was conducted using a Bruker AV-400 spectrometer (1H = 
400 MHz, 13C = 100 MHz and 19F = 376 MHz C-F decoupled), Bruker AV-
500(Cyroprobe) spectrometer (1H = 500 MHz and 13C = 125 MHz), JEOL 
ECA600ii 14.1 T spectrometer (1H = 600 MHz and 13C = 150 MHz), 750 MHz 
Oxford Magnet spectrometer (TCI-Cyroprobe, 1H optimized triple resonance 
NMR ‘inverse’ probe) (1H = 750 MHz and 15N =  76 MHz), or a 600 MHz 
Oxford Magnet spectrometer (QCI-P-Cryoprobe, 1H optimised quadruple 
resonance NMR ‘inverse’ probe) (1H = 600 MHz and 15N = 61 MHz) using an 
internal deuterium lock. Chemical shifts are quoted in parts per million (ppm) 
and coupling constants are given in Hz. Splitting patterns have been 
abbreviated as follows: s (singlet), d (doublet), dd (doublet of doublets), t 
(triplet), q (quartet) and m (multiplet). NMR data is reported in the format: 
ppm (number of protons, splitting pattern, coupling constant). Infrared 
spectra were recorded on a Bruker Alpha ATR FR-IR spectrometer; 
absorptions are reported in wavenumber (cm-1).  
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5.2 Materials and Methods for the Catalyst Knowledge Base 
5.2.1 Synthesis of Compounds for the High-Throughput 
Screening of Model Reactions 
 
Methyl 2‐diazo‐2‐phenylacetate, 5231 
 
DBU (7.0 mL, 46.6 mmol) was added slowly to a stirred solution of methyl 2-
phenylacetate (4.7 mL, 33.3 mmol) and 4-acetamidobenzenesulfonyl azide 
(9.6 g, 40.0 mmol) in acetonitrile (60 mL) at 0 oC. The reaction was allowed 
to warm to room temperature overnight, and after 20 hours of stirring gave a 
bright orange solution. The solvent was then removed under reduced 
pressure, and the residue dissolved in CH2Cl2 (25 mL) and partitioned with 
distilled water (75 mL). The product was subsequently extracted using Et2O 
(3 x 75 mL), and the organics collected and sequentially washed with 10% 
NH4Cl (3 x 30 mL) and brine (3 x 30 mL). The organics were collected and 
dried (Na2SO4), and the solvent was removed under reduced pressure to 
give a bright orange oil. The product was purified by silica gel 
chromatography eluting 5:95 tert-butylmethylether/cyclohexane to afford the 
diazo 5231 as a bright orange oil (4.3 g, 73%). Rf (90:10 Cyclohexane/Et2O) 
0.49. δH (500 MHz, Acetone-d6) 7.54 (2H, app. dd, J 8.5, 1.1 Hz, phenyl-2H 
and -6H), 7.41 (2H, app. dd, J 8.5, 7.6 Hz, phenyl-3H and -5H), 7.22 – 7.19 
(1H, m, phenyl-4H) and 3.85 (3H, s, methyl-H).  LCMS (ESI): C9H8N2O2 
requires [M+H]+, calculated 177.1, found 177.1. 
 
Methyl 2‐(oxolan‐2‐yl)‐2‐phenylacetate, 7272 
 
A three-neck 50 mL round-bottom flask, equipped with a dropping funnel, 
was charged with Rh2oct4 (2.5 mg, 3.2 µmol) and degassed under a stream 
of N2. THF (0.5 mL) was added and the dropping funnel charged with methyl 
2-diazo-2-phenylacetate (112.8 mg, 0.6 mmol) in heptane (4.5 mL) and 
degassed by bubbling a stream of N2 through the solution. After 5 minutes of 
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degassing, the stream of N2 was slowed and removed from the bulk solvent, 
and the diazo solution added dropwise over 105 minutes. Heptane (1 mL) 
was then added to the dropping funnel to wash through any remaining diazo. 
After 16 hours the solvent was removed under reduced pressure to give a 
blue residue. The residue was purified by MDAP (10 mM ammonium 
bicarbonate modifier gradient), and the appropriate fractions were combined 
and dried under a stream of nitrogen to afford the acetate 7272 as a 
colourless oil (74 mg, 52%, dr 2.7:1). δH major (500 MHz, CDCl3) 7.31 (2H, 
d, J 8.2 Hz, phenyl-2H and -6H), 7.27 – 7.25 (2H, m, phenyl-3H and -5H), 
7.22 – 7.19 (1H, m, phenyl-4H), 4.38 (1H, dt, J 8.3, 7.0 Hz, oxolanyl-2H), 
3.73 (1H, dt, J 8.2, 7.0 Hz, oxolanyl-5Ha), 3.66 – 3.62 (1H, m, oxolanyl-5Hb), 
3.60 (3H, s, methyl-H), 3.56 (1H, m, acetate-2H), 2.08 – 2.02 (1H, m, 
oxolanyl-3Ha), 1.82 – 1.78 (2H, m, oxolanyl-4H2) and 1.60 (1H, app. ddd, J 
15.8, 12.3, 8.0 Hz, oxolanyl-3Hb). δH minor (500 MHz, CDCl3) 7.29 – 7.19 
(5H, m, phenyl), 4.45 (1H, dt, J 9.9, 7.0 Hz Hz, oxolanyl-2H), 3.85 (1H, dt, J 
8.4, 7.0 Hz, oxolanyl-5Ha), 3.78 – 3.72 (1H, m, oxolanyl-5Hb), 3.63 (3H, s, 
methyl-H), 3.46 (1H, m, acetate-2H), 1.82 – 1.73 (2H, m, oxolanyl-3Ha and -
4Ha), 1.67 – 1.56 (1H, m, oxolanyl-4Hb) and 1.36 (ddd, 1H, J 16, 12.6, 7.6 
Hz, oxolanyl-3Hb). HRMS (ESI): C13H16O3 requires [M+Na]+, calculated 




A three-neck round bottom flask, equipped with a dropping funnel, was 
charged with Rh2tfa4 (2.1 mg, 3.2 µmol) and degassed with a stream of N2. 
Styrene (0.2 mL, 2.8 mmol) was added and the dropping funnel charged with 
methyl 2-phenyldiazoacetate (100 mg, 0.6 mmol) in CH2Cl2 (4.1 mL). The 
diazo solution was then degassed by bubbling a stream of N2 through the 
solution and after 5 minutes the stream of N2 was slowed and removed from 
the bulk solvent. The diazo was added dropwise to the solution over 2.5 
hours, and a further aliquot of CH2Cl2 (1.0 mL) was added to the dropping 
funnel to wash through any remaining diazo. After 16 hours of stirring the 
solvent was removed under reduced pressure to give a blue residue and 
was purified by MDAP (+0.1% TFA modifier gradient). The appropriate 
fractions were combined and dried under a stream of nitrogen to afford the 
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cyclopropane 8273,274 as a thick colourless oil (113 mg, 70%, dr 95:5). δH 
(500 MHz, CDCl3) 7.15 – 7.13 (3H, m, 1-phenyl-2H, -4H and -6H), 7.08 – 
7.03 (5H, m, 1-phenyl-3H and -5H, and  2-phenyl-2H, -4H and -6H), 6.79 – 
6.77 (2H, m, 2-phenyl-3H and 5H), 3.67 (3H, s, methyl), 3.13 (1H, dd, J 9.3, 
7.3 Hz, cyclopropane-2H), 2.15 (1H, dd, J 9.3, 4.9 Hz, cyclopropane-3Ha) 
and 1.90 (1H, dd, J 7.3, 4.9 Hz, cyclopropane-3Hb). HRMS (ESI): C17H16O2 
requires [M+Na]+, calculated 275.1048, found 275.1042. 
 
Methyl 2‐phenoxy‐2‐phenylacetate, 9275 
 
A three-neck round bottom flask, equipped with a dropping funnel, was 
charged with Rh2pfb4 (3.4 mg, 3.2 µmol) and phenol (602.3 mg, 6.4 mmol), 
and degassed with a stream of N2. CH2Cl2 (1.0 mL) was added and 
degassed by bubbling a stream of N2 through the stirred solution. The 
dropping funnel was then charged with methyl 2-diazo-2-phenylacetate 
(112.8 mg, 0.7 mmol) in CH2Cl2 (4.5 mL) and degassed by bubbling a 
stream of N2 through the solution. After 5 minutes of degassing, the stream 
of N2 was slowed and removed from the bulk solvent, and the diazo solution 
added dropwise over 105 minutes. CH2Cl2 (1.0 mL) was then added to the 
dropping funnel to wash through any remaining diazo. After 16 hours the 
solvent was removed under reduced pressure to give a blue residue and 
was purified by MDAP (10 mM ammonium bicarbonate modifier gradient). 
The appropriate fractions were combined and dried under a stream of 
nitrogen to afford the acetate 8275 as a colourless oil (89 mg, 57%). δH (500 
MHz, CDCl3) 7.50 (2H, m, phenoxy-2H and -6H), 7.34 – 7.28 (3H, m, 
phenoxy-3H, -4H and -5H), 7.21-7.17 (2H, m, phenyl-2H and -6H), 6.91 – 
6.86 (3H, m, phenyl-3H, -4H and -5H), 5.57 (1H, s, phenylacetate-2H) and 
3.66 (3H, s, methyl-H). HRMS (ESI): C15H14O3 requires [M+Na]+, calculated 
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1,1-Diethyl 2-phenylcyclopropane-1,1-dicarboxylate, 10276 
 
A three-neck round bottom flask, equipped with a dropping funnel, was 
charged with Rh2tfa4 (1.8 mg, 2.7 µmol) and degassed with a stream of N2. 
Heptane (6.0 mL) was added and degassed by bubbling a stream of N2 
through the stirred solution, followed by the addition of styrene (90 µL, 1.3 
mmol). The dropping funnel was charged with diethyl 2-diazomalonate (50 
mg, 0.3 mmol) in heptane (2.1 mL) and degassed by bubbling a stream of N2 
through the solution. After 5 minutes of degassing, the stream of N2 was 
slowed and removed from the bulk solvent, and the diazo solution added 
dropwise over 105 minutes. Heptane (1.0 mL) was then added to the 
dropping funnel to wash through any remaining diazo. After 16 hours of 
stirring the solvent was removed under reduced pressure to give a blue 
residue which was purified by MDAP (10 mM ammonium bicarbonate 
modifier gradient). The appropriate fractions were combined and dried under 
a stream of nitrogen to afford the cyclopropane 10276 as a colourless oil (10 
mg, 14%). δH (400 MHz, CDCl3) 7.28 – 7.22 (5H, m, 2-phenyl-H), 4.32 – 
4.21 (2H, m, ethyl-1H2), 3.89 – 3.84 (2H, m, ethyl-1’H2), 3.24 (1H, app. t, J 
8.6, cyclopropane-2H), 2.19 (1H, dd, J 8.0 and 5.2, cyclopropane-3Ha), 1.72 
(1H, dd, J 9.2 and 5.0, cyclopropane-3Hb), 1.32 (3H, t, J 7.1, ethyl-2H3) and 
0.89 (3H, t, J 7.1, ethyl-2’H3). 
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5.2.2 Protocols for the Screening of Model Reactions 
Reactions were carried out in 0.75 mL shell vials (Chemglass CV-2100-
0830) equipped with a teflon-coated stir bar (Biotage 0.2-0.5 mL magnetic 
stir bar #355545) and sealed using either a Freeslate 96-well reaction block 
or a Sigma-Aldrich Kitalysis 24-well reaction block (Z742107 Aldrich). Prior 
to the assembly of each reaction array the following stock solutions were 
made: diazo (5 or 6) in reaction solvent (1.25 M); catalyst in THF (25 mM); 
and a reactant (phenol) in reaction solvent (12.5 M). THF and styrene were 
added neat to reaction wells. Quantitative UPLC methods were developed 
by generating response factors for standard samples of products 7, 8, 9, 10 
against the external standard 4,4’-di-tBubiphenyl at 220 nM UV wavelength. 
All subsequent UPLC analysis was conducted at 220 nM detection 
wavelength and 0.5 mg/mL sample concentration relative to the initial mass 
of 5 or 6. 
Reaction assembly workflow (see general procedures for further detail): 
1. Dispense catalyst stock to reaction vial and dry under vacuum 
2. Add reaction solvent to each well for 200 μL total volume 
3. Stir for 2 minutes 
4. Add reactant to each well (THF, styrene or phenol) 
5. Add methyl 2-diazo 2-phenylacetate stock to each vial (3.5 
mg per well) 
6. Seal reaction block and stir for 24 hours at room temperature 
7. Remove solvent by N2 blowdown at 40 oC (16-20 hours) 
8. Add 0.5 mL 4,4’-di-tBubiphenyl solution in MeCN (1.66 mg/mL 
standard, 0.83 mg per well) 
9. Dilute 100 µL sample into 700 µL 80:20 MeCN/H2O (0.5 
mg/mL reactants, 0.025 mg/mL standard) and analyse 
reaction sample by UPLC at 220 nM UV wavelength 
The mass of product was calculated using the following formula: 
𝑃𝑟𝑜𝑑𝑢𝑐𝑡 𝑀𝑎𝑠𝑠
= 𝑃𝑟𝑜𝑑𝑢𝑐𝑡 𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒 𝐹𝑎𝑐𝑡𝑜𝑟 × 𝑀𝑎𝑠𝑠 𝑜𝑓 𝐸𝑥𝑡𝑒𝑟𝑛𝑎𝑙 𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑
× (
𝑃𝑟𝑜𝑑𝑢𝑐𝑡 𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎
𝐸𝑥𝑡𝑒𝑟𝑛𝑎𝑙 𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎
)  
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UPLC Gradients for Reaction Screening 
UPLC Gradient 5 minute (1 mL/min): 
Mobile Phase A (Aqueous) - 0.05% TFA in water 
Mobile Phase B (Organic) – 0.05% TFA in acetonitrile 
Time (mins) A(%) B(%) 
0 97.00 3.00 
3.7 5.00 95.00 
4.0 5.00 95.00 
4.1 97.00 3.00 
5.5 97.00 3.00 
 
UPLC Gradient 1 minute (2.2 mL/min): 
Mobile Phase A (Aqueous) - 0.05% TFA in water 
Mobile Phase B (Organic) – 0.05% TFA in acetonitrile 
Time (mins) A(%) B(%) 
0.00 97.00 3.00 
0.50 2.00 98.00 
0.60 2.00 98.00 
0.61 97.00 3.00 
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Procedure for the UPLC Screening of a C–H Insertion Reaction 
 
Catalyst stock (8 μL, 25 mM) for each screened catalyst was added to an 
individual vial and the solvent removed under vacuum. Heptane (168 μL) 
was then added to each vial and stirred for 2 minutes, followed by the 
sequential addition of THF (16 μL) and methyl 2-diazo 2-phenylacetate (16 
μL, 1.25 M). The reaction block was then immediately sealed and stirred at 
room temperature for 24 hours. After removal of solvent under a stream of 
N2 at 40 oC the reaction was analysed by UPLC. 
1 min UPLC trace: 
 
Compound 
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Procedure for the UPLC Screening of a Cyclopropanation Reaction 
 
Catalyst stock (8.0 μL, 25 mM) for each screened catalyst was added to an 
individual vial and the solvent removed under vacuum. CH2Cl2 (161.1 μL) 
was then added to each vial and stirred for 2 minutes, followed by the 
sequential addition of styrene (22.9 μL) and methyl 2-diazo 2-phenylacetate 
(16.0 μL, 1.25 M). The reaction block was then immediately sealed and 
stirred at room temperature for 24 hours. After removal of solvent under a 
stream of N2 at 40 oC the reaction was analysed by UPLC. Ratio of 
diastereomers was qualitatively measured using 5 min UPLC analysis to 
give a ratio of major/minor products. 
1 min UPLC trace:
 
5 min UPLC trace:
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Major(3.21)/minor(3.28) diastereomers, 5 min UPLC trace:
 
Compound 
Retention time for 












0.58 - - 
 
 
Procedure for the UPLC Screening of an O–H Insertion Reaction 
 
Catalyst stock (8 μL, 25 mM) for each screened catalyst was added to an 
individual vial and the solvent removed under vacuum. CH2Cl2 (168 μL) was 
then added to each vial and stirred for 2 minutes, followed by the sequential 
addition of phenol in CH2Cl2 (16 μL, 12.5 M) and methyl 2-diazo 2-
phenylacetate (16 μL, 1.25 M). The reaction block was then immediately 
sealed and stirred at room temperature for 24 hours. After removal of solvent 
under a stream of N2 at 40 oC the reaction was analysed by UPLC. 
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1 min UPLC trace:
  
Compound 
Retention time for 1 










Procedure for the UPLC Screening of an Alternative Cyclopropanation 
Reaction 
 
Catalyst stock (8.0 μL, 25 mM) for each screened catalyst was added to an 
individual vial and the solvent removed under vacuum. CH2Cl2 (161.1 μL) 
was then added to each vial and stirred for 2 minutes, followed by the 
sequential addition of styrene (22.9 μL) and diethyl 2-diazomalonate (16.0 
μL, 1.25 M). The reaction block was then immediately sealed and stirred at 
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room temperature for 24 hours. After removal of solvent under a stream of 
N2 at 40 oC the reaction was analysed by UPLC.  
1 min UPLC trace: 
 
Compound 
Retention time for 1 
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Solvent Screen for a C-H insertion Reaction 
Catalyst stock (8 μL, 25 mM) for each screened catalyst was added to an 
individual vial and the solvent removed under vacuum. A reaction solvent 
(168 μL) was then added to an individual vial and stirred for 2 minutes, 
followed by the sequential addition of THF (16 μL) and methyl 2-diazo 2-
phenylacetate (16 μL, 1.25 M). The reaction block was then immediately 
sealed and stirred at room temperature for 24 hours. After removal of solvent 
under a stream of N2 at 40 oC the reaction was analysed by UPLC. 
 
 
Figure 5.1. Solvent screen for C-H insertion of methyl 2-diazo 2-
phenylacetate into THF (n = 1). 
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Table 5.1 Summary of solvent screen yields for the formation of 7. 
 Yield of 7 % for each reaction solvent 
Catalyst Heptane Toluene TBME DMSO MeCN PhCl2 DCM DMF 
Rh2OAc4, 3a 37.4 26.8 0.5 0.0 0.3 11.3 5.4 0.7 
Rh2piv4, 3b 57.6 44.7 1.7 0.0 2.2 27.6 20.9 0.9 
Rh2oct4, 3c 51.2 29.9 0.6 0.0 1.2 16.2 6.1 1.2 
Rh2tfa4, 3e 43.0 36.8 12.4 0.0 2.3 13.5 14.1 0.0 
Rh2pfb4, 3h 42.2 24.4 11.0 0.0 4.6 23.7 16.7 0.0 
Rh2esp2, 3q 55.6 43.3 5.4 0.0 4.9 32.1 17.7 1.3 
Rh2S-DOSP4, 3r 61.4 44.0 5.9 0.0 2.7 25.1 14.9 1.3 
Rh2S-tertPTTL4, 3u 72.0 50.1 8.4 0.7 9.5 42.9 24.2 0.0 
Rh2S-PTAD4, 3s 59.3 46.5 3.4 0.0 2.4 38.3 20.4 0.8 
Rh2cap4, 4a 15.0 7.9 11.5 0.3 1.2 1.1 3.6 0.3 
Solvent screen for C-H insertion of methyl 2-diazo 2-phenylacetate into THF 
(n = 1). 
 
5.2.3 Computational Details 
Optimised geometries for all rhodium(II) complexes were calculated with the 
Gaussian09277 Software package in isolation using the standard BP86213,214 
density functional as implemented in Gaussian with the DZP basis set 6-
31G(d)208,278–280 on all atoms apart from rhodium where the 
Stuttgart/Dresden effective core potential MWB289 was used. Optimisations 
used ‘tight’ convergence criteria. Vibrational frequencies were not computed, 
and the energetic data does not include a correction for zero-point energy. In 
the absence of frequency calculations, stationary points have not been 
verified as minima. Geometry optimisations were started from crystal 
structure geometries of the complex of interest, where a structure was 
available (Table 5.4), or by careful structural modification of related 
complexes.  
Conformational searches were performed by Dr Natalie Fey (University of 
Bristol) to enhance conformational sampling. The description of the 
calculations below, and the results outlined in Tables 5.2 and 5.3, are the 
work of Dr Natalie Fey and the candidate jointly. Conformational searches 
used the default MMX force field in PCModel.281 GMMX was used for 
stochastic conformational searches, generally with default settings. 500 
iteration conformational searches were performed on the dirhodium complex 
as well as its carbene complex (stop criteria defined as Emin found 10 times 
and duplicates found 50 times). These conformational searches were 
hampered by missing parameters (circumvented by replacing atoms with 
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elements where parameters existed and suitable restraints) and difficulties 
with convergence, most likely due to the large number of connected rings 
arising from the dirhodium core. A selection of conformers was then re-
optimised fully at the DFT level, as described above. These DFT calculations 
were performed by the candidate. A full re-parameterisation of the force field 
lay outside the scope of this project, but for 3d and 4g, the impact of 
conformational change on the descriptors was explored. These are 
summarised in Tables 5.2 and 5.3 below. For complex 3d, the crystal 
structure geometry led to the lowest energy conformer. This was not the 
case for 4g, however, the range of energies found for 4g was small and the 
descriptors for the XRD-derived conformer and the lowest energy species 
found are reasonably similar. Inspection of descriptors shows limited 
variation in structural and energetic parameters, but a larger range for the 
steric descriptors (He8 and |wV|) as well as for the energy for Diazo 
precursor to form the carbene complex (E(coord)), as might be 
expected.177 While conformational change can have a large impact for the 
prediction of selectivity, reactivity and dynamic behaviour of some of the 
catalysts, in view of the computational problems with sampling conformer 
space reliably, it was decided that Boltzmann-averaged descriptors would 
not be included in the present version of this database. 
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Rel. E, kcal/mol 0.00 3.78 3.74 4.35 2.73 4.35 0.00 10.00 8.12 10.00 
r(Rh-Rh), 1 2.392 2.400 2.400 2.394 2.392 0.008 - - - - 
r(Rh-L), 1 2.058 2.059 2.060 2.057 2.057 0.003 - - - - 
∡(Rh-Rh-L), 1 88.6 88.5 88.5 88.6 88.6 0.1 - - - - 
∡(O-C-X) 126.5 126.5 126.5 126.5 126.5 0.0 - - - - 
r(αC-R1) 1.537 1.538 1.538 1.537 1.537 0.001 - - - - 
r(Rh-Rh), 2 - - - - - - 2.466 2.464 2.464 0.002 
r(Rh-L), 2 - - - - - - 2.069 2.069 2.069 0.000 
∡(Rh-Rh-L), 2 - - - - - - 87.7 87.7 87.7 0.0 
r(Rh-C) - - - - - - 1.979 1.975 1.978 0.004 
∡(C-C-C) - - - - - - 113.8 114.4 115.6 1.7 
ΔE(coord) - - - - - - 22.67 12.66 14.55 10.00 
He8 - - - - - - 33.25 37.49 33.19 4.29 
|wV| - - - - - - 26.70 26.70 19.40 7.30 
HOMO, 1 -0.1665 -0.1699 -0.1696 -0.1701 -0.1695 0.0036 - - - - 
LUMO, 1 -0.1310 -0.1304 -0.1302 -0.1347 -0.1340 0.0045 - - - - 
ΔE(FMO) -0.0355 -0.0395 -0.0394 -0.0354 -0.0355 0.0040 - - - - 
Q Rh, 1 0.8072 0.8164 1.0406 1.1353 1.1318 0.3281 - - - - 
Q(Donor Atoms, 
mean), 1 
-4.2841 -4.2822 -4.3875 -4.4222 -4.4212 0.1400 - - - - 
Q(L, mean), 1 -1.0253 -1.1395 -1.0406 -1.1353 -1.1319 0.1142 - - - - 
 

















Rel. E, kcal/mol 1.50 0.00 5.40 5.40 1.68 0.23 0.50 0.00 1.68 
r(Rh-Rh), 1 2.466 2.463 2.463 0.004 - - - - - 
r(Rh-L), 1 2.064 2.068 2.061 0.006 - - - - - 
∡(Rh-Rh-L), 1 87.8 88.0 88.1 0.2 - - - - - 
∡(O-C-X) 125.6 125.6 125.6 0.0 - - - - - 
r(αC-R1) 1.527 1.525 1.524 0.002 - - - - - 
r(Rh-Rh), 2 - - - - 2.540 2.522 2.536 2.533 0.017 
r(Rh-L), 2 - - - - 2.070 2.072 2.071 2.071 0.002 
∡(Rh-Rh-L), 2 - - - - 87.0 87.2 87.1 87.0 0.2 
r(Rh-C) - - - - 1.992 1.974 1.996 1.994 0.022 
∡(C-C-C) - - - - 110.4 110.7 111.6 110.3 1.3 
ΔE(coord) - - - - 8.73 10.18 9.91 10.41 1.68 
He8 - - - - 58.71 76.19 54.45 60.84 21.74 
|wV| - - - - 14.70 19.80 18.00 13.70 6.10 
HOMO, 1 -0.1261 -0.1337 -0.1330 0.0076 - - - - - 
LUMO, 1 -0.0866 -0.1175 -0.1088 0.0309 - - - - - 
ΔE(FMO) -0.0396 -0.0162 -0.0242 0.0233 - - - - - 
Q Rh, 1 0.6234 0.6197 0.6106 0.0128 - - - - - 
Q(Donor Atoms, 
mean), 1 
-4.1089 -4.1169 -4.1078 0.0091 - - - - - 
Q(L, mean), 1 -0.8028 -0.7340 -0.7828 0.0687 - - - - - 
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5.2.4 Design of a Descriptor Database 
A range of steric and electronic quantum chemical descriptors were then 
captured from optimised geometries of each rhodium(II) complex. The 
coordination energy of the carbene generated from a symmetrical α-diazo 
malonamide precursor was calculated from converged energies (a.u.) using 
the equation below. 
𝛥𝐸(𝑐𝑜𝑜𝑟𝑑) 𝑘𝑐𝑎𝑙 𝑚𝑜𝑙−1  =  627.5095 × ((𝐸𝟏 + 𝐸𝑫𝒊𝒂𝒛𝒐) − (𝐸𝟐 +  𝐸𝑵𝟐)) 
Natural population analysis (NBO) was calculated using the converged 
complex and the energy difference between the HOMO and LUMO 
molecular orbitals was calculated in atomic units using the equation below. 
𝛥𝐸(𝐹𝑀𝑂) 𝑎. 𝑢. =  𝐿𝑈𝑀𝑂 − 𝐻𝑂𝑀𝑂 
Other parameters captured from the NBO analysis include the charge on the 
rhodium atoms, charge on the ligand donor atoms and the average charge 
on the ligands. 
For the PCA model, 48 ligands (Table 5.4) were optimised as complexes 1 
and 2 (n = 96) and 19 chemical descriptors were extracted from these 
optimised complex geometries. Each descriptor (𝑥i) was scaled to 





Where 𝑢 =  
1
𝑁
∑ 𝑥𝑖𝑁𝑖=1  (sample mean of 𝑥), N = number of data points 
𝑠 =  √
1
𝑁
∑ (𝑥𝑖 − 𝑢)2𝑁𝑖=1  (sample standard deviation of 𝑥). 
Chemical descriptors considered: 
1. All bond lengths and angles (including dihedral angles) for both 
complexes 1 and 2 calculated at BP86/6-31G(d)/MWB28 level of 
theory in Gaussian09. Lengths and angles were assessed for their 
response to carbene formation and the following descriptors were 
selected: r(Rh-Rh), r(Rh-L), ∡(Rh-Rh-L), r(αC-R1), ∡(O-C-X), 
r(Rh-C) and ∡(C-C-C) as these showed a clear response to 
changes in ligand properties.  
2. Binding energies of ancillary ligands, including diazo malonamide 
(BP86/6-31G(d)/MWB28), methyl 2‐diazo‐2‐phenylacetate 
(BP86/6-31G(d)/MWB28), and acetonitrile (B3LYP/6-
31G(d)/MWB28). Complexes bearing acetonitrile ligands were 
found to possess extreme bond angles for complexes with 
- 133 - 
 
carboxamidate ligands and were thus removed from subsequent 
analyses. Acetonitrile complexes were initially calculated using the 
B3LYP functional, however, due to an inability to obtain 
convergence on several carboxamidate complexes, the functional 
was changed to BP86 for all other calculations. 
3. Several steric descriptors were considered, including an adapted 
version of the He8 ring used in Bristol’s LKBs,178–182 Distance-
Weighted Volume215 and first-generation Sterimol parameters.165 
He8 ring interaction energies were calculated as single-point 
energies at BP86/6-31G(d)/MWB28 level of theory, where the He8 
ring was aligned 1.9 Å from the rhodium core (average r(Rh-C) 
bond length). Distance-Weighted Volume was derived from the 
MolQuO web app (http://rodi.urv.es/~carbo/quadrants/index.html), 
aligning the quadrants with the Rh-C bond and then removing the 
carbene ligand from the optimised geometry. First-generation 
Sterimol parameters were calculated by aligning the L vector with 
the Rh-Rh bond and using a python script available here: 
https://github.com/bobbypaton/Sterimol. Sterimol parameters were 
found to be prone to outliers due to the extreme size of many of 
the ligands, and less capable of describing the steric environment 
around the Rh atoms, so were not used in subsequent analysis. A 
recently updated version of this descriptor, which explores 
conformational variation (wSterimol),282 may be able to address 
this limitation.  
4. Descriptors derived from the Natural Population Analysis of the 
converged complexes including: the HOMO and LUMO energies 
for complexes 1 and 2; charges on atoms including the core 
Rhodium atoms, ligand donor atoms and the average charge on 
the ligand for complexes 1 and 2; and the difference in energy 
between the frontier molecular orbitals. 
Distance weighted volume, or quadrant occupation (see discussion above 
for details), gives a measure of the steric bulkiness of the ligand and its 
influence over the metal centre, and was calculated using the formula below. 








where 𝑘 = 3 and 𝑙 = 1, 𝑑𝑙 = distance of atom to metal centre and 𝑟𝑘 = van 
der Waals radius of atom 
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Table 5.4. Modelled complexes. Cambridge Crystallographic Database 
accession codes are shown below catalyst names. 
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5.2.5 Exemplar Submission Script for Gaussian09 
The ARC3 high-performance computing cluster, at the University of Leeds, 
was used to calculate optimised geometries for all the rhodium(II) complexes 
shown in Table 5.4. An example submission script applicable to ARC3 is 
shown below. 
#$ -V -cwd 
#$ -l h_rt=24:00:00 
#$ -l h_vmem=4G 
#$ -l disk=4G 
#$ -pe smp 8 
 











# opt BP86/gen 5d 7f pseudo=cards 
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5.2.6 Exemplar Script for the Automated Extraction of Descriptors 
A python script for the automated extraction of parameters from the 
Guassian09 .log file of converged complexes was used to build the final 
version of the knowledge base, and the corresponding code is shown below.  
from __future__ import print_function 
import argparse 
parser = argparse.ArgumentParser() 
parser.add_argument("filenames", nargs="+") 
parser.add_argument("-p","--parameters", nargs="*", default=[]) 
args = parser.parse_args() 
 
def get_gaussian_results(filename, parameter_list): 
 file = open(filename, "r") 
 energy = None 
 optg_complete = False # default that the optimisation is NOT complete 
 parameters = {key: None for key in parameter_list} 
 for line in file: 
  if "SCF Done" in line: 
   energy = float(line.strip().split()[4]) 
  if "Optimized Parameters" in line: 
   optg_complete = True 
  if optg_complete: 
   for parameter in parameters.keys(): 
    if parameter in line: 
     value = float(line.strip().split()[3]) 
     parameters[parameter] = value 
 file.close() 
 return energy, parameters, optg_complete 
print("filename energy "+" ".join(args.parameters)) 
for filename in args.filenames: 
 #print(filename) 
 energy, parameters, optg_complete = get_gaussian_results(filename, 
args.parameters) 
 assert(optg_complete) # Check that optimisation IS complete then display result 
 #print(parameters) 
 #print(energy) 
 print(filename + " " + str(energy) + " " + " ".join([str(parameters[key]) for key in 
args.parameters])) 
 
get_gaussian_results(rhodium_complex.log, R(1,2)) # Pseudo-code for extracting the Rh-
Rh bond length assuming the rhodium atoms are atoms 1 and 2 in the gaussian file. 
 
  
- 139 - 
 
5.2.7 Data Extracted from DFT-Converged Rhodium(II) Complexes 

















Rh2OAc4 3a 2.3904 2.0556 88.69225 126.1627 1.515 2.4648 2.065525 87.69724 1.9729 115.5716 
Rh2tfa4 3e 2.4037 2.053688 88.60913 128.6942 1.5522 2.4921 2.064513 87.44825 1.9832 117.0577 
Rh2pfb4 3h 2.4084 2.0536 88.52184 128.7221 1.5533 2.4915 2.064563 87.45353 1.9851 117.54 
Rh2cap4 4a 2.4091 2.061563 88.60183 123.1859 1.52625 2.4624 2.077113 87.4265 1.9972 110.3102 
Rh2esp2 3q 2.3862 2.058725 88.64534 125.3802 1.54355 2.4551 2.0691 87.73745 1.9763 114.8787 
Rh2TBSP4 3d 2.3922 2.058038 88.64276 126.4889 1.536775 2.4661 2.069413 87.66359 1.9786 113.8305 
Rh2piv4 3b 2.3873 2.056675 88.64755 125.4675 1.5422 2.4593 2.06735 87.67254 1.9724 114.6697 
Rh2oct4 3c 2.3902 2.05645 88.6592 125.8777 1.5227 2.4608 2.067025 87.73165 1.9723 114.7489 
Rh2MEOX4 4d 2.4711 2.063213 87.92615 127.7151 1.369975 2.5479 2.072625 86.95375 2.0006 111.3165 
Rh2MEPY4 4g 2.4662 2.0637 87.84624 125.5897 1.526675 2.5396 2.070075 87.02478 1.9924 110.4379 
Rh2PTAD4 3s 2.3876 2.053638 88.63128 126.1072 1.547875 2.4578 2.0672 87.70965 1.9728 114.2438 
Rh2PTTL4 3t 2.3874 2.053725 88.63924 126.1469 1.54705 2.4581 2.066075 87.71286 1.9735 114.2253 
Rh2DOSP4 3r 2.3898 2.057938 88.68329 126.5004 1.536475 2.4645 2.069513 87.6764 1.9854 112.5911 
Rh2tertPTTL4 3u 2.387 2.05465 88.64523 126.1291 1.54715 2.4577 2.066013 87.71779 1.9731 114.2204 
Rh2pip4 4b 2.4082 2.060575 88.56604 123.2836 1.5276 2.4782 2.0751 87.63741 1.9917 107.7132 
Rh2pyr4 4e 2.4522 2.058213 88.31283 126.0343 1.5253 2.5288 2.071138 87.15415 1.9797 109.2122 
Rh2OXAZ4 4h 2.4143 2.061425 88.43944 125.0821 1.37215 2.4883 2.074538 87.5471 1.9989 109.4973 
Rh2OXAL4 4k 2.465 2.060988 88.32644 128.3155 1.3724 2.5429 2.0725 87.03189 1.9809 110.5352 
Rh2OXPN4 4n 2.428 2.063 88.54245 125.6473 1.3812 2.4929 2.075813 87.19973 1.9978 111.6562 
Rh2MIDO4 4q 2.4627 2.064025 88.40193 126.9106 1.40215 2.5415 2.075088 87.39979 1.9742 108.7325 
Rh2MPDO4 4c 2.4003 2.06295 88.5657 122.9188 1.401225 2.466 2.077913 87.5959 1.9932 106.1646 
Rh2PYOH4 4f 2.4048 2.0511 89.13498 121.3814 1.4303 2.4549 2.066513 87.29741 1.9959 111.4973 
Rh2dhpo4 4i 2.4603 2.055 88.3918 126.0434 1.4825 2.5414 2.064963 87.32451 1.981 112.0302 
Rh2pyo4 4l 2.4578 2.05685 88.38496 125.9489 1.5262 2.5383 2.068588 87.13825 1.9844 110.4622 
Rh2dhpd4 4o 2.4171 2.059275 88.61054 123.4697 1.5234 2.4739 2.073661 87.2797 1.9933 111.821 
Rh2dhpy4 4r 2.4178 2.05625 88.55289 123.7707 1.48325 2.4924 2.069713 87.61476 1.9901 108.5639 
Rh2dfpyr4 4t 2.4615 2.0532 88.28734 127.6318 1.536 2.5469 2.065088 87.00008 1.9875 111.4793 
Rh2mfpyr4 4w 2.4552 2.054375 88.34173 126.7989 1.5302 2.5368 2.066725 87.05054 1.9822 110.2788 
Rh2dfpip4 4u 2.4146 2.05555 88.56323 124.8482 1.54375 2.4957 2.069513 87.5174 1.9994 108.7959 
Rh2mfpip4 4x 2.4094 2.05675 88.49751 124.0973 1.53125 2.4829 2.07255 87.38653 1.9961 108.7212 
Rh2MACIM4 4p 2.4523 2.061175 88.42836 126.8245 1.41275 2.5252 2.076313 87.15031 1.98 107.6853 
Rh2MACIM4_A 4s 2.4711 2.0657 87.94701 126.4995 1.414175 2.5345 2.073588 86.92713 2.0015 110.3956 
Rh2MPPIM4 4j 2.4515 2.060813 88.43143 126.8015 1.4134 2.5293 2.077325 87.3054 1.9848 107.5012 
Rh2MPPIM4_A 4m 2.4707 2.064838 87.93806 126.5221 1.41505 2.5315 2.075563 86.84775 2.0041 109.4536 
Rh2DIZO4 4v 2.4155 2.057663 88.63804 124.5496 1.430175 2.4705 2.076325 87.44414 2.0118 107.645 
Rh2acam4 4y 2.4314 2.05445 88.23983 123.319 1.5193 2.4943 2.063113 87.37613 1.9551 117.3778 
Rh2tfam4 4z 2.4442 2.0509 88.26348 126.1411 1.541 2.5168 2.058513 87.30193 1.9628 118.1972 
Rh2DMU4 4aa 2.4206 2.058425 88.47038 123.0672 1.399125 2.4734 2.066438 87.4447 1.9553 115.8328 
Rh2bnz4 3j 2.3871 2.0506 88.7349 125.4768 1.4929 2.4615 2.060625 87.74085 1.9708 114.4433 
Rh2DABN4 3k 2.3855 2.050938 88.80255 125.2522 1.482025 2.4533 2.059425 87.89366 1.97 113.9495 
Rh2POMB4 3l 2.3883 2.051313 88.7262 125.3599 1.48625 2.4537 2.059513 87.86411 1.9704 114.6449 
Rh2TFMB4 3p 2.3886 2.0503 88.71806 125.6467 1.494 2.4595 2.059925 87.64995 1.9739 114.5271 
Rh2FBNZ4 3m 2.3874 2.050525 88.74549 125.4981 1.4898 2.4554 2.065975 87.83151 1.9718 114.8362 
Rh2TFBN4 3n 2.3942 2.054125 88.64741 126.5726 1.4924 2.4729 2.061125 87.65856 1.979 115.6387 
- 140 - 
 
Rh2PFBN4 3o 2.3852 2.0489 88.723 125.808 1.4957 2.4737 2.065 87.64573 1.9817 116.05 
Rh2dfa4 3f 2.4036 2.053625 88.58965 128.1126 1.5416 2.4836 2.065388 87.55831 1.9794 116.869 
Rh2mfa4 3g 2.3994 2.05775 88.62931 127.5868 1.529225 2.477 2.068275 87.58025 1.9793 117.6103 
Rh2FPIV4 3i 2.3944 2.051663 88.53656 127.1141 1.55695 2.4779 2.067038 87.4557 1.9948 115.8411 
 
Table 5.5 continued. 
No ΔE(coord) Sterimol L SterimolB1 SterimolB5 He8 |wV| HOMO, 1 LUMO, 1 ΔE(FMO) 
3a 22.26686 4.79 4.85 5.85 20.63117 0 -0.16939 -0.13257 0.03682 
3e 29.40413 4.8 5.42 6.2 19.99772 0 -0.22456 -0.18604 0.03852 
3h 29.794 4.89 6.83 8.57 20.30875 2.4 -0.22206 -0.1841 0.03796 
4a 12.23489 6.55 4.93 7.13 55.12895 15.2 -0.12038 -0.10225 0.01813 
3q 21.16797 4.79 6.14 8.35 21.26676 5.4 -0.16755 -0.13127 0.03628 
3d 22.66718 11.93 7.62 13.65 33.25419 26.7 -0.16652 -0.13099 0.03553 
3b 21.40432 4.79 6.05 6.99 21.47971 4.8 -0.16605 -0.12978 0.03627 
3c 21.55542 7.77 6.66 12.68 20.96546 7.8 -0.1665 -0.13009 0.03641 
4d 6.939207 8.96 5.16 6.62 60.30271 15.8 -0.14875 -0.12189 0.02686 
4g 8.726304 9.18 5.14 6.71 58.70671 14.7 -0.12613 -0.08658 0.03955 
3s 21.23446 9.09 7.82 9.64 22.61748 27.8 -0.1659 -0.13075 0.03515 
3t 21.47939 8.93 7.41 8.32 22.55454 28 -0.16636 -0.13104 0.03532 
3r 17.74799 23.89 8.21 25.03 31.69143 36.9 -0.16615 -0.13041 0.03574 
3u 21.45875 11.23 7.88 10.41 22.50282 40.2 -0.16223 -0.12691 0.03532 
4b 12.2192 5.99 5.32 7.08 53.03076 11.4 -0.12178 -0.10327 0.01851 
4e 16.30173 5.74 5.1 6.29 43.15772 8.5 -0.12889 -0.11513 0.01376 
4h 13.20737 5.77 5.26 6.91 51.69668 11.1 -0.12924 -0.11119 0.01805 
4k 19.22107 5.73 5.04 6.28 37.39957 8.2 -0.1429 -0.12104 0.02186 
4n 14.94868 6.51 4.83 7.02 44.66466 12.4 -0.13166 -0.11333 0.01833 
4q 17.58666 5.78 5.56 6.98 43.08334 10.2 -0.12058 -0.10892 0.01166 
4c 11.68626 5.89 5.56 6.98 54.14027 14.9 -0.10863 -0.09285 0.01578 
4f 15.79384 6.01 5.27 7.03 47.8954 10.8 -0.14863 -0.12872 0.01991 
4i 19.43113 5.55 4.66 6.41 38.71222 10.1 -0.13087 -0.12025 0.01062 
4l 18.81432 5.87 4.98 6.3 51.43823 7.8 -0.13861 -0.13147 0.00714 
4o 15.52796 6.04 5.08 7.02 46.78839 10.7 -0.13731 -0.1228 0.01451 
4r 13.79536 5.88 5.15 7.08 50.99556 10.7 -0.12572 -0.11039 0.01533 
4t 20.06076 5.73 5.44 6.37 39.91734 8.6 -0.16117 -0.14613 0.01504 
4w 17.60651 5.76 5.21 6.29 42.0534 8.3 -0.14679 -0.1319 0.01489 
4u 16.33769 5.99 5.43 7.07 51.85375 12.5 -0.14951 -0.13022 0.01929 
4x 11.40141 5.98 5.42 7.06 52.16438 12.5 -0.13864 -0.119 0.01964 
4p 16.1105 5.77 5.9 7.77 47.19848 11.1 -0.15853 -0.14624 0.01229 
4s 7.096756 9.1 5.84 7.8 64.71005 15.7 -0.15433 -0.1214 0.03293 
4j 15.19324 11.23 6.57 7.8 47.80398 21.5 -0.15762 -0.14472 0.0129 
4m 6.64862 11.25 6.56 8.26 53.56466 27 -0.15334 -0.11916 0.03418 
4v 13.2335 5.95 5.78 8.07 52.42294 12.9 -0.13221 -0.11508 0.01713 
4y 26.84968 4.83 4.91 5.81 22.07075 1 -0.13031 -0.11369 0.01662 
4z 30.73594 4.84 5.49 6.25 21.11823 1.7 -0.18067 -0.16188 0.01879 
4aa 26.33938 4.92 5.52 7 22.9179 5.5 -0.1129 -0.09669 0.01621 
3j 21.85532 4.85 6.78 9.13 21.57902 2 -0.16764 -0.13199 0.03565 
3k 20.6465 4.86 8.28 11.27 21.66365 3.2 -0.13792 -0.10356 0.03436 
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3l 20.5143 4.86 8.26 11.23 21.84006 2.3 -0.15525 -0.1204 0.03485 
3p 22.51241 4.84 8.56 10.47 21.33658 2 -0.18829 -0.15202 0.03627 
3m 21.47649 4.85 7.32 9.74 21.3375 2 -0.17349 -0.13785 0.03564 
3n 24.13533 4.95 7.28 9.76 21.18246 1.6 -0.17735 -0.14063 0.03672 
3o 28.75752 5.47 7.36 9.79 16.95986 4.6 -0.1891 -0.15127 0.03783 
3f 27.42214 4.8 5.35 6.2 20.06181 0 -0.21009 -0.17266 0.03743 
3g 26.32712 4.8 4.89 6.17 19.8209 1.4 -0.19209 -0.15556 0.03653 
3i 29.10249 5.49 6.59 7.66 22.4572 6.4 -0.22239 -0.18322 0.03917 
 
Table 5.5 continued. 




3a 0.80629 -4.31789 -1.00425 
3e 0.79276 -4.10036 -1.13426 
3h 0.78939 -4.08076 -1.12332 
4a 0.6522 -4.14731 -0.7166 
3q 0.83497 -4.33155 -1.0183 
3d 0.80715 -4.28413 -1.02527 
3b 0.82605 -4.33186 -1.00907 
3c 0.80827 -4.32914 -1.24281 
4d 0.6407 -4.33444 -0.83666 
4g 0.62339 -4.10886 -0.80275 
3s 0.89223 -4.41617 -1.11186 
3t 0.8317 -4.31028 -1.0441 
3r 0.82854 -4.28021 -1.01252 
3u 0.83201 -4.31165 -1.03985 
4b 0.62913 -4.1665 -0.73117 
4e 0.62541 -4.13542 -0.77352 
4h 0.65093 -4.403 -0.79159 
4k 0.63686 -4.37843 -0.83492 
4n 0.64834 -4.28228 -0.74896 
4q 0.64281 -4.38313 -0.76787 
4c 0.67141 -4.44688 -0.72964 
4f 0.63973 -3.90413 -0.79312 
4i 0.65438 -4.08522 -0.78647 
4l 0.64311 -4.06333 -0.81341 
4o 0.64013 -4.07627 -0.78234 
4r 0.63195 -4.08795 -0.76295 
4t 0.60243 -3.98149 -0.8322 
4w 0.60802 -4.03045 -0.80031 
4u 0.60649 -4.01033 -0.79638 
4x 0.61204 -4.0752 -0.76478 
4p 0.65817 -4.27235 -0.83569 
4s 0.65699 -4.25213 -0.86174 
4j 0.65467 -4.26562 -0.85483 
4m 0.65094 -4.23983 -0.86727 
4v 0.66967 -4.16472 -0.78785 
4y 0.60918 -4.90265 -0.70204 
- 142 - 
 
4z 0.59348 -4.71809 -0.82173 
4aa 0.65056 -5.20242 -0.69174 
3j 0.83369 -4.3023 -1.03784 
3k 0.83651 -4.36041 -0.99226 
3l 0.83654 -4.33368 -1.01773 
3p 0.8366 -4.28181 -1.0663 
3m 0.83729 -4.31196 -1.04071 
3n 0.8021 -4.14494 -1.04506 
3o 0.8102 -4.14632 -1.08255 
3f 0.78576 -4.16766 -1.09024 
3g 0.79037 -4.26683 -1.06525 
3i 0.81255 -4.11378 -1.1405 
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Table 5.6. PCA Eigenvalues for PC1/PC2/PC3 
Complex PC1 PC2 PC3 
3a 2.765124 0.394087 0.484166 
3b 2.540759 0.826934 0.045106 
3c 3.063959 0.547643 -0.55779 
3d 1.964327 0.611458 -1.67993 
3e 4.135164 -3.07732 0.48039 
3f 3.709259 -2.22617 0.528501 
3g 3.415276 -1.35453 0.537182 
3h 3.952224 -3.17644 0.358793 
3i 3.981831 -2.19594 -0.03057 
3j 2.816006 0.904917 0.259393 
3k 2.262869 2.254427 0.206891 
3l 2.618915 1.529706 0.209988 
3m 3.126386 0.931589 0.256251 
3n 2.910799 -0.25628 0.367238 
3o 3.692856 -0.27468 0.545152 
3p 3.271487 0.143183 0.224148 
3q 2.732144 0.955249 -0.02999 
3r 1.690642 1.041756 -2.77287 
3s 2.757774 0.918259 -2.03934 
3t 2.429197 0.918512 -1.74944 
3u 2.235113 1.202976 -2.59396 
4a -2.31806 2.673761 0.080818 
4aa -0.90338 1.722572 2.42053 
4b -2.42068 2.666118 0.217413 
4c -2.70736 3.442609 -0.17431 
4d -3.75862 -2.63471 -1.64474 
4e -3.08175 -0.70591 0.577585 
4f -0.73693 2.934292 1.212598 
4g -4.12887 -1.14019 -1.6823 
4h -2.05698 1.294935 -0.03218 
4i -2.40733 -0.89312 0.97583 
4j -2.34399 -1.14344 -0.74184 
4k -2.29413 -2.33117 0.200509 
4l -2.87215 -1.21016 0.982162 
4m -3.61938 -2.05115 -2.67747 
4n -2.06685 0.469549 0.283543 
4o -1.69553 1.427121 0.866271 
4p -2.32495 -1.46413 0.096215 
4q -3.05464 -0.58895 0.491496 
4r -2.31969 1.94737 0.45642 
4s -3.58574 -2.15338 -1.88819 
4t -2.20451 -2.84644 0.730663 
4u -1.69042 0.81985 0.236748 
4v -1.97567 1.848575 -0.10632 
4w -2.63137 -1.73973 0.658611 
4x -2.29055 1.450535 -0.01318 
4y -0.97945 0.235402 2.846985 
4z 0.396875 -2.64954 2.576822 
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5.2.8 Exemplar Python Code for Principal Component Analysis 
PCA (LAPACK implementation, single-value decomposition) was then 
performed with the sklearn (0.20.3) python (3.7.3) package for all the 
captured and scaled descriptors using the python code outlined below. 
# Required packages for PCA decomposition 
from sklearn.decomposition import PCA 
# PCA decomposition 
pca = PCA(n_components = 3) 
principal_components = pca.fit_transform(data) 
Outlined below is the python script used to find the top ranked solutions 
shown in Figures 2.10, 2.11 and 2.12, and Table 2.2. The script below 
selects the PCA model with the smallest mean squared error for the loss of 
reprojection (note: more than one solution will have a low value). 
# data is an array for the number of descriptors and x a DataFrame containing the 
knowledge base data 
def PCA_solution(x, data):  
    solution = {} 
    for L in range(min(x), max(x)+1): 
        res = []  
# The result of each combination of descriptors is appended here 
        for i in itertools.combinations(features, L):  
# loop that uses itertools to compute all combinations of descriptors 
            descriptors = data.loc[:, i].values # Extract descriptors from DataFrame 
            X_train = StandardScaler().fit_transform(descriptors)  
# Scaling data for PCA decomposition 
            pca = PCA(n_components=3)  
# Calling PCA and setting number of principal components to be computed 
            principal_components = pca.fit_transform(X_train)  
            X_projected = pca.inverse_transform(principal_components)  
# Reprojection of PCA decomposition 
            loss = ((X_train - X_projected) ** 2).mean()  
# Calculating mean squared error for loss of reprojection 
            var = sum(pca.explained_variance_ratio_)  
# Variation captured for each solution 
            res.append([loss, var, i]) # Appending results for each combination 
        std_loss = np.std([res[i][0] for i in range(len(res))])  
# Calculating standard deviation for the loss of all solutions 
        std_var = np.std([res[i][1] for i in range(len(res))])  
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# Calculating standard deviation for variation 
        solution["solution{0}".format(L)] = min(res), std_loss, std_var  
# Adding result to dictionary 
    return solution 
 
PCA_solution(x = [10, 11, 12 ,13, 14], data = knowledgebase)   
# Pseudo-code for computing solutions using 10, 11, 12, 13, and 14 descriptors 
 
5.3.9 Overlay of Alternative Model Reactions onto the PCA Map 
The yields for the C–H and O–H insertion reactions between 5 and THF 
(giving 7 as a product) or phenol (giving 9 as a product), and the 
cyclopropanation of styrene with an acceptor/acceptor diazo, 6, (giving 10 as 
a product) are projected onto the PCA plots below (Figures 5.2, 5.3, and 
5.4). For the overlay of the donor/acceptor diazo cyclopropanation of 
styrene, yielding 8, see Figure 2.17. All four model reactions gave a range of 
yields, with O,O catalysts generally giving higher yields than N,O catalysts. 
Product yields clustered based on PC1, PC2 and PC3 values demonstrating 
that both steric and electronic factors contribute to outcomes. 
 
Figure 5.2. PC1/PC2 and PC1/PC3 plots with yield overlay for C-H insertion. 
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Figure 5.3. PC1/PC2 and PC1/PC3 plots with yield overlay for O-H insertion. 
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5.3 Materials and Methods for Activity-Directed Synthesis 
5.3.1 Synthesis of Diazo Compounds 
CAUTION: All diazo compounds (excluding those isolated as solid material) 
described below appear to be volatile at room temperature under reduced 
pressure. Gradual loss of mass was observed when left under high vacuum. 
Diazo compounds are potentially explosive on contact and should be treated 
with caution, although no adverse events occurred during the experiments 
described in this thesis. 
General procedure for diazo transfer, A 
4-Acetamidobenzenesulfonyl azide (1.2 eq) was added portion-wise to a 
solution of benzylic ester or tertiary amide (1 eq) and 1,8-
Diazabicyclo[5.4.0]undec-7-ene (1.4 eq) in acetonitrile (substrate 
concentration: 0.01 M) at 0 oC using an ice-bath. After 16 hours, the solvent 
was removed under reduced pressure to give a crude product that was 
dissolved in diethyl ether (40 mL) and washed sequentially with 10% w/w 
citric acid (2 x 10 mL), brine (2 x 10 mL), 10% w/v ammonium chloride (2 x 
10 mL) and brine (2 x 10 mL). The organics were passed through a phase 
separation frit and concentrated under reduced pressure to give a crude 
product. 
General procedure for one-pot acylation and diazo transfer, B 
A secondary amine (1 eq) and 2,2,2,6-trimethyl-1,3-dioxin-4-one (1.5 eq) 
were added sequentially to a 20 mL microwave vial, dissolved in toluene 
(substrate concentration: 1.4 M) and heated under microwave irradiation at 
110 oC for 30 minutes. The solvent was then removed under reduced 
pressure and the crude material dissolved in acetonitrile (substrate 
concentration: 0.01 M). The solution was then cooled to 0 oC and 1,8-
Diazabicyclo[5.4.0]undec-7-ene (1.4 eq) and 4-Acetamidobenzenesulfonyl 
azide (1.2 eq) were added sequentially. After 16 hours, the solvent was 
removed under reduced pressure to give a crude product that was dissolved 
in diethyl ether (40 mL) and washed sequentially with 10% w/w citric acid (2 
x 10 mL), brine (2 x 10 mL), 10% w/v ammonium chloride (2 x 10 mL) and 
brine (2 x 10 mL). The organics were passed through a phase separation frit 
and concentrated under reduced pressure to give a crude product. 
General procedure for hydrazone decomposition, C 
Compound 3.17 (1 eq) was suspended in Toluene (substrate concentration: 
0.2 M) and stirred. Thionyl chloride (2 eq) was added and the reaction 
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heated to 90 oC for 3 hours, then the solvent removed under vacuum to give 
an orange solid. The solid was then dissolved in DCM (substrate 
concentration: 0.1 M) and cooled to 0 oC using an ice-bath. A solution of 
primary or secondary amine (3.4 mmol) and N,N-dimethylaniline (1 eq) in 
DCM (0.3 M) was subsequently added slowly to the stirred solution over 5 
minutes. After 1-hour triethylamine (5 eq) was added and the reaction 
allowed to warm to room temperature overnight. The organics were then 
washed sequentially with 10% w/w citric acid (2 x 20 mL), brine (2 x 20 mL), 
10% w/v ammonium chloride (2x 20 mL) and brine (2 x 20 mL), passed 
through a phase separation frit and concentrated under reduced pressure to 
give a crude product. 
 
2-(4-Methylbenzenesulfonamido)imino Acetic Acid, 3.17 
 
Glyoxylic acid (7.4g, 80 mmol) and p-toluenesulfonylhydrazide (10 g, 50 
mmol) were dissolved in THF and the mixture stirred vigorously. After 24 
hours, the solvent was removed under reduced pressure to give a viscous oil 
which was triturated with distilled water until a fine white powder was 
obtained. The solid was then air-dried overnight and then recrystallised in 
EtOAc to afford the hydrazone 3.17 as a white amorphous solid (10.9 g, 
90%). δH (400 MHz, Acetone-d6) 11.01 (1H, s, acetic acid-H), 7.82 (2H, d, J 
8.0, phenyl-2H and -6H), 7.43 (2H, d, J 8.0, phenyl-3H and -5H), 7.32 (1H, s, 
imino-2H) and 2.42 (3H, s, methyl). δC (100 MHz) 206.3, 163.8, 145.3, 137.3, 




4-Chlorophenyl acetic acid (1.00 g, 5.9 mmol) was dissolved in DCM (8 mL), 
then 4-chloro-N-methyl aniline (707 μL, 5.9 mmol) and DCC (1.33 g, 6.5 
mmol) were added sequentially. After 16 hours of stirring the reaction was 
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cooled to 0 oC using an ice-bath and a white precipitate formed. The by-
product precipitate was then removed by filtration and the solvent removed 
under reduced pressure to give a light-yellow oil, which passed through a 
silica plug eluting 9:1 Pentane/Et2O then 100% Et2O to give the amide as a 
crude colourless oil (885 mg, 30%). δH (400 MHz, Acetone-d6) 7.48 (2H, d, J 
8.3, N-chlorophenyl-2H and -6H), 7.35 – 7.33 (2H, m, chlorophenyl-2H and 
6H), 7.26 (2H, d, J 8.3, N-chlorophenyl-3H and -5H), 7.15 – 7.07 (2H, m, 




According to general procedure A, N,2‐bis(4‐chlorophenyl)‐N‐
methylacetamide (300 mg, 1.0 mmol) gave a crude material. The viscous 
orange oil was purified by flash column chromatography eluting with 8:2 
Pentane/Et2O to yield the diazo D3 as an orange oil (114 mg, 35%), RF 0.14 
(1:1 Pentane/Et2O); δH (400 MHz, Acetone-d6) 7.42 – 7.30 (8H, m, phenyl-H) 
and 3.36 (3H, s, methyl). δC (100 MHz) 164.9, 144.2, 132.7, 131.7, 130.8, 
130.0, 129.7, 128.3, 127.7, 127.2 and 38.7. IR νmax (CH2Cl2 film/cm-1 2066 
(diazo), 1635, 1490 and 1313. HRMS (ESI): C15H1135Cl2N3O requires 




According to general procedure B, 4-Chloro-N-methyl aniline (1.00 mL, 8.3 
mmol) gave a crude material. During the reaction a white precipitate formed, 
which was removed by filtration, and the solvent then removed under 
reduced pressure to give a dark red oil which was purified by flash column 
chromatography eluting with 100% DCM, then 9:1 DCM/Et2O, to yield the 
diazo D1 as a yellow oil that solidified on standing (1.34 g, 64%), RF 0.10 
(DCM); δH (400 MHz, CDCl3) 7.39 (2H, d, J 8.7, chlorophenyl-2H and -6H), 
7.14 (2H, d, J 8.7, chlorophenyl-3H and -5H), 3.34 (3H, s, N-methyl) and 
2.46 (3H, s, oxobutanamide-H3). δC (100 MHz) 191.4, 161.1, 157.1, 141.7, 
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133.9, 130.6, 127.5, 38.6 and 28.5. IR νmax (CH2Cl2 film)/cm-1 2184 (diazo), 
1636, 1590, 1487, 1356. HRMS (ESI): C11H1035ClN3O2 requires [M+Na]+, 




According to general procedure C, 3-phenyl pyrrolidine (500 mg, 3.4 mmol) 
gave a crude material. The dark, viscous orange oil which was purified by 
flash column chromatography eluting with 100% DCM for 3 column volumes 
then 90:10 DCM/Et2O to afford the diazo D4 as a bright orange oil (574 mg, 
78%), RF 0.32 (Et2O); δH (500 MHz, CD2Cl2) 7.33 (2H, dd, J 8.0 and 7.0, 
phenyl-3H and -5H), 7.26 (3H, m, phenyl-2H, -4H and -6H), 4.89 (1H, s, 
ethenone-2H), 4.02 – 3.81 (1H, m, pyrrolidinyl-3H), 3.61 – 3.23 (4H, m, 
pyrrolidinyl-4H2 and -5H2), 2.35 – 2.29 (1H, m, pyrrolidinyl-2Ha) and 2.07 – 
2.00 (1H, m, pyrrolidinyl-2Hb). δC (125 MHz) 163.8 (rot-A and rot-B), 141.4 
(rot-B), 141.1 (rot-A), 129.9 (rot-B), 129.8 (rot-A), 128.7 (rot-A and rot-B), 
127.14 (rot-A and rot-B), 52.5 (rot-A and rot-B), 52.3 (rot-A and rot-B), 46.2 
(rot-A), 45.8 (rot-B), 44.6 (rot-A), 42.9 (rot-B), 33.4 (rot-A) and 33.1 (rot-B). 
IR νmax (CH2Cl2 film)/cm-1 2095 (diazo), 1600, 1417 and 1166. HRMS (ESI): 




According to general procedure C, (S)-3-phenyl pyrrolidine (147 mg, 1.0 
mmol) gave a crude material. The dark, viscous orange oil which was 
purified by flash column chromatography eluting with 100% DCM for 3 
column volumes then 90:10 DCM/Et2O to afford the diazo D4a as a bright 
orange oil (58.1 mg, 27%), RF 0.46 (Et2O); [𝛼]𝐷
20 = –35 degrees cm2 g-1 (c 
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According to general procedure C, (R)-3-phenyl pyrrolidine (147 mg, 1.0 
mmol) gave a crude material. The dark, viscous orange oil which was 
purified by flash column chromatography eluting with 100% DCM for 3 
column volumes then 90:10 DCM/Et2O to afford the diazo ent-D4a as a 
bright orange oil (143 mg, 67%), RF 0.54 (Et2O); [𝛼]𝐷
20 = +28 degrees cm2 g-1 





According to general procedure C, N-methyl-N-tetrahydro-2H-pyran-4-
ylamine (500 mg, 4.3 mmol) gave a crude material. The dark orange oil was 
purified by flash column chromatography eluting with 90:10 DCM/Et2O for 3 
column volumes then 100% Et2O to afford diazo D5 as a bright orange oil 
(708 mg, 90%), RF 0.10 (Et2O); δH (500 MHz, CD2Cl2) 5.01 (1H, s, 
acetamide-2H), 3.97 (2H, dd, J 11.2, 4.6, oxanyl-3Ha and -5Ha), 3.44 (2H, 
app. t, J 11.4, oxanyl-3Hb and -5Hb), 2.7 (3H, s, N-methyl), 1.77 – 1.73 (3H, 
m, oxanyl-1H and 2H2) and 1.55 – 1.52 (2H, m, oxanyl-6H2). δC (125 MHz) 
165.9, 104.6, 67.8, 64.2, 46.8 and 30.7. IR νmax (CH2Cl2 film)/cm-1 2098 
(diazo), 1600, 1410, 1256, 1144 and 1086. HRMS (ESI): C8H13N3O2 requires 
[M+Na]+, calculated 206.0905, found 206.0892. 
 
 




According to general procedure C, 5-amino-3-methylisoxazole (422 mg, 4.3 
mmol) gave a crude material. The dark orange oil was purified by flash 
column chromatography eluting with 90:10 DCM/Et2O to afford diazo D7 as 
a bright orange oil (170 mg, 24%), RF 0.49 (Et2O); δH (500 MHz, Acetone-d6) 
10.17 (1H, broad s, N-acetamide-H), 6.13 (1H, s, oxazolyl-4H), 5.99 (1H, s, 
acetamide-2H) and 2.19 (3H, s, methyl). δC (125 MHz) 162.7 (rot-A), 162.6 
(rot-B), 162.2 (rot-A), 162.1 (rot-B), 161.6 (rot-A and rot-B), 88.7 (rot-A), 88.6 
(rot-B), 49.3 (rot-A and rot-B) and 11.6 (rot-A and rot-B). IR νmax (CH2Cl2 
film)/cm-1 3205, 2109 (diazo), 1648, 1551, 1381, 1364, 1197 and 1155. 





4-Chlorophenyl acetic acid (1.0 g, 5.9 mmol) was suspended in 2,2,2-
trifluoroethanol (60 mL) and concentrated H2SO4 (0.4 mL) was added, then 
the suspension heated to reflux. After 16 hours the reaction was cooled to 
room temperature and neutralised to pH 7 with 1M NaOH, and the solvent 
removed under vacuum. The oil was then dissolved in DCM (75 mL) and 
washed sequentially with brine (3 x 30 mL). The organics were then 
collected, passed through a phase separation frit, and dried under vacuum 
to afford the ester as a crude colourless oil (1.4 g, 98%). δH (500 MHz, 
Chloroform-d) 7.32 (2H, d, J 8.5, chlorophenyl-2H and -6H), 7.22 (2H, d, J 
8.5, chlorophenyl-2H and -6H), 4.48 (2H, q, J 8.4, ethyl-1H2), 3.70 (2H, s, 
acetate-2H). δC (100 MHz) 169.7, 133.7, 131.3, 130.8, 129.0, 123.0 (q, JC-F 
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2,2,2‐Trifluoroethyl 2‐(4‐chlorophenyl)‐2‐diazoacetate, D2220 
 
According to general procedure A, 2,2,2‐Trifluoroethyl 2‐(4‐
chlorophenyl)acetate (500 mg, 2.0 mmol) gave a crude material which was 
purified by flash column chromatography eluting with 20:1 Pentane/Et2O to 
give the diazo D2 as an orange oil (235 mg, 43%), RF 0.25 (20:1 
Pentane/Et2O); (235 mg, 43%). δH (500 MHz, Chloroform-d) 7.39 (4H, m, 
chlorophenyl) and 4.65 (2H, q, J 8.3, ethyl-1H2). δC (125 MHz) 163.1, 132.2, 
129.4, 124.3, 123.0 (q, JC-F 277), 121.6 and 60.5 (q, JC-F 37). IR νmax (CH2Cl2 
film)/cm-1 2093 (diazo), 1715, 1494, 1283, 1168 and 1141. 
 
6-Chloro-3-diazo-1H-indol-2-one, D8284  
 
According to general procedure A, 6-chloro-2-oxindol (336 mg, 2.0 mmol) 
gave a crude material that was purified by flash column chromatography 
eluting with 100% DCM then 95:5 DCM/Et2O to yield the diazo D8 as an 
orange oil (256 mg, 72%), RF 0.19 (95:5 DCM/Et2O); δH (500 MHz, Acetone-
d6) 9.72 (1H, broad s, indolone-NH), 7.39 (1H, d, J 8.2, indolone-4H), 7.06 
(1H, dd, J 8.2 and 1.9, indolone-5H) and 7.02 (1H, d, J 1.9, indolone-7H). δC 
(125 MHz) 168.2, 134.8, 131.0, 122.2, 120.9, 117.2, 111.0, 111.0 and 61.4. 
HRMS (ESI): C8H435ClN3O requires [M+Na]+, calculated 215.9940, found 
215.9929. 
 
Cyclobutylmethyl 2-(4-chlorophenyl)-2-diazoacetate, D9 
 
N,N-diisopropylethylamine (2.9 mL, 17 mmol) was added to a stirred 
suspension of EDC.HCl (882 mg, 4.6 mmol) and 4-dimethylaminopyridine 
(51 mg, 0.40 mmol) in DCM (50 mL), followed by the sequential addition of 
cyclobutane methanol (0.4 mL, 4.6 mmol) and 4-chlorophenyl acetic acid 
(717 mg, 4.2 mmol). After 20 hours half the solvent was removed under 
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vacuum and the reaction mixture washed with 10% w/v aqueous citric acid 
(2 x 50 mL), brine (1 x 50 mL), 10% v/v aqueous NaHCO3 (2 x 50 mL), brine 
(1 x 50 mL) and distilled water (3 x 100 mL). The combined organic layer 
was then passed through a phase separation frit and concentrated under 
reduced pressure to give a crude oil. The oil was then dissolved in 
acetonitrile (42 mL, 0.1 M) and cooled to 0 oC using an ice-bath, 1,8-
Diazabicyclo[5.4.0]undec-7-ene (0.9 mL, 1.4 eq) was then added followed by 
the portion-wise addition of 4-Acetamidobenzenesulfonyl azide (1.1 g, 1.2 
eq). After 16 hours, the solvent was removed under reduced pressure to 
give a crude product that was dissolved in diethyl ether (40 mL) and washed 
sequentially with 10% w/w citric acid (2 x 10 mL), brine (2 x 10 mL), 10% w/v 
ammonium chloride (2 x 10 mL) and brine (2 x 10 mL). The organics were 
passed through a phase separation frit and concentrated under reduced 
pressure to give a crude material that was purified by flash column 
chromatography eluting with 20:1 Pentane/Et2O to give the diazo D9 as an 
orange oil (1.1 g, 99%), RF 0.46 (20:1 Pentane/Et2O); δH (500 MHz, 
Acetone-d6) 7.57 (2H, d, J 8.7, chlorophenyl-2H and -6H), 7.43 (2H, d, J 8.7, 
chlorophenyl-3H and -5H), 4.24 (2H, d, J 6.6, cyclobutylmethyl-4H2), 2.71 
(1H, dt, J 14.9 and 7.3, cyclobutylmethyl-3H), 2.12 – 2.06 (2H, m, 
cyclobutylmethyl-1H2) and 1.97 – 1.81 (4H, m, cyclobutylmethyl-2H2 and -
2’H2). δC (125 MHz) 165.3, 131.6, 129.7, 126.2, 126.0, 69.1, 63.7, 35.1, 25.1 
and 18.9. IR νmax (CH2Cl2 film)/cm-1 2084 (diazo), 1682 and 1490. HRMS 





According to general procedure C, 3-(4-chlorophenyl)isoxazole-5-amine 
(668 mg, 3.4 mmol) gave a crude material that was purified by flash column 
chromatography eluting with 9:1 DCM/Et2O to afford diazo D10 as a bright 
orange oil (165 mg, 19%), RF 0.09 (9:1 DCM/Et2O); δH (500 MHz, 
Acetonitrile-d3) 9.14 (1H, s, diazoacetamide-NH), 7.82 (2H, d, J 8.7, phenyl-
2H and -6H), 7.49 (2H, d, J 8.7, phenyl-3H and -5H), 6.65 (1H, s, oxazolyl-
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4H) and 5.31 (1H, s, diazoacetamide-2H). δC (125 MHz) 163.3, 163.2, 163.1, 
136.5, 130.0, 129.2, 129.1, 86.3, and 49.9. IR νmax (CH2Cl2 film)/cm-1 2994, 
2113 (diazo), 1678 and 1364. HRMS (ESI): C11H735ClN4O2 requires [M+H]+, 




According to general procedure C, pyrrolidine (2 mL, 24 mmol) gave a crude 
material that was purified by flash column chromatography eluting with 100% 
Et2O to afford the diazo 3.14 as a bright orange oil (828 mg, 50%), RF 0.2 
(Et2O); δH (500 MHz, Acetone-d6) 5.34 (1H, s, ethenone-2H), 3.41 – 3.27 
(4H, m, pyrrolidinyl-2H2 and -2’H2) and 1.95 – 1.80 (4H, m, pyrrolidinyl-3H2 
and -3’H2). δC (125 MHz) 164.0, 57.7, 46.5 and 18.9. HRMS (ESI): C6H9N3O 




According to general procedure C, aniline (600 µL, 6.6 mmol) gave a crude 
material that was purified by flash column chromatography eluting with 9:1 
DCM/Et2O to afford the diazo 3.14 as an orange solid (682 mg, 72%), RF 
0.52 (9:1 DCM/Et2O); δH (400 MHz, Acetone-d6) 8.88 (1H, s, acetamide-NH), 
7.62 – 7.58 (2H, m, phenyl-2H and -6H), 7.30 – 7.24 (2H, m, phenyl-3H and 
-5H), 7.04 – 6.99 (1H, m, phenyl-4H) and 5.40 (1H, S, acetamide-2H). δC 
(100 MHz) 164.4, 140.7, 129.6, 123.7, 119.7, 119.6 and 48.6. IR νmax 
(CH2Cl2 film)/cm-1 3085, 2093 (diazo), 1631, 1548, 1442 and 1369. HRMS 









According to general procedure C, 3-trifluoromethyl aniline (378 µL, 3 mmol) 
gave a crude material that was purified by flash column chromatography 
eluting with 9:1 DCM/Et2O to afford the diazo 3.14 as a pale yellow solid 
(145 mg, 21%), RF 0.30 (9:1 DCM/Et2O); δH (400 MHz, Acetone-d6) 9.21 
(1H, s, acetamide-NH), 8.13 (1H, s, phenyl-2H), 7.75 (1H, broad app. d, J 
8.0, phenyl-3H), 7.50 (1H, t, J 8.0, phenyl-5H), 7.35 (1H, broad app. d, J 8.0, 
phenyl-6H), 5.46 (1H, s, acetamide-2H). δC (100 MHz) 165.0 (rot A), 164.9 
(rot B), 141.5 (rot A), 141.4 (rot B), 131.4 (q, JC-F 32), 130.6, 125.2 (q, JC-F 





According to general procedure C, N-methylaniline (650 µL, 6 mmol) gave a 
crude material that was purified by flash column chromatography eluting with 
9:1 DCM/Et2O to afford the diazo 3.12 as an orange oil (419 mg, 80%), RF 
0.45 (1:1 pentane/Et2O). δH (400 MHz, Acetone-d6) 7.48 – 7.28 (2H, m, 
phenyl-2H and -6H), 7.28 – 7.18 (1H, m, phenyl-4H), 7.20 – 7.16 (2H, m, 
phenyl-3H and -5H), 4.81 (1H, s, acetamide-2H) and 3.12 (3H, s, methyl). δC 
(100 MHz) 165.7, 144.4, 130.5, 128.4, 128.2, 47.4 and 37.1. IR νmax (CH2Cl2 
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5.3.2 Synthesis of Co-Substrates 
2-Cyclopropyl‐1‐(1,2,3,6‐tetrahydropyridin‐1‐yl)ethan‐1‐one, S5 
 
Cyclopropylacetic acid (0.5 g, 5.0 mmol) and carbonylimidazole (0.8 g, 5.0 
mmol) were dissolved in THF (20 mL) and stirred for 30 minutes, followed by 
dropwise addition of 1,2,3,6-tetrahydropyridine (0.4 g, 5.0 mmol) in THF (4 
mL). After 16 hours 1M HCl (10 mL) was added and the mixture stirred 
vigorously for 10 minutes. The solvent was then reduced to a minimum 
under vacuum and partitioned with DCM (30 mL). The organics were 
washed sequentially with 20% v/v NaHCO3 (1 x 20 mL) and brine (1 x 20 
mL), passed through a phase separation filter, and dried under vacuum to 
afford amide S5 as a colourless oil (0.7 g, 86%). δH (500 MHz, Chloroform-d) 
5.89 – 5.77 (1H, m, *THP-5H), 5.70 – 5.61 (1H, m, THP-4H), 4.05 – 3.90 
(2H, m, THP-6H2), 3.67 (1H, t, J 5.8, THP-2Ha), 3.49 (1H, t, J 5.8, THP-2Hb), 
2.26 (2H, dd, J 6.8 and 12.0, ethanone-2H2), 2.18 – 2.11 (2H, m, THP-3H2), 
1.07 – 1.01 (1H, m, cyclopropyl-1H), 0.56 – 0.51 (2H, m, cyclopropyl-2Ha 
and 2’Ha) and 0.18 – 0.13 (2H, m, cyclopropyl-2Hb and 2’Hb). δC (125 MHz) 
171.5 (rot-A), 171.5 (rot-B), 126.8 (rot-A), 125.1 (rot-B), 124.6 (rot-A), 123.4 
(rot-B), 45.1 (rot-A), 42.7 (rot-A), 42.0 (rot-B), 39.1 (rot-B), 38.8 (rot-A), 38.3 
(rot-B), 26.0 (rot-A), 25.0 (rot-B), 7.4 (rot-A), 7.2 (rot-B), 4.6 (rot-A), 4.5 (rot-
B). IR νmax (CH2Cl2 film)/cm-1 3079, 2918, 1622 and 1431. HRMS (ESI): 
C10H15NO requires [M+H]+, calculated 166.1231, found 166.1226. *THP = 
tetrahydropyridin-1-yl. 
 
5.3.3 Synthesis of MDM2 Ligands 
General procedure for the scale-up of ADS hits, D 
A crimp vial (10 or 20 mL) was sequentially charged with solutions of 
rhodium(II) catalyst in CH2Cl2 (240 µL, 12.5 mM) and co-substrate in CH2Cl2 
(240 µL, 6.25 M) and stirred. A solution of diazo in CH2Cl2 (240 µL, 1.25 M) 
was added and the vial capped. After 24 hours 900 mg of Quadrapure TUTM 
resin was added, followed by a further 720 µL CH2Cl2. After a further 24 
hours the resin was removed by filtration and the solvent evaporated under 
reduced pressure to yield the crude reaction product. 
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General procedure for the scale-up of ADS hits/analogues using a 
syringe pump, E 
A 20 mL vial was charged with Rhodium(II) catalyst (1 mol%) and degassed 
under N2 atmosphere, followed by the addition of co-substrate (6.25 M) in 
CH2Cl2. Diazo (1.25 M) in CH2Cl2 was then added dropwise to the stirred 
solution over 6 hours using a syringe pump. After 24 hours Quadrapure 
TUTM resin was then added and the reaction left for a further 24 hours. The 
resin was then removed by filtration and the solvent removed under reduced 





According to general procedure D, Rh2piv4 (2.8 mg, 4.6 µmol), 2‐diazo‐1‐(3‐
phenylpyrrolidin‐1‐yl)ethan‐1‐one (100 mg, 0.46 mmol) and 5-chloro-2,3-
dihydro-1H-inden-1-ol (391 mg, 2.32 mmol) gave an orange oil. The crude 
oil was then purified by flash column chromatography eluting with 100% 
Et2O to afford ether P2 as a colourless oil (127 mg, 78%), RF 0.18 (100% 
Et2O); δH (600 MHz, d6-DMSO, 1:1 mixture of diastereomers; 1:1 mixture of 
rotamers): 7.48 – 7.45 (1H, m, indenyl-6H), 7.35 – 7.23 (7H, m, phenyl-H, 
and indenyl-4H and -7H), 4.97 – 4.93 (1H, m, indenyloxy-1H), 4.21 – 4.14 
(2H, m, ethenone-2H), 3.89 – 3.83 (1H, m, pyrrolidinyl-3H), 3.66 – 3.59 (1H, 
m, pyrrolidinyl-2Ha), 3.50 – 3.39 (1H, m, pyrrolidinyl-2Hb), 3.37 – 3.21 (2H, 
m, pyrrolidinyl-5H), 3.00 – 2.74 (2H, m, pyrrolidinyl-4H), 2.33 – 2.219 (2H, m, 
2,3-dihydroindenyl-3H) and 2.03 – 1.87 (2H, m, 2,3-dihydroindenyl-2H). δC 
(150 MHz, d6-DMSO): 167.3 (broad s, major), 167.3 (rot-A, minor), 167.2 
(rot-B, minor), 146.3 (broad s, major), 146.3 (broad s, minor), 141.6 (broad s, 
major), 141.6 (broad s, minor), 141.2 (broad s, major), 141.1 (broad s, 
minor), 132.9 (broad s, major+minor), 128.5 (broad s, major+minor), 127.1 
(major), 127.0 (minor), 126.8 (major), 126.8 (minor), 126.7 (broad s, major), 
126.6 (broad s, minor), 126.2 (broad s, major), 126.2 (broad s, minor), 124.7 
(broad s, major+minor), 82.0 (broad s, major), 81.9 (broad s, minor), 67.7 
(rot-A, major), 67.7 (rot-B, major), 67.6 (broad s, minor), 51.6 (broad s, 
major), 51.2 (broad s, minor), 45.4 (broad s, major), 45.0 (broad s, minor), 
43.7 (broad s, major), 41.6 (broad s, minor), 33.0 (broad s, major), 33.0 
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(broad s, minor), 32.0 (broad s, major), 32.0 (broad s, minor), 30.8 (broad s, 
major) and 30.0 (broad s, minor). HRMS (ESI): C21H2235ClNO2 requires 





According to general procedure D, Rh2piv4 (0.6 mg, 1.0 µmol), 2‐diazo‐1‐
((S)-3‐phenylpyrrolidin‐1‐yl)ethan‐1‐one (21.5 mg, 0.1 mmol) and (1R)-5-
chloro-2,3-dihydro-1H-inden-1-ol (84.0 mg, 0.5 mmol) gave an orange oil. 
The crude oil was then purified by flash column chromatography eluting with 
100% Et2O to afford ether P2a as a colourless oil (24 mg, 67%), RF 0.48 
(100% Et2O); δH (500 MHz, Chloroform-d): 7.32 – 7.09 (16H, m, Ar, rot-A 
and rot-B), 4.93 (1H, ddd, J 17.6, 6.4 and 3.7, inden-1-yloxy-1H, rot-A and 
rot-B), 4.11 – 4.09 (2H, m, ethenone-2H2, rot-A and rot-B), 3.98 – 3.93 (1H, 
m, pyrrolidinyl-2Ha, rot-A), 3.80 – 3.72 (2H, m, pyrrolidinyl-3H, rot-A and rot-
B), 3.65 – 3.60 (1H, m, pyrrolidinyl-2Ha, rot-B), 3.50 – 3.25 (6H, m, 
pyrrolidinyl-2Ha and -5H2, rot-A and rot-B), 3.01 – 2.96 (2H, m, 2,3-
dihydroindenyl-3Ha, rot-A and rot-B), 2.74 – 2.71 (2H, m, 2,3-dihydroindenyl-
3Hb, rot-A and rot-B), 2.33 – 2.20 (4H, m, pyrrolidinyl-4H2, rot-A and rot-B), 
2.13 – 2.05 (2H, m, 2,3-dihydroindenyl-2Ha, rot-A and rot-B) and 2.00 – 1.88 
(2H, m, 2,3-dihydroindenyl-2Hb, rot-A and rot B). δC (125 MHz, Chloroform-
d): 168.3 (rot A), 168.2 (rot B), 146.4 (rot A), 146.4 (rot B), 141.0 (rot-A and 
rot-B), 140.8 (rot A), 140.6 (rot B), 134.6 (rot-A and rot-B), 128.9 (rot A), 
128.8 (rot B), 127.2 (rot A), 127.1 (rot B), 126.8 (rot A), 126.7 (rot B), 126.6 
(rot A), 126.6 (rot B), 125.3 (rot-A and rot-B), 83.1 (rot-A and rot-B), 68.6 (rot 
A), 68.5 (rot B), 52.6 (rot A), 52.1 (rot B), 46.1 (rot A), 46.0 (rot B), 44.7 (rot-
A and rot-B), 42.3 (rot-A and rot-B), 33.8 (rot-A and rot-B), 32.6 (rot-A and 
rot-B), 31.3 (rot-A and rot-B) and 30.3 (rot-A and rot-B). HRMS (ESI): 









According to general procedure D, Rh2piv4 (0.6 mg, 1.0 µmol), 2‐diazo‐1‐
((R)-3‐phenylpyrrolidin‐1‐yl)ethan‐1‐one (21.5 mg, 0.1 mmol) and (1S)-5-
chloro-2,3-dihydro-1H-inden-1-ol (84.0 mg, 0.5 mmol) gave an orange oil. 
The crude oil was then purified by flash column chromatography eluting with 
100% Et2O to afford ether ent-P2a as a colourless oil (19 mg, 54%), RF 0.32 





According to general procedure D, Rh2piv4 (0.6 mg, 1.0 µmol), 2‐diazo‐1‐
((S)-3‐phenylpyrrolidin‐1‐yl)ethan‐1‐one (21.5 mg, 0.1 mmol) and (1S)-5-
chloro-2,3-dihydro-1H-inden-1-ol (84.0 mg, 0.5 mmol) gave an orange oil. 
The crude oil was then purified by flash column chromatography eluting with 
100% Et2O to afford ether P2b as a colourless oil (28 mg, 79%), RF 0.47 
(100% Et2O); δH (500 MHz, Chloroform-d): 7.33 – 7.08 (16H, m, rot-A and 
rot-B), 4.94 (2H, ddd, J 12.4, 6.5 and 3.7, inden-1-yloxy-1H, rot-A and rot-B), 
4.14 – 4.09 (4H, m, ethenone-2H2, rot-A and rot-B), 3.97 – 3.93 (1H, m, 
pyrrolidinyl-2Ha, rot-A), 3.83 – 3.72 (2H, m, pyrrolidinyl-3H, rot-A and rot-B), 
3.65 – 3.61 (1H, m, pyrrolidinyl-2Hb, rot-B), 3.48 – 3.24 (6H, m, pyrrolidinyl-
2Ha and -5H2, rot-A and rot-B), 3.02 – 2.95 (2H, m, 2,3-dihydroindenyl-3Ha, 
rot-A and rot-B), 2.76 – 2.68 (2H, m, 2,3-dihydroindenyl-3Hb, rot-A and rot-
B), 2.32 – 2.18 (4H, m, pyrrolidinyl-4H2, rot-A and rot-B), 2.11 – 2.06 (2H, m, 
2,3-dihydroindenyl-2Ha, rot-A and rot-B) and 2.01 – 1.84 (2H, m, 2,3-
dihydroindenyl-2Hb, rot-A and rot B). δC (125 MHz, Chloroform-d): 168.3 (rot 
A), 168.3 (rot B), 146.4 (rot-A and rot-B), 141.0 (rot A), 140.7 (rot-A and rot-
B), 140.6 (rot B), 134.6 (rot-A and rot-B), 128.9 (rot A), 128.8 (rot B), 127.2 
(rot-A and rot-B), 127.1 (rot A), 127.1 (rot B), 126.8 (rot A), 126.7 (rot B), 
126.6 (rot A), 126.6 (rot B), 125.3 (rot A), 125.3 (rot B), 83.2 (rot A), 83.1 (rot 
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B), 68.7 (rot A), 68.5 (rot B), 52.6 (rot A), 52.1 (rot B), 46.1 (rot A), 46.0 (rot 
B), 44.7 (rot-A and rot-B), 42.3 (rot-A and rot-B), 33.7 (rot A), 32.6 (rot A and 
rot-B), 31.3 (rot B), 30.3 (rot-A) and 30.3 (rot B). HRMS (ESI): C21H2235ClNO2 





According to general procedure D, Rh2piv4 (0.6 mg, 1.0 µmol), 2‐diazo‐1‐
((R)-3‐phenylpyrrolidin‐1‐yl)ethan‐1‐one (21.5 mg, 0.1 mmol) and (1R)-5-
chloro-2,3-dihydro-1H-inden-1-ol (84.0 mg, 0.5 mmol) gave an orange oil. 
The crude oil was then purified by flash column chromatography eluting with 
100% Et2O to afford ether ent-P2b as a colourless oil (18 mg, 51%), RF 0.59 




According to general procedure E, Rh2piv4 (1.4 mg, 2.5 µmol), 2‐diazo‐1‐(3‐
phenylpyrrolidin‐1‐yl)ethan‐1‐one (50 mg, 0.25 mmol) and cyclopentanol 
(105 µL, 1.2 mmol) gave an orange oil. The crude oil was then purified by 
flash column chromatography eluting with 100% Et2O to afford ether 4.1 as a 
colourless oil (34 mg, 50%), RF 0.29 (100% Et2O); δH (500 MHz, CDCl3): 
7.29 – 7.16 (10H, m, phenyl-H, rot-A and rot-B), 4.00 (4H, d, J 11.4, 
ethenone-2H2, rot-A and rot-B), 3.98 – 3.86 (4H, m, cyclopentyloxy-1H and 
pyrrolidinyl -2Ha, rot-A and rot-B), 3.74 (2H, ddd, J 10.9, 8.2 and 2.9, 
pyrrolidinyl-2Hb, rot-A),  3.68 (1H, ddd, J 10.9, 8.2 and 2.9, pyrrolidinyl-2Hb, 
rot-B), 3.54 – 3.25 (6H, m, pyrrolidinyl-3H and -5H2, rot-A and rot-B), 2.33 – 
219 (2H, m, pyrrolidinyl-4Ha, rot-A and rot-B), 2.04 – 1.87 (2H, m, 
pyrrolidinyl-4Hb, rot-A and rot-B) and 1.67 – 1.62 (16H, m, cyclopentyloxy-2H 
and -3H, rot-A and rot-B). δC (125 MHz, CDCl3): 168.6 (rot A), 168.5 (rot B), 
141.1 (rot A), 140.9 (rot B), 128.9 (rot A), 128.8 (rot B), 127.2 (rot A), 127.1 
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(rot B), 127.1 (rot A), 127.0 (rot B), 82.4 (rot A), 82.3 (rot B), 69.4 (rot A), 
69.2 (rot B), 52.6 (rot A), 52.0 (rot B), 46.1 (rot A), 46.0 (rot B), 44.8 (rot A), 
42.3 (rot B), 33.8 (rot A), 32.2 (rot A), 32.2 (rot B), 31.4 (rot B), 23.6 (rot A) 
and 23.6 (rot B). HRMS (ESI): C17H23NO2 requires [M+H]+, calculated 





According to general procedure E, Rh2piv4 (2.2 mg, 3.6 µmol), 2-diazo-1-
(pyrrolidin-1-yl)ethenone (50 mg, 0.36 mmol) and 5-chloro-2,3-dihydro-1H-
inden-1-ol (120 mg, 0.72 mmol) gave an orange oil. The crude oil was then 
purified by flash column chromatography eluting with 100% Et2O to afford 
ether 4.2 as a colourless oil (51 mg, 50%), RF 0.09 (100% Et2O); δH (500 
MHz, CDCl3): 7.37 (1H, d, J 8.0, indenyloxy-7H), 7.22 (1H, broad s, 
indenyloxy-4H), 7.18 – 7.16 (1H, m, indenyloxy-6H), 4.99 (1H, dd, J 6.5 and 
3.7, indenyloxy-1H), 4.14 (2H, m, ethenone-1H), 3.49 (2H, app. t, J 6.9, 
pyrrolidinyl-2Ha), 3.45 – 3.38 (2H, m, pyrrolidinyl-2Hb), 3.09 – 3.03 (1H, m, 
indenyloxy-3Ha), 2.81 – 2.76 (1H, m, indenyloxy-3Hb), 2.35 (1H, ddt, J 13.0, 
8.5 and 6.4, indenyloxy-2Ha), 2.15 (1H, dddd, J 13.3, 8.4, 4.8 and 3.8, 
indenyloxy-2Hb), 1.95 – 1.90 (2H, m, pyrrolidinyl-3Ha) and 1.86 – 1.81 (2H, 
m, pyrrolidinyl-3Hb). δC (125 MHz, CDCl3) 168.3, 146.4, 140.7, 134.5, 126.7, 
126.6, 125.2, 83.0, 68.5, 46.2 (rot-A), 46.1 (rot-B), 32.5, 30.3, 26.3 (rot-A) 
and 24.0 (rot-B). HRMS (ESI): C15H1835ClNO2 requires [M+Na]+, calculated 













According to general procedure E, Rh2pfb4 (3.8 mg, 3.6 µmol), 2,2,2‐
trifluoroethyl 2‐(4‐chlorophenyl)‐2‐diazoacetate (100 mg, 0.36 mmol) and 6-
chloroindole (272 mg, 1.8 mmol) gave an orange oil. The crude oil was then 
purified by flash column chromatography eluting with 9:1 pentane/Et2O to 
afford indole P1 as a colourless oil (20 mg, 14%), RF 0.19 (3:1 
Pentane/Et2O); δH (500 MHz, CDCl3): 8.10 (1H, s, 6-chloroindolyl-NH), 7.30 
(1H, d, J 1.8, 6-chloroindolyl-4H), 7.28 – 7.24 (4H, m, 4-chlorophenyl-2H2 
and -3H2), 7.21 (1H, d, J 8.5, 6-chloroindolyl-2H), 7.14 (1H, dd, J 2.5 and 
0.8, 6-chloroindolyl-7H), 6.99 (1H, dd, J 8.5 and 1.8, 6-chloroindolyl-5H), 
5.24 (1H, s, acetate-2H) and 4.49 (2H, qq, J 12.7 and 8.4, trifluoroethyl-1H). 
δC (125 MHz, CDCl3): 170.9, 136.8, 135.8, 133.9, 129.8, 129.1, 128.8, 
124.9, 124.0, 121.8, 121.0, 119.9, 112.5, 111.5, 61.0 (q, JC-F 36.7), 47.9. 





According to general procedure D, Rh2pfb4 (2.8 mg, 2.6 µmol), 6-chloro-3-
diazo-1H-indol-2-one (50 mg, 0.26 mmol) and 6-chloroindole (254 mg, 1.3 
mmol) gave an orange oil. The crude oil was then purified by flash column 
chromatography eluting with 9:1 DCM/Et2O to afford oxindole P6 as a 
colourless oil (44 mg, 53%), RF 0.17 (9:1 DCM/Et2O); δH (500 MHz, CDCl3): 
8.54 (1H, broad s, biindol-2-one-NH), 8.29 (1H, broad s, biindol-NH), 7.31 
(1H, d, J 1.8 Hz, biindol-4H), 7.14 (1H, d, J 8.4, biindol-2H), 7.06 – 7.04 (2H, 
m, biindol-2-one-4H and -7H), 6.99 (2H, td, J 8.4 and 1.8, biindol-2-one-5H 
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and biindol-5H), 6.94 (1H, d, J 1.8, biindol-7H) and 4.83 (1H, s, biindol-2-
one-3H). δC (125 MHz, CDCl3): 178.5, 142.4, 137.1, 134.2, 128.7, 127.8, 
126.1, 124.7, 124.3, 122.9, 121.0, 120.1, 111.5, 110.7, 110.4 and 44.5. 





According to general procedure E, Rh2pfb4 (2.8 mg, 2.6 µmol), 6-chloro-3-
diazo-1H-indol-2-one (50 mg, 0.26 mmol) and 5-chloroindole (254 mg, 1.3 
mmol) gave an orange oil. The crude oil was then purified by flash column 
chromatography eluting with 9:1 DCM/Et2O to afford oxindole 4.4 as a 
colourless oil (31.2 mg, 38%), RF 0.17 (9:1 DCM/Et2O); δH (500 MHz, 
DMSO-d6): 11.27 (1H, s, biindol-2-one-NH), 10.71 (1H, s, biindol-NH), 7.39 
(1H, dd, J 8.6 and 0.5, biindol-2-one-4H), 7.31 (1H, d, J 2.5, biindol-4H), 
7.11 – 7.04 (3H, m, biindol-2-one-5H, biindol-2H and -5H), 6.98 – 6.95 (2H, 
m, biinol-2-one-7H and biindol-7H) and 4.98 (1H, s, biindol-2-one-3H). δC 
(125 MHz, DMSO-d6): 177.4, 144.0, 134.9, 132.1, 128.9, 127.1, 126.2, 
125.9, 123.3, 121.3, 121.2, 117.6, 113.3, 109.4, 109.4 and 43.6. HRMS 






According to general procedure D, Rh2piv4 (1.6 mg, 2.6 µmol), 6-chloro-3-
diazo-1H-indol-2-one (50 mg, 0.26 mmol) and 4-chlorostyrene (156 µL, 1.3 
mmol) gave an orange oil. The crude oil was then purified by flash column 
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chromatography eluting with 9:1 DCM/Et2O to afford oxindole P5 as a 
colourless oil (46 mg, 58%), RF 0.17 (9:1 DCM/Et2O); δH (500 MHz, CDCl3): 
8.57 (1H, broad s, indolone-NH), 7.28 (2H, d, J 8.2, 4-chlorophenyl-3H2), 
7.11 (2H, d, J 8.2, 4-chlorophenyl-2H2), 6.96 (1H, d, J 1.8, indol-2-one-7H), 
6.69 (1H, dd, J 8.1 and 1.9, indol-2-one-5H) 5.84 (1H, d, J 8.1, indol-2-one-
4H), 3.28 (1H, app. t, J 8.6, cyclopropane-1H), 2.23 (1H, dd, J 9.2 and 4.8, 
cyclopropane-2Ha), 1.97 (1H, dd, J 8.0 and 4.8, cyclopropane-2Hb). δC (125 
MHz, CDCl3): 178.3, 142.0, 133.7, 133.3, 132.8, 131.4, 128.9, 126.0, 121.9, 
121.8, 110.5, 35.7, 33.5 and 22.9. HRMS (ESI): C16H1135Cl2NO requires 





According to general procedure E, Rh2piv4 (1.6 mg, 2.6 µmol), 6-chloro-3-
diazo-1H-indol-2-one (50 mg, 0.26 mmol) and 3-chlorostyrene (165 µL, 1.3 
mmol) gave an orange oil. The crude oil was then purified by flash column 
chromatography eluting with 9:1 DCM/Et2O to afford oxindole 4.3 as a 
colourless oil (39 mg, 49%), RF 0.38 (9:1 DCM/Et2O); δH (500 MHz, CDCl3): 
8.42 (1H, br s, indol-2-one-NH), 7.27 – 7.22 (3H, m, 3-chlorophenyl-4H, -5H 
and -6H), 7.04 (1H, broad dd, J 7.3 and 0.6, 3-chlorophenyl-2H), 6.96 (1H, d, 
J 1.8, indol-2-one-7H), 6.69 (1H, dd, J 8.1 and 1.9, indol-2-one-5H), 5.87 
(1H, d, J 8.1, indol-2-one-4H), 3.29 (1H, app. t, J 8.6, cyclopropane-1H), 
2.23 (1H, dd, J 9.2 and 4.8, cyclopropane-2Ha) and 1.99 (1H, dd, J 8.0 and 
4.8, cyclopropane-2Hb). δC (125 MHz, CDCl3): 178.0, 142.0, 136.9, 134.6, 
132.9, 130.0, 129.9, 129.9, 128.3, 128.1, 125.9, 121.9, 110.5, 35.8, 33.5 and 










According to general procedure D, Rh2piv4 (1.9 mg, 3.0 µmol) and N,2‐bis(4‐
chlorophenyl)‐2‐diazo‐N‐methylacetamide (100 mg, 0.3 mmol) gave an 
orange oil. The crude oil was then purified by flash column chromatography 
initially eluting with 100% DCM, which gave a mixture of products, and the 
oil was re-purified eluting 8:2 pentane/EtOAc to afford oxindole P3 as a 
colourless oil (3.5 mg, 4%), RF 0.15 (8:2 pentane/EtOAc); δH (500 MHz, 
CDCl3): 7.33 – 7.31 (3H, m, 4-chlorophenyl-3H2 and indol-2-one-4H), 7.14 – 
7.11 (3H, m, 4-chlorophenyl-2H2 and indol-2-one-5H), 6.82 (1H, d, J 8.3, 
indol-2-one-4H), 4.57 (1H, s, indol-2-one-3H) and 3.24 (3H, s, indol-2-one-
NCH3). δC (125 MHz, CDCl3): 175.2, 143.2, 134.4, 134.0, 130.0, 129.9, 
129.3, 128.8, 128.4, 125.6, 109.4, 51.5 and 26.8. HRMS (ESI): 




According to general procedure D, Rh2piv4 (1.9 mg, 3.0 µmol) and N,2‐bis(4‐
chlorophenyl)‐2‐diazo‐N‐methylacetamide (100 mg, 0.3 mmol) gave an 
orange oil. The crude oil was then purified by flash column chromatography 
initially eluting with 100% DCM, which gave a mixture of products, and the 
oil was re-purified eluting 8:2 pentane/EtOAc to afford oxoacetamide P4 as a 
colourless oil (3.6 mg, 4%), RF 0.38 (8:2 pentane/EtOAc); δH (500 MHz, 
CDCl3): 7.81 (2H, d, J 8.4, acetamide Ar-3H), 7.44 (2H, d, J 8.4, acetamide 
Ar-2H), 7.24 (2H, d, J 8.5, oxo Ar-3H), 7.06 (2H, d, J 8.5, oxo Ar-2H) and 
3.45 (3H, s, oxoacetamide-NCH3). δC (125 MHz, CDCl3): 189.3, 166.6, 
141.3, 139.8, 134.3, 131.9, 130.9, 130.0, 129.5, 128.2 and 36.5. HRMS 
(ESI): C15H1135Cl2NO2 requires [M+Na]+, calculated 330.0064, found 
330.0059. 
 




According to general procedure D, Rh2piv4 (1.3 mg, 2.1 µmol), 6-chloro-3-
diazo-1H-indol-2-one (40 mg, 0.21 mmol) and 3-methoxy-1-propene (113 
µL, 1.0 mmol) gave an orange oil. The crude oil was then purified by flash 
column chromatography eluting with 9:1 DCM/Et2O to afford oxindole P7 as 
a colourless oil (7.3 mg, 14%), RF 0.08 (9:1 DCM/Et2O); δH (500 MHz, 
CDCl3): 8.31 (1H, s, indol-2-one-NH), 6.98 (1H, dd, J 8.0 and 1.9, indol-2-
one-5H), 6.94 (1H, d, J 1.5, indol-2-one-7H), 6.90 (1H, d, J 8.0, indol-2-one-
4H), 3.77 (1H, dd, J 11.2 and 5.5, methyl-Ha), 3.64 (1H, dd, J 11.2 and 7.6, 
methyl-Hb), 3.45 (2H, q, J 7.0, ethoxy-1H2), 2.24 (1H, dtd, J 13.1, 7.6 and 
5.5, cyclopropane-3H), 1.95 (1H, dd, J 9.4 and 4.5, cyclopropane-2Ha), 1.57 
(1H, dd, J 7.8 and 4.5, cyclopropane-2Hb) and 1.16 (3H, t, J 7.0, ethoxy-
2H3). δC (125 MHz, CDCl3): 178.3, 142.3, 132.7, 126.9, 122.2, 121.8, 110.6, 
67.4, 66.3, 32.0, 31.6, 22.0 and 15.2. HRMS (ESI): C13H1435ClNO2 requires 
[M+H]+, calculated 252.0791, found 252.0777.  
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5.3.4 Implementation of High-Throughput Chemistry for Activity-
Directed Synthesis Reaction Arrays 
Activity-Directed Synthesis reactions were carried out in 0.75 mL shell vials 
(Chemglass CV-2100-0830) equipped with a teflon-coated stir bar (Biotage 
0.2-0.5 mL magnetic stir bar #355545) and sealed using either a Freeslate 
96-well reaction block or a Sigma-Aldrich Kitalysis 24-well reaction block 
(Z742107 Aldrich). Prior to the assembly of each reaction array the following 
stock solutions were made: diazo reaction solvent (1.25 M); catalyst in THF 
(25 mM); and co-substrate in CH2Cl2 (6.25 M). Each reaction vial was 
charged with catalyst stock (8 µL) and the solvent allowed to evaporate to 
dryness, then CH2Cl2 (84 µL) was added and the reaction block placed on a 
magnetic stirring plate. Each reaction vial was then sequentially charged 
with co-substrate stock (8 µL) and diazo stock (8 µL), then the plate sealed 
using a Teflon film and stirred. After 24 hours Quadrapure TU resin (30 mg) 
was added to each vial and left overnight to scavenge the catalyst. The 
solvent was then evaporated under a stream of nitrogen gas and the crude 
material dissolved in molecular biology grade DMSO (200 µL) to create a 50 
mM total product concentration biological screening master stock that was 
passed through a 96-well filter plate (Agilent Technologies: #200933-100) 
and stored at -20 oC. 
Example 96-well reaction plate layout: 
  
1 2 3 4 5 6 7 8 9 10 11 12 Catalyst 
D1 A S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 D1 Control Rh2piv4 Control PIV 
D2 B S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 D2 Control BLANK PIV 
D3 C S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 D3 Control BLANK PIV 
D4 D S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 D4 Control BLANK PIV 
D1 E S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 D1 Control Rh2pfb4 Control PFB 
D2 F S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 D2 Control BLANK PFB 
D3 G S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 D3 Control BLANK PFB 
D4 H S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 D4 Control BLANK PFB 
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5.3.4.1 LC/MS Analysis of Round One Reaction Mixtures 
All 154 reactions from the round 1 reaction array were analysed by LC-MS to 
investigate how many combinations had produced a desired product (Table 
5.7). All samples were diluted to 1 mg/mL concentrations from the original 50 
mM DMSO master stock, with respect to the initial diazo starting 
concentration. Reaction wells containing diazo and substrate were analysed 
for intermolecular product(s) and blank control wells were analysed for 
intramolecular product(s). Dark green squares indicate clear m/z for the 
desired product(s) and a clear corresponding UV peak(s). Light green 
squares indicate m/z for the desired product(s) and either weak or no 
corresponding UV peak(s). Blank squares indicate that no m/z was observed 
for the desired product(s). 
Table 5.7. LC-MS data from the round 1 reaction array. 
Diazo/ 
Substrate 




D1S1 Rh2piv4 C19H16Cl2N2O2 - 374.06 - - N 
D1S2 Rh2piv4 C17H15Cl2NO3 - 351.04 - - N 
D1S3 Rh2piv4 C25H22Cl3NO2 - 473.07 - - N 
D1S4 Rh2piv4 C18H21ClN2O4 - 364.12 - - N 
D1S5 Rh2piv4 C21H25ClN2O3 H 389.16 389.16 5x106 N 
D1S6 Rh2piv4 C20H18ClNO3 - 355.10 - - N 
D1S7 Rh2piv4 C22H23ClN2O2 H 383.15 383.15 1x107 N 
D1S8 Rh2piv4 C20H19Cl2NO3 H 392.07 392.08 5X106 N 
D1S9 Rh2piv4 C20H17Cl2NO2 H 374.06 374.07 5x106 N 
D1S10 Rh2piv4 C15H18ClNO4S H 344.07 344.07 3x106 N 
D1blank Rh2piv4 C11H10ClNO2 2M + 2H 448.10 448.64 7.5x107 Y 
D1S1 Rh2pfb4 C19H16Cl2N2O2 H 375.06 375.07 1x107 N 
D1S2 Rh2pfb4 C17H15Cl2NO3 H 352.04 352.24 4x107 Y 
D1S3 Rh2pfb4 C25H22Cl3NO2 Na 496.06 498.1 4x107 Y 
D1S4 Rh2pfb4 C18H21ClN2O4 H 365.12 365.03 1x107 Y 
D1S5 Rh2pfb4 C21H25ClN2O3 - 388.16 - - N 
D1S6 Rh2pfb4 C20H18ClNO3 - 355.10 - - N 
D1S7 Rh2pfb4 C22H23ClN2O2 - 382.15 - - N 
D1S8 Rh2pfb4 C20H19Cl2NO3 Na 414.06 413.97 3x106 Y 
D1S9 Rh2pfb4 C20H17Cl2NO2 H 374.06 374.07 2x107 N 
D1S10 Rh2pfb4 C15H18ClNO4S - 343.07 - - N 
D1blank Rh2pfb4 C11H10ClNO2 - 223.04 - - N 
D2S1 Rh2piv4 C18H12Cl2F3NO2 H 402.02 401.98 3x106 N 
D2S2 Rh2piv4 C16H11Cl2F3O3 H 379.00 379.01 7.5x106 N 
D2S3 Rh2piv4 C24H18Cl3F3O2 -H 499.02 498.86 7.5X107 Y 
D2S4 Rh2piv4 C17H17ClF3NO4 H 392.08 392.02 3x107 Y 
D2S5 Rh2piv4 C20H21ClF3NO3 -H 414.11 414.11 6x107 Y 
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D2S6 Rh2piv4 C19H14ClF3O3 Na 405.04 404.80 1x107 Y 
D2S7 Rh2piv4 C21H19ClF3NO2 H 409.11 410.02 7.5x108 Y 
D2S8 Rh2piv4 C19H15Cl2F3O3 Na 441.02 440.97 6x106 Y 
D2S9 Rh2piv4 C19H13Cl2F3O2 H 401.02 400.93 2x106 N 
D2S10 Rh2piv4 C14H14ClF3O4S -H 369.01 368.85 2x107 Y 
D2blank Rh2piv4 C20H12Cl2F6O4 -H 498.99 498.99 1x106 N 
D2S1 Rh2pfb4 C18H12Cl2F3NO2 -H 400.01 399.92 1x108 Y 
D2S2 Rh2pfb4 C16H11Cl2F3O3 Na 400.99 400.89 1.5x106 N 
D2S3 Rh2pfb4 C24H18Cl3F3O2 - 500.03 - - N 
D2S4 Rh2pfb4 C17H17ClF3NO4 H 392.08 392.09 5x107 Y 
D2S5 Rh2pfb4 C20H21ClF3NO3 - 415.12 - - N 
D2S6 Rh2pfb4 C19H14ClF3O3 - 382.06 - - N 
D2S7 Rh2pfb4 C21H19ClF3NO2 H 410.11 410.02 7.5x108 Y 
D2S8 Rh2pfb4 C19H15Cl2F3O3 Na 441.02 440.96 2x106 Y 
D2S9 Rh2pfb4 C19H13Cl2F3O2 H 401.02 400.92 1x107 Y 
D2S10 Rh2pfb4 C14H14ClF3O4S - 370.03 - - N 
D2blank Rh2pfb4 C20H12Cl2F6O4 - 500.00 - - N 
D3S1 Rh2piv4 C23H17Cl3N2O H 445.04 444.93 2.5X107 Y 
D3S2 Rh2piv4 C21H16Cl3NO2 H 422.02 421.90 2x108 Y 
D3S3 Rh2piv4 C29H23Cl4NO - 541.05 - - N 
D3S4 Rh2piv4 C22H22Cl2N2O3 H 433.10 432.98 2x108 Y 
D3S5 Rh2piv4 C25H26Cl2N2O2 K 495.10 495.07 1.25x107 N 
D3S6 Rh2piv4 C24H19Cl2NO2 - 423.08 - - N 
D3S7 Rh2piv4 C26H24Cl2N2O H 451.13 451.13 2x107 N 
D3S8 Rh2piv4 C24H20Cl3NO2 - 459.06 - - N 
D3S9 Rh2piv4 C24H18Cl3NO - 441.05 - - N 
D3S10 Rh2piv4 C19H19Cl2NO3S -H 410.05 410.04 2x105 N 
D3blank Rh2piv4 C15H11Cl2NO -H 290.01 289.71 5x106 Y 
D3S1 Rh2pfb4 C23H17Cl3N2O H 445.04 444.95 7.5x107 Y 
D3S2 Rh2pfb4 C21H16Cl3NO2 - 419.02 - - N 
D3S3 Rh2pfb4 C29H23Cl4NO - 541.05 - - N 
D3S4 Rh2pfb4 C22H22Cl2N2O3 H 433.10 432.97 4x108 Y 
D3S5 Rh2pfb4 C25H26Cl2N2O2 - 456.14 - - N 
D3S6 Rh2pfb4 C24H19Cl2NO2 - 423.08 - - N 
D3S7 Rh2pfb4 C26H24Cl2N2O - 450.13 - - N 
D3S8 Rh2pfb4 C24H20Cl3NO2 - 459.06 - - N 
D3S9 Rh2pfb4 C24H18Cl3NO - 441.05 - - N 
D3S10 Rh2pfb4 C19H19Cl2NO3S - 411.05 - - N 
D3blank Rh2pfb4 C15H11Cl2NO H 292.02 292.02 4x107 Y 
D3S1 Rh2piv4 C20H19ClN2O H 339.12 339.02 1x108 Y 
D3S2 Rh2piv4 C18H18ClNO2 H 316.10 315.96 1.5x108 Y 
D3S3 Rh2piv4 C26H25Cl2NO - 437.13 - - N 
D4S4 Rh2piv4 C19H24N2O3 NH4 347.18 347.08 1x107 Y 
D4S5 Rh2piv4 C22H28N2O2 - 352.2151 - - N 
D4S6 Rh2piv4 C21H21NO2 H 320.16 320.01 7x107 Y 
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D4S7 Rh2piv4 C23H26N2O - 346.21 - - N 
D4S8 Rh2piv4 C21H22ClNO2 2M + Na 733.26 733.19 2x108 Y 
D4S9 Rh2piv4 C21H20ClNO H 338.12 338.03 1.7x108 Y 
D4S10 Rh2piv4 C16H21NO3S H 308.12 307.97 2x107 Y 
D4blank Rh2piv4 C24H26N2O2 H 375.20 375.1 3x108 Y 
D4S1 Rh2pfb4 C20H19ClN2O H 339.12 339.01 1x108 Y 
D4S2 Rh2pfb4 C18H18ClNO2 - 315.10 - - N 
D4S3 Rh2pfb4 C26H25Cl2NO Na 460.12 460.23 1x107 Y 
D4S4 Rh2pfb4 C19H24N2O3 H 329.18 329.19 3x107 N 
D4S5 Rh2pfb4 C22H28N2O2 -H 351.22 351.21 5x105 N 
D4S6 Rh2pfb4 C21H21NO2 H 320.16 320.05 8x106 Y 
D4S7 Rh2pfb4 C23H26N2O - 346.20 - - N 
D4S8 Rh2pfb4 C21H22ClNO2 2M + Na 733.26 733.21 2x107 N 
D4S9 Rh2pfb4 C21H20ClNO H 338.12 338.04 4x107 Y 
D4S10 Rh2pfb4 C16H21NO3S H 308.12 308.13 1x107 N 
D4blank Rh2pfb4 C24H26N2O2 H 375.20 375.08 3x108 Y 
D5S1 Rh2piv4 C16H19ClN2O2 H 307.11 306.94 1x108 Y 
D5S2 Rh2piv4 C14H18ClNO3 H 284.10 283.88 3x107 Y 
D5S3 Rh2piv4 C22H25Cl2NO2 H 406.13 406.13 5x106 N 
D5S4 Rh2piv4 C15H24N2O4 H 297.17 297.18 4x106 N 
D5S5 Rh2piv4 C18H28N2O3 NH4 338.24 338.23 1x107 N 
D5S6 Rh2piv4 C17H21NO3 H 288.15 287.94 1x107 Y 
D5S7 Rh2piv4 C19H26N2O2 - 314.30 - - N 
D5S8 Rh2piv4 C17H22ClNO3 2M + Na 669.25 669.24 1x108 Y 
D5S9 Rh2piv4 C17H20ClNO2 H 306.12 305.94 3x107 Y 
D5S10 Rh2piv4 C12H21NO4S - 275.12 - - N 
D5blank Rh2piv4 C8H13NO2 - 155.09 - - N 
D5S1 Rh2pfb4 C16H19ClN2O2 H 307.11 306.92 3x107 Y 
D5S2 Rh2pfb4 C14H18ClNO3 H 284.10 283.86 2x107 Y 
D5S3 Rh2pfb4 C22H25Cl2NO2 Na 428.12 428.22 2x106 Y 
D5S4 Rh2pfb4 C15H24N2O4 H 297.17 297.18 5x106 N 
D5S5 Rh2pfb4 C18H28N2O3 - 320.21 - - N 
D5S6 Rh2pfb4 C17H21NO3 H 288.15 288.16 5x106 N 
D5S7 Rh2pfb4 C19H26N2O2 H 315.20 315.21 1x107 N 
D5S8 Rh2pfb4 C17H22ClNO3 2M + Na 669.25 669.24 5x107 Y 
D5S9 Rh2pfb4 C17H20ClNO2 H 306.12 305.93 2.5x106 Y 
D5S10 Rh2pfb4 C12H21NO4S - 275.12 - - N 
D5blank Rh2pfb4 C8H13NO2 2M + H 311.20 311.04 1.5X107 N 
D6S1 Rh2piv4 C17H14ClNO2 -H 298.07 298.06 1x106 N 
D6S2 Rh2piv4 C15H13ClO3 H 277.06 277.06 3x106 N 
D6S3 Rh2piv4 C23H20Cl2O2 - 398.08 - - N 
D6S4 Rh2piv4 C16H19NO4 H 290.13 290.14 5x106 N 
D6S5 Rh2piv4 C19H24NO3 K 353.14 353.05 2x107 Y 
D6S6 Rh2piv4 C18H16O3 H 281.11 281.12 7.5x106 N 
D6S7 Rh2piv4 C20H22NO2 H 309.17 309.17 1.5x108 Y 
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D6S8 Rh2piv4 C18H17ClO3 H 317.09 317.06 3x107 Y 
D6S9 Rh2piv4 C18H15ClO2 H 299.08 299.08 7.5x106 N 
D6S10 Rh2piv4 C13H16O4S H 269.08 269.08 3x107 N 
D6blank Rh2piv4 C18H16O4 H 297.11 297.11 7.5x107 Y 
D6S1 Rh2pfb4 C17H14ClNO2 H 300.07 299.94 1x107 Y 
D6S2 Rh2pfb4 C15H13ClO3 - 276.06 - - N 
D6S3 Rh2pfb4 C23H20Cl2O2 - 398.08 - - N 
D6S4 Rh2pfb4 C16H19NO4 H 290.13 290.14 5x106 N 
D6S5 Rh2pfb4 C19H24NO3 K 353.14 353.11 1x107 N 
D6S6 Rh2pfb4 C18H16O3 - 280.11 - - N 
D6S7 Rh2pfb4 C20H22NO2 H 309.17 309.17 1.5x108 Y 
D6S8 Rh2pfb4 C18H17ClO3 2M + Na 655.16 655.05 6x107 Y 
D6S9 Rh2pfb4 C18H15ClO2 H 299.08 299.08 4x107 N 
D6S10 Rh2pfb4 C13H16O4S H 269.08 269.00 3x107 Y 
D6blank Rh2pfb4 C18H16O4 - 296.10 - - N 
D7S1 Rh2piv4 C14H12ClN3O2 H 290.06 289.93 2x107 Y 
D7S2 Rh2piv4 C12H11ClN2O3 H 267.05 266.89 6x106 Y 
D7S3 Rh2piv4 C20H18Cl2N2O2 H 389.08 389.08 6x106 Y 
D7S4 Rh2piv4 C13H17N3O4 Na 302.11 302.01 2x106 Y 
D7S5 Rh2piv4 C16H21N3O3 -H 302.16 302.01 1x106 Y 
D7S6 Rh2piv4 C15H14N2O3 H 271.10 270.93 3x107 Y 
D7S7 Rh2piv4 C17H20N3O2 NH4 316.19 316.10 2x106 N 
D7S8 Rh2piv4 C15H15ClN2O3 H 307.08 306.96 5x107 Y 
D7S9 Rh2piv4 C15H13ClN2O2 H 289.07 288.93 4x107 Y 
D7S10 Rh2piv4 C10H14N2O4S H 259.07 258.87 6x106 Y 
D7blank Rh2piv4 C12H12N4O4 H 276.09 276.95 8x106 Y 
D7S1 Rh2pfb4 C14H12ClN3O2 H 290.06 289.92 1.5x107 Y 
D7S2 Rh2pfb4 C12H11ClN2O3 H 267.05 266.89 1x107 Y 
D7S3 Rh2pfb4 C20H18Cl2N2O2 H 389.07 389.06 1.5x107 Y 
D7S4 Rh2pfb4 C13H17N3O4 -H 278.12 278.11 4x106 N 
D7S5 Rh2pfb4 C16H21N3O3 H 304.16 304.17 4x106 N 
D7S6 Rh2pfb4 C15H14N2O3 H 271.10 270.91 1x107 Y 
D7S7 Rh2pfb4 C17H19N3O2 H 298.15 298.06 1.5x107 Y 
D7S8 Rh2pfb4 C15H15ClN2O3 2M + Na 635.14 635.04 1x107 Y 
D7S9 Rh2pfb4 C15H13ClN2O2 H 289.07 288.92 1.5x107 Y 
D7S10 Rh2pfb4 C10H14N2O4S H 259.07 258.91 3x106 Y 
D7blank Rh2pfb4 C12H12N4O4 H 277.09 276.95 7x107 Y 
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5.3.5 Fluorescence Anisotropy Assay for the Inhibition of the 
p53/MDM2 Protein-Protein Interaction 
The fluorescein-labelled p5315-31 Flu transactivation domain peptide (Ac-
SQETFSDLWKLLPENNVC(Flu)-NH2) was purchased from Peptide 
Synthetics. The assay was carried out using Perkin-Elmer 384-well Opti-
plate assay plates (6007270). Fluorescence anisotropy assays were 
performed in a buffer containing 40 mM phosphate pH 7.5, 200 mM NaCl 
and 0.02 mg/mL bovine serum albumin (PBSA). 
Results were collected using a Perkin-Elmer Envision 2103 Multilabel 
Reader using a 431 nm mirror, 480(104) nm excitation filter, and 535(208) 
and 535(209) nm emission filters after 2.5 or 24 hours of incubation at room 
temperature. Test well anisotropy values were then calculated using the 
blank corrected S and P channel values using the following formula: 
Eq. 5.1:  𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 = (2 × 𝑃𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑  × 𝐺 𝑓𝑎𝑐𝑡𝑜𝑟) + 𝑆𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 




The fraction of bound tracer was calculated using the following formula: 




Where λ is the intensity of bound/unbound tracer (λ = Ibound/Iunbound) and r is 
anisotropy. 
 
5.3.5.1 Binding of p5315-31 Flu to hDM217-125 
A serial dilution of hDM217-125 (0.0006 µM to 20.75 µM, final concentration) 
was added to a fixed concentration of p5315-31 Flu (54.5 nM) and PBSA buffer 
(20 µL), to give a 60 µL total volume per assay well. Each dilution was 
performed in triplicate and the measured intensity of each well calculated 
using equation 5.1, then anisotropy was calculated using equation 5.2. 
Fraction bound of the p5315-31 Flu tracer could also be determined using 
equation 5.3 (Figure 5.5). 
 




Figure 5.5. Fluorescence anisotropy titration of human-MDM2 (0.0006 µM to 
20.75 µM) into fixed concentration p53-IAF tracer (54.5 nM) in aqueous 
phosphate buffer (pH 7.5, 40 mM phosphate, 200 mM NaCl and 0.02 mg/mL 
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5.3.5.2 Inhibition of the p5315-31 Flu/hDM217-125 protein-protein interaction 
with Nutlin-3a 
Nutlin-3a was serially diluted in DMSO and then diluted 33-fold in PBSA to 
give effective concentrations between 73 µM and 0.4 nM in 3% 
DMSO/PBSA. Each serial dilution was repeated in triplicate. An aliquot of 
each point (20 µL) was then added to a 384-well assay plate, followed by 
hDM2 (150 nM) and p5315-31 Flu (25 nM), to give final concentrations of 
Nutlin-3a between 24 µM and 0.08 nM (Figure S2). 
EC50 values were determined and curves were fit in Origin Pro 2019b using 
a non-linear curve fitting with the dose response fitting procedure and 
Levenberg Marquardt iteration algorithm. 
 
 
Figure 5.6. Dose response of Nutlin-3a (positive control) in our p53/MDM2 
fluorescence anisotropy assay in pH 7.5 aqueous phosphate buffer (40 mM 
phosphate, 200 mM NaCl and 0.02 mg/mL Bovine Serum Albumin). 




- 176 - 
 
5.3.6 Procedure for the Screening of Reaction Mixtures 
An aliquot from the master stock of each reaction mixture (2 µL, 50 mM) was 
diluted into 48 µL DMSO to create a 2 mM total product concentration 
intermediate screening stock that was used for all subsequent reaction 
mixture screening. An aliquot of each 2 mM reaction mixture stock (4.9 µL) 
was then diluted into 155.1 µL PBSA buffer (pH 7.5, 40 mM phosphate, 200 
mM NaCl and 0.02 mg/mL Bovine Serum Albumin, PBSA) to create a 60 µM 
3% DMSO screening stock. 20 µL of each screening stock was then added 
to its corresponding well in a 384-well PerkinElmer Opti-plate (see example 
plate layouts above). Each test well was then charged sequentially with 20 
µL 450 nM hDM2 in pH 7.5 PBSA buffer and 20 µL 75 nM p53-tracer in pH 
7.5 PBSA buffer. Each blank well was then charged with 20 µL 450 nM 
hDM2 in pH 7.5 PBSA buffer and 20 µL pH 7.5 PBSA buffer. The total 
volume of each well was 60 µL and the final concentrations of each reagent 
were: 
• Reaction mixture: 20 µM (Total Product Concentration) 
• hDM2: 150 nM 
• p53-tracer: 25 nM 
Results were collected using a Perkin-Elmer Envision 2103 Multilabel 
Reader using a 431 nm mirror, 480 nm excitation filter and 535 nm emission 
filter after 2.5 or 24 hours of incubation at room temperature. Test well 
anisotropy values were then calculated using the blank corrected S and P 
channel values using the following equations 5.1 and 5.2. 
Percentage inhibition values were then calculated using Nutlin-3a (10 µM) as 
the positive control reference and a 1% DMSO blank well containing 150 nM 
hDM2 and 25 nM p53-tracer as the negative control reference. 
% 𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑡𝑜 10 µ𝑀 𝑁𝑢𝑡𝑙𝑖𝑛 − 3𝑎
=  
𝐷𝑀𝑆𝑂 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝐴𝑛𝑖𝑠𝑜𝑡𝑟𝑜𝑝𝑦 − 𝑆𝑎𝑚𝑝𝑙𝑒 𝐴𝑛𝑖𝑠𝑜𝑡𝑟𝑜𝑝𝑦
𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝐴𝑛𝑖𝑠𝑜𝑡𝑟𝑜𝑝𝑦 − 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝐴𝑛𝑖𝑠𝑜𝑡𝑟𝑜𝑝𝑦
 × 100 
Total product concentration was used to standardise the effective screening 
concentrations for the high-throughput screening of reaction mixtures and is 
defined as the concentration of the limiting reagent in each well before the 




- 177 - 
 
Example 384-well biological assay plate layout: 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
A A1 A1 A2 A2 A3 A3 A4 A4 A5 A5 A6 A6 A7 A7 A8 A8 A9 A9 A10 A10 A11 A11 PIV PIV 
B A1B A1B A2B A2B A3B A3B A4B A4B A5B A5B A6B A6B A7B A7B A8B A8B A9B A9B A10B A10B A11B A11B PIVB PIVB 
C B1 B1 B2 B2 B3 B3 B4 B4 B5 B5 B6 B6 B7 B7 B8 B8 B9 B9 B10 B10 B11 B11 neg neg 










































E C1 C1 C2 C2 C3 C3 C4 C4 C5 C5 C6 C6 C7 C7 C8 C8 C9 C9 C10 C10 C11 C11 neg neg 










G D1 D1 D2 D2 D3 D3 D4 D4 D5 D5 D6 D6 D7 D7 D8 D8 D9 D9 D10 D10 D11 D11 neg neg 










I E1 E1 E2 E2 E3 E3 E4 E4 E5 E5 E6 E6 E7 E7 E8 E8 E9 E9 E10 E10 E11 E11 PFB PFB 









PFB B PFB B 
K F1 F1 F2 F2 F3 F3 F4 F4 F5 F5 F6 F6 F7 F7 F8 F8 F9 F9 F10 F10 F11 F11 pos pos 









pos B pos B 














































pos B pos B 














































pos B pos B 
 
5.3.7 Fluorescence Anisotropy Data for Reaction Mixtures from Rounds 
One and Two 
Round 1 HTS at 20 µM total product concentration: 
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Reaction array 1 reagents: 
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Reaction array 2 reagents: 
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5.3.8 Determining EC50 Values for Isolated Compounds 
Pure compounds (P1 – P7 and 4.1 – 4.4) were serially diluted in 100% 
DMSO (using 12 two-fold dilution steps) to achieve the correct effective 
concentrations (15.8 – 0.007 mM), then diluted 33-fold in pH 7.5 aqueous 
phosphate buffer (40 mM phosphate, 200 mM NaCl and 0.02 mg/mL Bovine 
Serum Albumin) to achieve a 3% DMSO intermediate stock solution (480 – 
0.23 µM). The assay was then implemented similarly to the examples above 
to give final compound concentrations between 0.08 and 160 µM. 
EC50 values were determined and curves were fit in Origin Pro 2019b using 
a non-linear curve fitting with the dose response fitting procedure and 








Due to poor compound solubility a full dose-response curve could not be 
obtained. 
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Due to poor compound solubility a full dose-response curve could not be 
obtained. 
 
Due to poor compound solubility a full dose-response curve could not be 
obtained. 
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Due to poor compound solubility a full dose-response curve could not be 
obtained. 
 






Due to poor compound solubility a full dose-response curve could not be 
obtained. Curve fitting failed and EC50 could not be determined. 
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5.3.9 NMR Measurements for Kd Estimation  
5.3.9.1 Kd Estimation Using 1H/15N-HSQC NMR 
NMR titrations were performed by recording a series of 1H/15N-HSQC 
experiments on a 750 MHz Oxford Magnet spectrometer (TCI-Cyroprobe, 1H 
optimized triple resonance NMR ‘inverse’ probe) (1H = 750 MHz and 15N =  
76 MHz) in pH 7.5 aqueous phosphate buffer containing 100 mM phosphate, 
1 mM DTT and 2.5% glycerol with 50 µM 15N-labelled hDM217-125, 10% D2O 
and 1% DMSO. Temperature was maintained at 298 K throughout the 
experiments. Pure compounds were titrated into the 15N-MDM2 sample in 
0.5-, 1-, 1.5- and 2-molar equivalents relative to 15N-MDM2 as standard and 
further molar equivalents of 4- and 6-times compound-to-MDM2 were added 
if the protein was not fully saturated. Data was processed using Topspin and 
analysed with Sparky.285 
Kd values were obtained by plotting the observed chemical shift perturbation 
(csp) of the reporter peaks L54, L57, G58, M62, V75, V93, K94, H96 and 
K98 against the molar ratio of ligand. The csp of each reporter peak was 
calculated as the deviation from the free protein resonances using the 
equation: 
𝑐𝑠𝑝 =  √(𝜔2 𝑓𝑟𝑒𝑒 − 𝜔2 𝑏𝑜𝑢𝑛𝑑)2 +  




Where ω1 is the 15N chemical shift and ω2 is the 1H chemical shift 
corresponding to the observed HSQC cross-peak for a given reporter 
residue. 
Kd values for each reporter peak were then obtained by solving the equation: 
∆ =  ∆𝑜
(𝐾𝑑 + [𝐿] + [𝑃]) − √((𝐾𝑑 + [𝐿] + [𝑃])2 − 4[𝑃][𝐿])
2[𝑃]
 
Where Δ is the observed csp, Δo is the maximum csp, and [P] and [L] are the 
protein and ligand concentrations respectively. The global Kd was then 
obtained from the average Kd for the combined reporter peaks: 
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5.3.9.1 1H/15N-HSQC Spectra and Fitting 
P1 – due to intermediate and slow exchange chemical shift perturbation Kd 
could not be estimated using the reporter peaks outlined above. 
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Figure 5.8. 15N-H HSQC chemical shift perturbation of assigned peaks for 50 
µM 15N-labelled hDM2 on addition of Nutlin-3a (100 µM). Unassigned 
residues are highlighted in grey. 
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5.3.9.2 19F-CPMG Ligand-Observed NMR 
NMR titrations were performed by recording a series of 19F-CPMG 
experiments on a Bruker AV-400 NMR spectrometer (1H = 400 MHz, 13C = 
100 MHz and 19F = 376 MHz C-F decoupled) in pH 7.5 aqueous phosphate 
buffer containing 100 mM phosphate and 1 mM DTT with 100 µM P1, 10% 
D2O and 5% d6-DMSO. Temperature was maintained at 298 K throughout 
the experiments. hDM217-125 was titrated into the P1 sample in 0.0025, 
0.005, 0.01, 0.015, 0.02, 0.04, and 0.1 molar equivalents and the CPMG 
spectra286 was recorded at 50 ms and 300 ms delay times. Data was 
processed using Topspin. 
 
5.4 Computational Methods for the Design and Evaluation of 
Reaction Arrays 
Diazo substrates were selected during the round 1 reaction array design by 
filtering a database of commercially available compounds for primary and 
secondary amines. The filtering workflow was primarily conducted using 
Pipeline Pilot and amines with undesirable functional groups, more than 20 
heavy atoms, or AlogP values <-2 and >5 were removed from the library 
(Scheme 5.1). The amines were then enumerated in RDKit, using 
diazotization workflows described in Chapter 3, to form a library of virtual 
diazo substrates (Figure 5.9). This library was then used to select amines for 
diazo synthesis in round 1. 
 
Scheme 5.1 Examples of undesirable functional groups removed from the 
amine library. 
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Figure 5.9 Distribution of molecular properties (heavy atom count and 
ALogP) for diazo substrates considered for use in the round 1 reaction array. 
 
Co-substrates were also selected for evaluation during array design by 
filtering a database of commercially available compounds for functional 
groups known to react with rhodium(II) carbenes (Figure 5.10). The Pipeline 
Pilot PAINS filter was applied to the database before substructure matching 
for reactive motifs. After substructure matching was complete a library of co-
substrates was manually selected for consideration in array design. 
 
Figure 5.10 Top: Examples of functional groups used with substructure filters 
for the selection of co-substrates. Bottom: Examples of undesirable 
molecules removed from the database. 
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After compiling libraries of potential diazo substrates and co-substrates, a 
virtual reaction array was enumerated, and the theoretical coverage of 
chemical space was investigated. The goal of virtual reaction array 
enumeration was to discard array designs with particularly poor coverage of 
chemical space, rather than select the best array design. The final round 1 
array design, described in Chapter 3, was chosen to balance the diversity in 
reactants with the ability to synthesise diazo substrates (Figure 3.3 and 3.4). 
 
5.4.1 Exemplar Reaction SMARTS for the Enumeration of Virtual 
Products from Reaction Arrays 
Described below are reaction SMARTS for common rhodium(II) catalysed 
reactions with diazo compounds (Table 5.8). The SMART strings were used 
to enumerate libraries of virtual products for hypothetical ADS reaction 
arrays. The libraries were used to assess potential product diversity within a 
reaction array and were used to aid in the selection of substrates and co-
substrates. 









C–H insertion α-to a 
nitrogen atom 
[#6:1]=[N+:2]=[#7-:3].[#6:4]-[#7:5]>>[#6:1]-[#6:4]-[#7:5] 
C–H insertion α-to an 
oxygen atom 
[#6:1]=[N+:2]=[#7-:3].[#6:4]-[#8:5]>>[#6:1]-[#6:4]-[#8:5] 




Benzylic C–H insertion 
[#6:1]=[N+:2]=[#7-:3].[#6:4]-[c:5]:[c:6]>>[#6:1]-[#6:4]-
[c:5]:[c:6] 
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5.4.2 A Python Script for the Enumeration of Virtual Reaction 
Arrays using RDKit 
Described below is a python function for the enumeration of virtual libraries 
using RDKit. The function was used to compare the chemical space covered 
by a hypothetical ADS reaction array to the chemical space covered by 
MDM2 ligands deposited into the ChEMBL database.258 
# RDKit Modules 
from rdkit import rdBase 
from rdkit import Chem 
from rdkit.Chem import AllChem 
from rdkit.Chem import rdChemReactions 
from rdkit.Chem import PandasTools 
# Nested Functions for Reaction Enumeration (Remove '#' From Writer to Save 
Excel File of Results) 
# rxn is nested into multi_rxn -> only need to run multi_rxn for concatenated results 
# Single Reaction Enumerator -> DOES NOT GIVE MOLECULES OBJECTS,  
# ONLY SMILES 
# Give SUBSTRATES and CO_SUBSTRATES as SMILES 
def rxn(i):  # i = reaction SMART string 
    r = AllChem.EnumerateLibraryFromReaction(i,[SUBSTRATES, 
CO_SUBSTRATES]) 
    r = pd.DataFrame([Chem.MolToSmiles(x[0]) for x in list(r)], columns=['SMILES']) 
    r = r.drop_duplicates() 
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# Function for Concatenating Results of Multiple reactions 
# Takes RXN Output and Concatenates into Complete DataFrame 
# Generates Molecules on Complete DataFrame and Removes Duplicates 
def multi_rxn(*i):  # i = array of SMARTS strings 
r = pd.DataFrame() 
for x in i: 
r = r.append([r, rxn(x)]) 
PandasTools.AddMoleculeColumnToFrame(r,'SMILES','Molecule', 
includeFingerprints=True) 
r = r.replace(to_replace='None',  
value=np.nan).dropna().drop_duplicates(subset='SMILES'). 
reset_index(drop=True) 
    #writer = pd.ExcelWriter('virtual_library.xlsx') 
    #r.to_excel(writer,'Sheet1') 
     #writer.save() 
     return r 
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5.4.3 An Exemplar Virtual Reaction Array 
Once a virtual reaction array was enumerated it was compared to the 
chemical space of some known MDM2 ligands (Figure 5.10). PCA or t-
Distributed Stochastic Neighbour Embedding (t-SNE) methods were used to 
evaluate the molecular fingerprints (Morgan fingerprints) of the virtual 
product library and the library of known MDM2 ligands. Below is an example 
of this approach using the substrates and co-substrates from the round 1 
ADS reaction array for the discovery of MDM2 ligands (Figure 5.11). 
Figure 5.10. PCA decomposition of a library of known MDM2 ligands. 
Figure 5.11. PCA decomposition of a library of known MDM2 ligands and 
virtual ADS products. ADS reaction products are represented in black. 
 
5.5 Similarity Analysis of Hit Molecules 
1769 compounds with annotated bioactivity towards MDM2 were obtained 
from the ChEMBL database (accessed: 16/01/2020). Subsequent 
processing gave 1314 compounds which were then used for further analysis. 
The Morgan molecular fingerprint was then computed for each molecule 
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using RDKit and the pairwise Tanimoto similarity scores were calculated 
(Table 5.9). 
Table 5.9. Tanimoto similarity analysis comparing ADS products P1 – P6 to 
1314 known hDM2 ligands from the ChEMBL database. 
Metric P1 P2 P3 P4 P5 P6 
Mean 0.37 0.34 0.36 0.26 0.43 0.44 
Median 0.38 0.34 0.36 0.25 0.44 0.45 
Minimum similarity 0.12 0.12 0.13 0.13 0.13 0.12 
Maximum similarity 0.50 0.48 0.46 0.37 0.61 0.51 
 
 
Lipophilic ligand efficiency (LLE) was calculated using the equation below 
𝐿𝐿𝐸 = 𝑝𝐼𝐶50 − 𝑐𝐿𝑜𝑔𝑃 
 
5.6 Molecular Docking 
ADS products P2, P4, P5 and P6 were docked, using Autodock Vina,255 into 
an X-ray crystal structure of hDM2 (PDB: 6Q9H) with the small molecule 
ligand removed. Representative, DFT-optimised, 3-dimensional structures 
for P2 and P4 – P6 were generated in Gaussian09277 at the B3LYP/6-31G(d) 
level of theory. Each ligand was docked as its individual stereoisomers. The 
cartesian coordinates for the DFT-optimised structures were then used as 
initial ligand geometries in Autodock Vina. The hDM2 crystal structure was 
then prepared by removing all hydrogen atoms and water molecules, and 
then the hydrogens for polar residues or residues that would be protonated 
under physiological conditions were re-added. 
The following grid space (Å) was used for docking with PDB:6Q9H 
 center_x = 5.659 
 center_y = 15.381 
 center_z = -1.815 
 size_x = 22 
 size_y = 22 
 size_z = 22 
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Ligand files were then prepared by setting the rotatable bonds for each 
ligand, setting aromaticity, and constraining the rotation of amide bonds. The 
molecular docking of each ligand into hDM2 was then computed with an 
exhaustiveness value of 64. Top ranked docking poses were then manually 
evaluated for the quality of the docked pose. 
Example configuration file for Autodock Vina: 
receptor = YOUR_STRUCTURE_HERE.pdbqt 
ligand = YOUR_LIGAND_HERE.pdbqt 
out = RESULT_HERE.pdbqt  
 
center_x = 5.659 
center_y = 15.381 
center_z = -1.815 
 
size_x = 22  # remember to convert from a.u. to Angstroms when setting this in  
size_y = 22  # Autodock Tools otherwise it’ll be very wrong (i.e. massive) 
size_z = 22 
 
exhaustiveness = 64  # 8 is the default and is pretty quick if docking many  
# molecules. Use higher values if docking fewer molecules 
# for greater accuracy/quality 
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Appendix A 
Establishing the p53/hDM2 Fluorescence Anisotropy Assay 
for Photoredox Reaction Conditions 
Each component required in a photoredox Minisci reaction was tested in the 
established p5315-31 Flu/hDM217-125 fluorescence anisotropy assay to check 
for assay interference. All concentrations tested for the catalysts/catalytic 
systems were tolerated across the entire range of the titration experiment up 
to 0.1-1 µM concentrations (Figure A1), giving an estimated maximum assay 
window between 1-100 µM for ADS reaction screening. Potentially higher 
concentrations can be used with the (Ir[dF(CF3)ppy]2(dtbpy))PF6 and 
Acridinium photocatalysts (i.e. above 100 µM) due to low residual emission 
intensities under the assay conditions (Figure A2).  
 
Figure A1. Dose-response of the individual photoredox Minisci reaction 
components, with 150 nM MDM2, 25 nM p53-tracer and pH 7.4 Tris buffer 
containing 50 mM Tris, 150 mM NaCl and 0.1% Triton X-100. IC50 values 
between 45 – 140 nM and no time-dependent change in inhibition was 
observed. 
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Figure A2. Measured fluorescent intensities for the photoredox catalysts in 
dose-response. 4CzIPN shows clear interference at 1 and 0.3 µM 
concentrations, but rapidly diminishes. 
 
A dose-response titration of Nutlin-3a, identical to the procedure described in 
Chapter 5.3.5.2, was undertaken with 0, 1 and 2 molar equivalents of 
trifluoroacetic acid (TFA) to investigate if the Tris-Triton X-100 pH 7.4 buffer 
system could be effected by TFA. Each titration experiment gave similar 




Figure 2. Dose-response of Nutlin-3a with zero, one or two equivalents of 
TFA, with 150 nM MDM2, 25 nM p53-tracer and pH 7.4 Tris buffer 
containing 50 mM Tris, 150 mM NaCl and 0.1% Triton X-100. IC50 values 
between 45 – 140 nM and no time-dependent change in inhibition was 
observed. 
